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Summary
Aerosolised DNA administration could potentially advance the treatment of 
inheritable lung diseases and lung malignancies and provide genetic 
immunisation against infection. Pressurised metered dose inhalers (pMDIs) 
offer a potentially efficacious and pragmatic, although unexplored, means for 
pDNA delivery. The aim of this thesis was to investigate the potential of a 
novel low-energy nanotechnology process, to prepare surfactant-coated pDNA 
particles for pulmonary gene delivery via pMDI technology.
Following process optimisation using salbutamol sulphate as the model drug, 
water-in-oil microemulsions containing pEGFP-Nl reporter plasmid were 
investigated using carbohydrate lyoprotectants in aqueous solution, 
lecithin:propan-2 -ol (surfactant) and iso-octane (organic phase). Resultant 
microemulsions were snap-frozen in liquid nitrogen and lyophilised. Agarose 
gel electrophoresis with ethidium bromide staining revealed that pDNA 
integrity was retained after lyophilisation and reduction of excess surfactant by 
organic solvent. pDNA particles were incorporated into pMDI formulations 
containing hydrofluoroalkane 134a (HFA134a) propellant and ethanol as co­
solvent. A549 human lung epithelial cells were exposed to pMDI aerosolised 
pDNA particles with dioleoyl-trimethylammonium propane (DOTAP) in the 
culture medium. Cellular gene expression studies demonstrated that pDNA 
biological functionality was maintained whilst an in vitro toxicity (MTT) assay 
showed no significant loss o f cell viability follow ing pMDI aerosolised pDNA 
treatment. Subsequent investigations incorporating DOTAP transfection agent 
into pDNA pMDI formulations demonstrated a proof-of-concept that 
aerosolised pMDI DOTAP-pDNA formulations can confer significant cellular 
gene expression with the potential for pulmonary gene delivery.
Methods have been successfully developed and evaluated to aerosolise 
surfactant-coated pDNA particles and maintain pDNA viability. Furthermore, 
investigations have demonstrated that the pDNA particles and a transfection 
agent (DOTAP) can be incorporated into a generic HFA134a formulation and 
successfully aerosolised using a standard valve and actuator. Further studies 
demonstrated the performance of these formulations after four week 
accelerated stability conditions.
Table of Contents
Declaration................................................................................................................... i
Acknowledgments.................................................................................................... iii
Summary.................................................................................................................... iv
Table o f Contents..........................................................................................................
List o f Figures............................................................................................................xi
List o f Tables...........................................................................................................xiv
Abbreviations............................................................................................................ xv
CHAPTER ONE Introduction........................................................................ 1
1.1 Pulmonary Delivery Devices....................................................................... 4
1.2 Pulmonary Gene Therapy............................................................................. 5
1.3 Macromolecule Particle Preparation M ethods..........................................7
1.3.1 Preparation of Particles for pM DI...............................................................9
1.3.2 Nanoparticles............................................................................................... 10
1.4 Particle Sizing.............................................................................................. 12
1.4.1 Andersen Cascade Impactor.......................................................................15
1.4.2 Andersen Viable Sampler (AV S).............................................................. 17
IJS Scope of Thesis~~...................................................................................... 20
CHAPTER TWO Process Optimisation......................................................22
2.1 Introduction  .................................................................................. 23
2.1.1 W/O Microemulsion System..................................................................... 23
2.1.2 pMDI Formulation Excipients................................................................... 28
2.1.3 Specific Aims and Objectives o f the Chapter..........................................31
2 2  Materials and Methods............................................................................ 32
2.2.1 Optimisation of Microemulsion Formulation Parameters..................... 32
2.2.2 Preparation of Nanoparticles......................................................................33
2.2.3 Microscopic Characterisation of SS Nanoparticles................................ 33
2.2.4 HPLC Assay to Quantify S S ......................................................................35
2.2.5 Production of SS pMDI Formulations...................................................... 36
2.2.6 Assessment of SS pMDI Formulations.................................................... 37
2.2.6.1 Microscopic Characterisation of Aerosolised SS Formulation.............40
2.2.7 Statistical Analysis......................................................................................41
2 3  Results.................. ................................................................................ 42
2.3.1 Optimisation of Microemulsion Formulation Parameters..................... 42
2.3.2 Microscopic Characterisation of SS Nanoparticles............................. 43
2.3.3 HPLC Assay to Quantify S S ...................................................................46
2.3.4 Assessment of SS pMDI Formulations................................................. 47
2.3.4.1 Assessment of SS Deposition Following Aerosolisation from a pMDI. 
 48
2.3.4.2 Microscopic Characterisation of Aerosolised SS Formulation.......... 51
2.4 Discussion  53
2.4.1 Optimisation of Microemulsion Formulation Parameters...................53
2.4.2 Microscopic Characterisation of SS Nanoparticles..............................53
2.4.3 Assessment of SS pMDI Formulations..................................................56
2.4.3.1 Assessment of SS Deposition Following Aerosolisation from a pMDI
.....................................................................................................................57
2.4.3.2 Microscopic Characterisation of Aerosolised SS Formulation.......... 62
2^  Conclusion  64
CHAPTER THREE Preparation of pDNA Particles................................... 65
3.1 Introduction  66
3.1.1 Plasmid EGFP-N1.................................................................................... 69
3.1.2 Specific Aims and Objectives o f the Chapter........................................71
3 2  Materials and Methods..........................................................................72
3.2.1 Bacterial Transformation..........................................................................72
3.2.2 pDNA Amplification and Purification...................................................75
3.2.3 Assessment of pDNA Quality................................................................. 76
3.2.3.1 Gel Electrophoresis -  Analysis o f pDNA Purification Procedure 76
3.2.3.2 Determination of pDNA Yield and Purity..............................................77
3.2.3.3 pEGFP-Nl Restriction Enzyme Double Digest -  Determination o f
Plasmid Identity......................................................................................... 77
3.2.4 Investigating the Effect o f Lyoprotectant and Freezing Rate on
Lyophilised pDNA....................................................................................79
3.2.5 Preparation of pDNA Particles................................................................ 80
3.2.6 Analysis o f pDNA Particles.....................................................................81
3.2.6.1 Integrity of pDNA Particles......................................................................81
3.2.6.2 Microscopic Characterisation of pDNA particles.................................82
3.2.6.3 Integrity o f Solvent-Washed pDN A Particles....................................... 83
3.2.6.4 Measurement o f Particle Size.................................................................. 83
3 J  Results^™.......-.......................................—**———..............................84
3.3.1 Bacterial Transformation..........................................................................84
3.3.2 Assessment o f pDNA Quality.................................................................86
3.3.2.1 Gel Electrophoresis -  Analysis o f pDNA Purification Procedure 86
3.3.2.2 Determination of pDNA Yield and Purity.............................................. 87
3.3.2.3 pEGFP-Nl Restriction Enzyme Double Digest -  Determination of 
Plasmid Identity.....................................   87
3.3.3 Investigating the Effect of Lyoprotectant and Freezing Rate on 
Lyophilised pDNA....................................................................................88
3.3.4 Preparation of pDN A Particles................................................................91
3.3.5 Investigating the Effect o f Freeze-Drying versus Spray-Drying During
pDN A Processing......................................................................................92
3.3.5.1 Integrity of pDNA Particles..................................................................... 92
3.3.5.2 Microscopic Characterisation of pDNA particles................................ 93
3.3.6 Analysis of Solvent-Washed pDN A Particles.......................................96
3.3.6.1 Integrity o f Solvent-Washed pDN A Particles.......................................96
3.3.6.2 Measurement o f Particle Size.................................................................. 97
3.4 Discussion ............. 98
3.4.1 Choice of lyoprotectant............................................................................98
3.4.2 Preparation of pDN A Particles.............................................................100
3.4.2.1 Investigating the Effect o f Freeze-Drying versus Spray-Drying During
pDN A Processing.................................................................................... 101
3.4.3 Analysis of Solvent-Washed pDN A Particles................................... 105
3.5 Conclusion ......  107
CHAPTER FOUR Characterisation, Transfection and Cellular
Toxicity of pDNA Delivered by pM D I.................... 108
4.1 Introduction ................................................................109
4.1.1 Cationic Liposomes................................................................................ 109
4.1.1.1 Preparation of Cationic Liposomes.......................................................110
4.1.1.2 Liposomal Gene Delivery....................................................................... 111
4 .1.2 Cell Culture of a Mammalian Cell Line............................................... 113
4.1.3 Specific Aims and Objectives of the Chapter.......................................115
4 2  M aterials and M ethods ............................................... 116
4.2.1 Cell culture.............................................................................................. 116
4.2.2 A549 Cell Growth Study........................................................................ 118
4.2.3 DOTAP Liposome Preparation............................................................. 119
4.2.4 Optimising DOTAP: pDNA Ratio for Transfection Studies............. 119
4.2.4.1 Analysis of Gene Expression..................................................................120
4.2.5 Assessing the Transfection Competency o f Lyophilised pDNA
Particulates...............................................................................................121
4.2.6 Production of pDNA pMDI Formulations.......................................... 122
4.2.7 Assessment of pDNA pMDI Formulations......................................... 123
4.2.7.1 Integrity of pDNA Particles Following Aerosolisation from a pMDI
................................................................................................................... 123
4.2.7.2 Aerosolised Delivery to Cell Culture Flask..........................................123
4.2.7.3 Assessment o f pDNA Functionality Following Aerosolisation from a
pM DI.........................................................................................................125
4.2.7.4 Microscopic Characterisation of Particles............................................126
4.2.8 Cell Toxicity Assay.................................................................................126
4.2.9 Statistical Analysis.................................................................................. 128
4 3  Results-. ...............  129
4.3.1 A549 Cell Growth Study........................................................................ 129
4.3.2 Measurement of DOTAP Liposome Size............................................. 129
4.3.3 Optimising DOTAP: pDNA Ratio for Transfection Studies............. 130
4.3.4 Assessing the Transfection Competency of Lyophilised pDNA 
Particulates............................................................................................... 131
4.3.5 Assessment o f pDNA pMDI Formulations.......................................... 132
4.3.5.1 Integrity of pDNA Particles Following Aerosolisation from a pMDI 
................................................................................................................... 132
4.3.5.2 Aerosol Delivery to Cell Culture Flask.................................................133
4.3.5.3 Assessment o f pDNA Functionality Following Aerosolisation from a 
pM D I.........................................................................................................135
4.3.5.4 Visual Assessment of Washed lyophilised pDNA pMDI Formulations 
................................................................................................................... 136
4.3.5.5 Microscopic Characterisation of Particles...........................................137
4.3.6 Cell Toxicity Assay............................................................................... 138
4.4 Discussion  140
4.4.1 A549 Cell Growth Study....................................................................... 140
4.4.2 Optimising DOTAP: pDNA Ratio for Transfection Studies 140
4.4.3 Assessing the Transfection Competency of Lyophilised pDNA 
Particulates...............................................................................................141
4.4.4 Assessment o f pDNA pMDI Formulations.......................................... 142
4 i  Conclusion...—......................................................................................147
viii
CHAPTER FIVE Characterisation, Transfection and Stability of
DOTAP-pDNA pMDI Formulation.........
5.1 Introduction ...........................................................................
5.1.1 Envisaged Formulation Challenges.......................................
5.1.2 Characterising Liposome-DNA Complex Structure.........................151
5.1.3 Characterising Aerosolised Particles.....................................
5.1.4 Specific Aims and Objectives o f the Chapter..................................... 155
5J Materials and Methods........................................................ .
5.2.1 Incorporation of DOTAP into a pDNA pMDI System ...... .............. 156
5.2.1.1 Microscopic Characterisation of Aerosolised DOTAP-pDNA
Formulation............................................................................. .............. 158
5.2.2 Assessment of DOTAP-pDNA Deposition Following Aerosolisation
from a pMDI............................................................................ .............. 159
5.2.2.1 Validation of the Abbreviated Andersen Viable Sampler.. .............. 160
5.2.3 Investigating the Stability o f DOTAP-pDNA pMDI Formulation
Following Accelerated Storage............................................. .............. 162
5.2.4 Statistical Analysis................................................................. .............. 163
5 3 Results.......................... .......................................................... .............. 164
5.3.1 Incorporation of DOTAP into a pDNA pMDI System ..... .............. 164
5.3.1.1 Microscopic Characterisation of Aerosolised DOTAP-pDNA
Formulation............................................................................. .............. 165
5.3.2 Assessment of DOTAP-pDNA Deposition Following Aerosolisation
from a pMDI............................................................................ .............. 168
5.3.2.1 Validation of the Abbreviated Andersen Viable Sampler.. .............. 169
5.3.3 Investigating the Stability o f DOTAP-pDNA pMDI Formulation
Following Accelerated Storage............................................................170
5.4 Discussion — - — .................................................... ...............174
5.4.1 Incorporation of DOTAP into a pDNA pMDI System ..... ............... 174
5.4.2 Assessment of DOTAP-pDNA Deposition Following Aerosolisation
from a pMDI........................................................................... ............... 176
5.4.3 Investigating the Stability o f DOTAP-pDNA pMDI Formulation
Following Accelerated Storage............................................ ............... 178
5 3 Conclusion..^...................................................................... ............... 183
CHAPTER SIX General Discussion
6.1 Discussion.........................................
6.2 Further W ork....................................
184
185 
191
References ...........   193
Appcndii . ...~.......~~.~~»~.~~~.............................................................................. 220
x
List of Figures
Figure 1.1..... A schematic representation o f a typical pMDI................................. 5
Figure 1.2 The effect of particle size on the deposition o f aerosol particles in
the human respiratory tract following inhalation and a 5 sec breath hold 10
Figure 2.1 Schematic illustration of the novel process involved in the
formulation o f a nanoparticulate pMDI...................................................................23
Figure 2.2 Schematic representation of the three common microemulsion
systems adapted from Lawrence and Rees (2000)................................................ 26
Figure 2.3 Schematic illustration o f the chemical structure of
phosphatidylcholine.................................................................................................. 28
Figure 2.4 Pseudotemary phase diagram o f lecithin: Propan-2-ol ( 1:3 (w/w))/
iso-octane/ water at room temperature.................................................................... 42
Figure 2.5 Photographs of stable and unstable biphasic microemulsion
systems....................................................................................................................... 43
Figure 2.6 Scanning electron micrographs o f the freeze-dried SS
microemulsion formulation washed in iso-octane using Method One...............44
Figure 2.7 Scanning electron micrographs o f the freeze-dried SS
microemulsion formulation washed in propan-2-ol using Method One 44
Figure 2.8 Scanning electron micrographs o f the freeze-dried SS
microemulsion formulation washed in iso-octane using Method Two 45
Figure 2.9 Scanning electron micrographs o f the freeze-dried SS
microemulsion formulation washed in propan-2-ol using Method Two 45
Figure 2.10 Calibration curve for the quantification o f SS................................46
Figure 2.11 Sedimentation behaviour o f washed SS pMDI formulations 47
Figure 2.12 Comparison of aerodynamic particle size distribution of two
commercially available SS inhalers and a novel SS formulation........................48
Figure 2.13 A comparison of fine particle fraction (FPF5 g ^  ex-actuator) and 
mass median aerodynamic diameter (MMAD) between two commercially
available SS inhalers and a novel SS formulation.................................................50
Figure 2.14. Scanning electron micrographs of a sol vent-washed freeze-dried 
pMDI formulation containing SS collected at Stage 5 (A and B) and 6  (C and 
D) o f an ACI..............................................................................................................52
Figure 3.1 Schematic diagram of plasmid enhanced green fluorescent protein 
construct ............................................................................................................. 69
Figure 3.2 Restriction map and multiple cloning site o f pEGFP-N 1............. 78
Figure 3.3 Photographs taken of treated Luria agar plates during bacterial
transformation........................................................................................................... 85
Figure 3.4 A typical agarose gel analysis o f the pEGFP-N 1 purification
procedure ............................................................................  86
Figure 3.5 A typical gel electrophoresis image of pEGFP-N 1 after a single
and double digest...................................................................................................... 88
Figure 3.6 Gel electrophoresis image of pEGFP-N 1 after rapid freezing and
lyophilisation in the presence of various lyoprotectants...................................... 89
Figure 3.7 Gel electrophoresis image of pEGFP-N 1 after controlled freezing
and lyophilisation in the presence of various lyoprotectants...............................89
Figure 3.8 A comparison of pDNA lyoprotection conferred using sugars and
freezing rates............................................................................................................. 91
Figure 3.9 A typical gel electrophoresis image o f pEGFP-N 1 after freeze-
drying and spray-drying........................................................................................... 93
Figure 3.10 Scanning electron micrograph of unwashed surfactant-coated 
freeze-dried pDN A formulation containing lecithin. pEGFP-N 1 and sucrose. 94 
Figure 3.11 Scanning electron micrographs o f solvent-washed freeze-dried
pDNA formulation containing pEGFP-N 1 and sucrose.......................................94
Figure 3.12 Scanning electron micrograph of unwashed surfactant-coated 
spray-dried pDNA formulation containing lecithin. pEGFP-N 1 and sucrose.. 95 
Figure 3.13 Scanning electron micrographs of solvent-washed spray-dried
pDNA formulation containing pEGFP-N I and sucrose.......................................95
Figure 3.14 A typical gel electrophoresis image of pEGFP-N 1 before and 
after freeze-drying and solvent-washes.................................................................. 96
Figure 4.1 Schematic illustration of the chemical structure of 1.2
dioleoyioxypropyI-3 (trimethylammonium)- propane methylsulphate
(DOTAP)................................................................................................................ 110
Figure 4.2 Schematic drawing of one haemocytometer counting chamber........
 118
Figure 4.3 Diagrammatic representation o f the production of samples for
subsequent in vitro analysis.................................................................................. 122
Figure 4.4 Schematic representation o f aerosolisation into a cell culture flask
.......................................................................................................... 125
Figure 4.5 A549 cell growth curve with annotations o f the cell growth
phases ............................................................................................................ 129
Figure 4.6 Quantitative gene expression o f pDNA particles using various
ratios o f DOTAP liposome: pDNA.......................................................................130
Figure 4.7 Quantitative gene expression o f pDNA particles....................... 132
Figure 4.8 Gel electrophoresis of unwashed and solvent-washed freeze-dried
pEGFP-N 1 particles actuated from a pMDI formulation..................................133
Figure 4.9 A typical photograph taken of Brilliant Blue pMDI actuated into a
cell culture flask.....................................................................................................134
Figure 4.10 Relative deposition efficiency of Brilliant Blue when actuated 
from a pMDI in the vertical and horizontal orientation relative to the control....
............................................................................................................135
Figure 4 .11 Quantitative gene expression of aerosolised pDNA particles... 136 
Figure 4.12 Photograph of PET pMDI vials containing sol vent-washed freeze- 
dried pEGFP-N 1 particles in HFA 134a propellant with absolute ethanol as a
co-solvent................................................................................................................. 137
Figure 4.13 Scanning electron micrographs of a solvent-washed freeze-dried 
pMDI formulation containing pEGFP-N 1 and sucrose collected at Stage 4 and
5 of an ACI ............................................................................................................138
Figure 4.14 Percentage cell viability' o f cells following aerosolisation of 
treatments................................................................................................................139
Figure 5.1 Quantitative gene expression o f aerosolised DOTAP-pDNA
formulations.............................................................................................................165
Figure 5.2 Typical transmission electron microscopy of aerosolised DOTAP-
pDNA formulations............................................................................................... 167
Figure 5.3 Aerodynamic particle size distribution of transfection competent
aerosolised DOTAP coating canister-pDNA formulation..................................168
Figure 5.4 A comparison of fine particle fraction (FPF4 7 mm ex-actuator)
measured from an ACI, AVS and AAVS using an Airomir® pMDI...............169
Figure 5.5 Aerodynamic particle size o f transfection competent aerosolised 
DOTAP coating canister-pDNA formulation deposited in a validated
abbreviated Andersen viable sampler..................................................................170
Figure 5.6 Quantitative gene expression of aerosolised DOTAP coating
canister-pDNA formulation stored under accelerated storage conditions 172
Figure 5.7 Photograph of plastic PET pMDI vials containing DOTAP 
coating canister-pDNA formulation in HFA 134a propellant with absolute 
ethanol as a co-solvent.......................................................................................... 173
List of Tables
Table 1.1 Particle cut-off diameters using Mark II eight stage ACI at a flow
rate o f 28.3 1/min adapted from Andersen (1985)................................................ 16
Table 1.2 Particle cut-off diameters using Andersen six stage viable sampler
at a flow rate of 28.3 1/min adapted from Andersen (1958)...............................  18
Table 2.1 Chromatographic conditions for the analysis of SS...................... 36
Table 2.2 Comparison of aerosol characteristics, using geometric standard 
deviation (GSD). Extra fine particle fraction (EPF) and emitted dose (ED) per 
actuation, between two commercially available SS inhalers and a novel SS 
formulation. Data are presented as mean ± sd/ % rsd; n = 3............................... 51
Table 3.1 Single digest and double digest components....................................78
Table 3.2 Investigating the maximum quantity o f pDNA that can be
successfully incorporated into the aqueous phase of an optimised
microemulsion system (n = 3)..................................................................................92
Table 3.3 Percentage yield of surfactant-coated pDNA particles recovered 
from the freeze-drying and spray-drying process (mean ± sd; n = 3)................ 92
xiv
Abbreviations
pg Micrograms
til Microlitres
pm Micrometres
AAT a-1 antitrypsin
ACI Andersen-type cascade impactor
ANOVA Analysis of variance
AUC Area under the curve
A VS Andersen viable sampler
AAVS Abbreviated Andersen viable sampler
bp Base pairs
cDNA Chromosomal deoxyribonucleic acid
CFC Chlorofluorocarbons
cm Centimetres
CMV Human cytomegalovirus promoter
CPP Critical packing parameter
CTAB Cetyltrimethylammoniumbromide
DMEM Dulbecco’s Modified Eagle's Medium
DNA deoxyribonucleic acid
DOSPA 2,3-dioleyloxy-A-[2(sperminecarboxaminino)ethyl]-ArJV-
dimethyl- 1 -propanaminium 
DOTAP 1,2 dioleoyloxypropyl-3 (trimethylammonium)- propane
DOTMA N-[ 1 -(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium
chloride
DPI Dry powder inhalers)
dsDNA Double stranded deoxyribonucleic acid
E. coli Escherichia coli
ECD Effective cut-off diameter
ED Emitted dose
EDTA Ethylenediaminetetraacetic acid
EGFP Enhanced green fluorescent protein
EHD Electrohydrodynamic
xv
EPF Extra fine particle fraction
EtBr Ethidium bromide
FEP Fluorinated ethylene propylene
FPF Fine particle fraction
g Grams
GFP Green fluorescent protein gene
GSD Geometric Standard Deviation
HFA Hydrofluoroalkane
HLB Hydrophite-lipophile balance
HPLC High performance liquid chromatography
hr Hours
IS Internal standard
kb Kilobase pairs
1 Litres
LB Luria-Bertani
Lipoplex Lipid-DNA complex
LPD Lipid:protamine:pDNA
MCS Multiple cloning site
mg Milligrams
min Minutes
ml Millilitres
MLV Multilamellar vesicles
mm Millimetres
MMAD Mass Median Aerodynamic Diameter
MMI Marple-Miller impactor
mN Milli Newtons
MOUDI Micro-orifice uniform deposit impactor
MSLI Multi-stage liquid impinger
MTT 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide
n Number of replicates
ng Nanograms
NGI Next generation impactor
xvi
nm Nanometres
o/w Oil-in-water
PBS Phosphate buffered saline
pDNA Plasmid deoxyribonucleic acid
pEGFP-N 1 Plasmid enhanced green fluorescent protein
PEG Polyethyleneglycol
PET Polyethylene terephthalate
Pg Picograms
pMDI Pressurised metered dose inhaler(s)
RNA Ribonucleic acid
rpm Revolutions per minute
RSD Relative standard deviation
sd Standard deviation
sec Seconds
SEM Scanning electron microscopy
SS Salbutamol sulphate
SOC Super optimal broth with catabolite repression medium
SUV Small unilamellar vesicles
T25 25 cm2 angled neck, cell culture flasks
TBE buffer Tris-borate EDTA buffer
TE buffer Tris-EDTA buffer
TEM Transmission electron microscopy
Tg Glass transition temperature
TGLD Task group on lung dynamics
TSI Twin stage impinger
USP United States of America pharmacopoeia
UV-vis Ultraviolet-visible
v/v Volume/volume
VS Andersen six stage viable sampler
w/o Water-in-oil
w/v Weight/volume
w/w Weight/weight
xvii
Chapter One
CHAPTER OMF
Introduction
1
Chapter One
Pulmonary administration of nucleic acids may be particularly relevant for 
treating localised lung disorders of genetic origin (Driskell and Engelhardt 
2003; Birchall 2007). Disease states such as cystic fibrosis and a-1 antitrypsin 
(AAT) deficiency have been favoured as early targets for treatment by inhaled 
gene therapy as both are monogenic disorders, therapy would therefore involve 
correction of the single malfunctioning gene by the introduction and expression 
o f its correct copy to restore normal function (Riordan et al 1989; Brantly et al 
2006). Other possible candidates for pulmonary gene therapy include lung 
malignancies. Gene therapy for lung cancer would involve for example, 
blockade of activated tumour-promoting oncogenes or replacement of 
inactivated tumour-suppressing genes (Zou et al 2007; Choi et al 2008). The 
pulmonary route would also be appropriate for the delivery of inhaled DNA 
vaccines, as this would follow the natural route o f infection for many common 
airborne diseases (Bivas-Benita et al 2005; Lu and Hickey 2007), such as 
measles (Fennelly et al 1999), Mycobacterium tuberculosis (Bivas-Benita et al 
2004) and respiratory syncytial virus (Harcourt et al 2004). The advantage of 
gene therapy includes its potential for treating diseases for which there is no 
effective treatment to date, such as cystic fibrosis (Riordan 2008; Griesenbach 
and Alton 2009). Additionally, gene therapy offers the ability to selectively 
recognise molecular targets. This specificity o f action offers the possibility for 
reduced toxicity and side effects (Patil et al 2005). Aerosolised gene therapy 
provides a direct, non-invasive means for targeted delivery to the lung, with the 
potential for delivering a high dose to the target site of pulmonary based 
disorders (Birchall 2007).
The success of therapeutic strategies using genetic material depends on the 
efficiency o f systems for the delivery of nucleic acids into the target cells. 
Whilst it is established that nucleic acid therapy can correct genetic defects in 
diseased cells (Rich et al 1990), cellular uptake o f naked deoxyribonucleic acid 
(DNA) in its native form remains relatively inefficient (Zabner et al 1997; 
Remaut et al 2006). Thus, therapy is a formulation and delivery quandary 
where success requires optimisation of both transfection and drug delivery
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strategies. As a consequence, gene transfer vectors are employed to promote 
cellular uptake and processing of the nucleic acid cargo (Remaut et al 2006; 
Davies et al 2008; Jiang et al 2008). Gene transfer vectors fall into two groups, 
viral gene vectors and non-viral gene vectors.
Viruses have the natural ability to infect cells efficiently and consequently a 
number of recombinant viruses, which carry the therapeutic chromosomal 
DNA within their genome, have been exploited for delivering genes into 
eukaryotic cells (Kay et al 2001). Examples o f such viral vectors include the 
lentivirus (Limberis et al 2002), adenovirus (Perricone et al 2001), and adeno- 
associated virus (Moss et al 2004, 2007). Although viral gene delivery systems 
are often very efficient at stimulating cell transfection and can be modified to 
reduce both their pathogenicity and ability to replicate, they still face inherent 
safety and immunogenicity issues and are sometimes inappropriate for repeated 
use (Thomas et al 2003).
As an alternative, non-viral gene vectors employ synthetic carriers that 
complex with plasmid DNA (pDNA) to form particulates that are generally 
regarded as safer and less immunogenic (Li and Huang 2007), although not as 
efficient as viral vectors (Ferrari et al 2003; El-Aneed 2004). In this category of 
non-viral agents, cationic lipids and liposomes have demonstrated proof-of- 
principle for gene transfer to the airway for over two decades (Stribling et al 
1992; Alton et al 1993; McDonald et al 1998). Whilst impressive results have 
been achieved in some animal models including mice (Alton et al 1993; Hyde 
et al 1993). rats (Rosenfeld et al 1992; Logan et al 1995), rabbits (Canonico et 
al 1994), monkeys (McDonald et al 1998) and pigs (Cunningham et al 2002), 
non-viral gene transfer has yet to deliver a clear therapeutic benefit in human 
studies. For example, although correction o f the chloride transport defect in 
cystic fibrosis has been demonstrated to some extent in a number of clinical 
trials (Alton et al 1999; Moss et al 2007), the level of effect has been found to 
be variable, usually lasting for less than 15 days (Hyde et al 2000; Ruiz et al 
2001). Clinical trials using gene therapy have also been undertaken in an
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attempt to restore normal AAT function. This involved either nasal instillation 
o f the AAT gene with a cationic liposome (Brigham et al 2000), or 
intramuscular injection of the gene with a viral vector (Brantly et al 2006). As 
with the cystic fibrosis trials, although proof-of-principle of successful gene 
expression has been demonstrated, there was a notable lack of significant 
functional correction.
It is accepted, therefore, that the development of more efficient vectors is 
essential for the progression of gene delivery science towards the clinic (Ferrari 
et al 2002; Moss et al 2007; Ratjen 2008). Equally, however, the 
administration method selected to deliver the therapeutic material to the 
cellular target is of paramount importance, yet is often overlooked. The 
efficiency o f delivery to the cell targets, the avoidance of biological barriers 
and clearance mechanisms (Agu et al 2001), the physical and chemical 
durability of the nucleic acid cargo during delivery (Birchall 2007) and the 
manageable dose are all critical parameters that require optimisation (Robinson 
eta l  2000 ).
1.1 Pulmonary Delivery Devices
Pulmonary drug delivery devices can be broadly classified into three main 
categories; (i) Nebulisers convert aqueous drug solutions or micronized 
suspensions into aerosols by the use o f compressed air or ultrasonic energy, (ii) 
Dry powder inhalers (DPI) deliver solid aerosolised particles o f the drug, 
produced most commonly from the action of the patient inhaling deeply with 
the inspiratory' air flow passing through a powder mixture of micronised drug 
and a carrier such as lactose, (iii) Pressurised metered dose inhalers (pMDI) 
produce aerosolised drug from the evaporation of propellant.
pMDI systems, the delivery method utilised in this thesis, typically contain a 
drug formulated as a solution or suspension within a propellant or blend of 
propellants maintained under pressure as liquefied gases. The basic 
components of a pMDI inhaler include a canister, a metering valve and
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actuator (Figure 1.1). The canister is sealed by the metering valve, the stem o f 
which sits in the body o f the actuator. On depression o f the metering valve 
stem, the metering chamber undergoes a pressure drop due to exposure with 
atmospheric pressure. This initiates the propulsion o f a fixed volume o f 
formulation from the metering chamber into the expansion chamber, where the 
propellant flash boils causing a mixture o f  vapour and liquid to form before 
passing through the actuator spray orifice. The aerodynamic shear between the 
liquid and vapour phases o f the mixture as they exit the spray orifice result in 
the formation o f droplets (Clark 1996). As the aerosolised droplets move away 
from the actuator, the heat o f the surrounding air causes the propellant to 
evaporate leaving aerosolised drug particles.
Canister
Drug suspension or solution
Metering valve
Valve stem Actuator mouthpiece
Expansion chamber Spray orifice
Figure 1.1 A schematic representation o f a typical pMDI. Adapted from 
O'Callaghan and Wright (2002).
1.2 Pulmonary Gene Therapy
To date, most pre-clinical and clinical research studies in pulmonary gene 
therapy have used nebulisers to deliver the gene ‘cargo' in liquid suspension 
(Alton et al 1999; Moss et al 2004, 2007). Nebulisation is, however, an
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inherently inefficient process for the delivery of large charged macromolecules 
(Arulmuthu et al 2007; Lu and Hickey 2007) due to; adhesion o f the 
formulated therapeutic agent to the device components, large residual dead 
volume, limitations on suspension concentration without causing precipitation, 
chemical degradation through high shearing forces (Birchall et al 2000; Lentz 
et al 2006a; Arulmuthu et al 2007) and evaporation (Hyde et al 1993).
Conventional jet and ultrasonic nebulisers have both been reported to 
extensively damage naked pDNA due to the shearing forces generated on 
creation of the aerosol (Kleemann et al 2004; Lentz et al 2005; Lentz et al 
2006a). Relatively newer nebuliser technologies have claimed greater pDNA 
aerosolisation efficiency (Davies et al 2005). Aerosolisation, based on 
electrohydrodynamic (EHD) delivery for example, has been found to cause no 
detectable pDNA degradation or loss in transfection efficiency in plasmids up 
to 15 kb in size (Davies et al 2005; Lentz et al 2006b). Additionally the 
eFlow<8> electronic nebuliser has also shown potential for delivering nucleic 
acids (Bitterle et al 2006). Whilst these encouraging new generation nebuliser 
technologies are under development, DFls have shown promise in gene 
delivery. Aerosolised gene based DPI formulations have been shown to 
produce powders of a respirable size range whilst maintaining significant in 
vitro transfection (Li et al 2005a; Li and Birchall 2006). However, DPI 
formulations can succumb to hygroscopic and agglomeration issues which can 
result in reduced inhaler performance, drug degradation and changes in the 
particle size distribution (Byron 1990).
pMDls offer a sparsely investigated alternative to nebulisers and DPI. Potential 
advantages of pMDIs over other pulmonary delivery systems include their 
portability, low cost, rapid drug administration and disposability (Dolovich et 
al 2005). Many doses can be stored in a relatively small canister and the 
metering valve ensures reproducible dose delivery. pMDIs offer a more 
convenient alternative to nebulisers, especially for therapies requiring repeated 
administration.
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To date, there has been very little published research on methods for 
incorporating pDNA into pMDIs. Brown and Chowdhury (1997), demonstrated 
that pDNA, lyophilised in the presence of a both non-ionic (Tween 40) and 
ionic surfactant (lipofectin or lipofectamine), could be incorporated into a 
metered-dose inhaler resulting in suspended pDNA particles in dimethylether 
propellant. In addition, they demonstrated that gene expression could be 
obtained in the lungs of mice following exposure to the aerosolised pDNA 
formulation (Brown and Chowdhury 1997). Clearly, further investigations in 
this area are warranted.
13 Macromolecule Particle Preparation Methods
Macromolecule particles have been prepared for DPI or pMDI systems using a 
variety o f methods used to dehydrate the formulation including; spray-drying 
(Li and Seville 2009), freeze-drying (Maitani et al 2008), spray freeze drying 
(Maa et al 1999) and supercritical drying (Bustami et al 2003). However, 
although a variety of methods are available, macromolecule powders are 
generally manufactured using one of two methods;
Spray-drying, a one step process, involves the atomisation of a liquid sample 
into a spray of droplets and evaporation of the droplets using hot air conditions 
to form dried particles. The process of spray-drying has been used in the food 
industry to prepare spices and flavourings. In the context of the pharmaceutical 
industry, spray-drying has been applied to the preparation of dry powder 
antibiotics (Broadhead et al 1992). This process has attracted some interest as a 
technique to prepare macromolecules such as proteins (Maa et al 1999; Liao et 
al 2005) and DNA for inhaled therapy (Li et al 2005a). Spray-drying has been 
found to offer potential advantages as the process has been shown to generate 
stable, efficient and potentially respirable protein and DNA/lipid powders 
(Seville et al 2002; Colonna et al 2008; Li and Seville 2009). However, large 
quantities o f the drug are required to produce a sufficient powder yield, leading 
to high costs (Bosquillon et al 2004; Li et al 2005a). There is also potential for 
shear-induced and thermal degradation of macromolecules (Mumenthaler et al
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1994; Stahl et al 2002).
Freeze-drying, also known as lyophilisation, is a dehydration process which 
comprises three stages, freezing, primary drying and secondary drying. Briefly, 
the process of freeze-drying involves initially freezing the sample often by 
submersion into liquid nitrogen. Following freezing the sample is then dried by 
applying temperatures and pressures to promote sublimation and subsequent 
removal of solvent from the solid phase directly into the gaseous phase.
In the past, the process of freeze-drying has been used in the food industry to 
prepare instant coffee and preserve foods such as dried fruit. In the context of 
the pharmaceutical industry, freeze-drying is the most commonly used method 
to increase the shelf life of injectables such as vaccines by dehydrating the 
samples which can be later reconstituted prior to use (Amorij et al 2008; Prego 
et al 2010 ).
Freeze-drying is a commonly employed manufacturing strategy for 
thermolabile macromolecules. It is particularly suited to the preparation of 
thermolabile powders as the process avoids denaturation caused through 
heating the thermolabile product, by working on the principle of sublimation 
using low temperatures and reduced pressures (Seville et al 2002; Prego et al 
2010).
The method of freeze-drying has been used to prepare macromolecules such as 
proteins for inhaled therapy (Brown and George 1997; Williams III and Liu 
1999; Nyambura et al 2009a, b). More recent studies have shown lyophilised 
DNA/lipid systems, in the presence of a lyoprotectant, to preserve their 
physicochemical properties and in vitro transfection activity after rehydration 
(Seville et al 2002; Maitani et al 2008).
However, lyophilised powders are often found to be unsuitable for pulmonary 
delivery due to inadequate control of particle size distribution achieved during
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the freeze-drying process (Seville et al 2002). Further processing using a 
milling step, necessary to render particles into dimensions suitable for 
inhalation, is potentially damaging to macromolecules due to localised heat 
generation and destructive of the solid state properties of many 
pharmaceuticals (Shoyele and Cawthome 2006; Mumane et al 2008).
13.1 Preparation of Particles for pMDI
The lyophilisation technique has been previously reported to produce particles 
outside the respirable size range. Dickinson et al (2001), however, proposed an 
alternative approach, comprising a lyophilisation step, to produce nanoparticles 
suitable for incorporation into pMDI systems. Their nanotechnology process 
utilised the nanoparticle size range of water droplets dispersed in the oil phase 
of a reverse microemulsion as a ‘template’. These swollen reverse micelles 
containing a low molecular weight drug were then reduced to surfactant-coated 
nanoparticles using the process of lyophilisation. The technology proposed by 
Dickinson et al (2001) offers potential advantages as it is able to ‘capture the 
microemulsion template, dehydrate and form the nanoparticle in one step’ 
without the use of additional milling steps. This technique has a relatively low 
risk of toxicity, is ideal for formulating thermolabile drugs for the reasons 
mentioned earlier and offers the potential for industrial scale-up and 
development.
More recently the lyophilisation of carefully prepared emulsions has been used 
to formulate macromolecules into nanoparticles suitable for pMDI systems 
(Nyambura et al 2009a, b). However, emulsions inherently require a larger 
input o f energy to form than microemulsions (Schulman and Cockbain 1940; 
Capek 2004). The energy input in the form of mechanical agitation required to 
prepare emulsions can expose macromolecules to high shear stress with the 
potential for their degradation. This limitation is not encountered when 
working with microemulsions which spontaneously form thermodynamically 
stable systems (Gillberg et al 1970). For these reasons, the process proposed by 
Dickinson et al (2001) is worthy of further investigation to ascertain its
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potential in preparing macromolecule nanoparticles, such as pDNA, suitable 
for incorporation into pMDI systems. Such investigations were carried out in 
this thesis.
1.3.2 Nanoparticles
Nanoparticles are generally regarded as colloidal particles which range in size 
from 10 nm to 1000 nm. They offer the potential to act as carriers for 
macromolecular drugs or biologically active materials which can be 
encapsulated, entrapped, dissolved or attached to the nanoparticle (Dickinson 
et al 2001; Grenha et al 2005; Cui et al 2006; de Martimprey et al 2009).
Particle size, density and hence aerodynamic diameter play a crucial role in 
governing the particle deposition within the respiratory tract (Figure 1.2) (Task 
group on lung dynamics 1966; Taylor and Kellaway 2001). Research has 
shown that as the particle size decreases the likelihood of deep lung penetration 
increases (Task group on lung dynamics 1966), and so it would follow that 
nanoparticles offer a great potential for improved pulmonary delivery. In fact, 
such properties have already been exploited as nanoparticles have been 
proposed for use as radiolabelled aerosols in lung ventilation scanning, where 
they offer deep penetration in the lung (Burch et al 1986).
1<XH
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—  Airways
—  Mouth and throatij
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Fine particles
are exhaled
Figure 1.2 The effect of particle size on the deposition of aerosol particles in the 
human respiratory tract following inhalation and a 5 sec breath hold. Adapted 
from Patton and Byron (2007).
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However although smaller particles can penetrate deeper into the lung, the 
effect of exhalation plays an important role on particle deposition (Figure 1.2). 
The utility of pulmonary delivered nanoparticles can therefore be hindered 
because of their low inertia, due to their small dimensions and mass, preventing 
the particle from depositing and making the particles prone to exhalation. The 
TGLD (Task group on lung dynamics 1966) reported dust particles ranging 
from 2-3 pm diameter have higher deposition values than smaller particles 
ranging from 0.2-0.5 pm. The work conducted by the TGLD emphasises that 
when designing a formulation, a balance between particle size and the effects 
of exhalation is required.
Nevertheless nanoparticles do offer potential advantages for achieving 
prolonged drug deposition in the alveolar region of the lung. A reason for this 
being that alveolar macrophages, which are responsible for engulfing ‘foreign 
substances’, can often reduce the particle retention time in the alveolar region. 
However, as phagocytic activity has been reported to decrease for particles 
smaller than 1 pm in size (Makino et al 2003), nanoparticles offer the potential 
of deep lung penetration, reduced macrophage uptake and potentially increased 
lung retention time.
Although the use of nanoparticles for inhalation offers significant 
advantageous, there is growing concern regarding the potential toxicity of these 
particles. It has been suggested that some nanoparticles are more toxic than 
their larger chemical forms due to the increase in their surface area leading to a 
greater biological activity (Donaldson et al 2000; Oberdorster 2000). The 
mechanism of action of nanoparticles in the lung is yet to be fully understood. 
Reports have suggested that poorly soluble nanoparticles such as ultrafme 
polymer fumes and asbestos retained in the lungs can cause oxidative stress, 
due to the presence of free radicals on the nanoparticles surface or by 
triggering the influx of defence cells and the release of various mediators such 
as chemokines and cytokines, leading to inflammation, fibrosis and cancer 
(Maynard and Kuempel 2005; Muller et al 2006). However, it is important to
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note that toxicity data available so far on inhaled nanoparticles does not 
primarily concern therapeutic molecules and, therefore, is not directly 
applicable to inhalation therapies (Oberdorster et al 2005; Rogueda and Traini 
2007a).
1.4 Particle Sizing
Particle sizing of aerosolised nanoparticle formulations is important for 
predicting pulmonary deposition. There are a variety of techniques available 
for aerosol particle sizing analysis in the pharmaceutical industry some of 
which are based on light scattering or inertial impaction.
Laser diffraction, a light scattering technique, can offer a rapid particle size 
analysis of aerosolised formulations (Ziegler and Wachtel 2005; Mitchell et al 
2006). However, this technique has been criticised as it quantifies the droplet 
size distribution without reference to the drug mass content within the droplets 
of aerosolised suspensions (de Boer et al 2002; Mitchell et al 2006).
Inertial impaction techniques, however, directly measure aerodynamic particle 
diameter. The aerodynamic particle diameter is considered a relevant parameter 
used to indicate the likely deposition of a particle in the respiratory tract as it 
takes into account the influence of particle size, shape and density (Mitchell 
and Nagel 2003). The aerodynamic diameter of a particle is defined as the 
diameter o f a sphere with unit density (p = 1), having the same terminal settling 
velocity in still air as the particle in consideration;
D A = D s x  pp 05 
Where DA = Aerodynamic diameter; Ds = Stokes diameter; 
pp = particle density
Inertial impactors, which are used to measure the aerodynamic particle 
diameter, are made up of a throat (and induction port) and one or more stages 
which contain particle collection plates. During testing, aerosol clouds
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discharged from an inhaler are drawn through the impactor, with the aid of a 
vacuum set at a fixed flow rate which is connected to the outlet of the impactor. 
Impaction techniques rely on the separation of particles present in the aerosol 
plume by differences in their inertia. Once the inhaler is actuated, the 
aerosolised particles generated become entrained into the air stream. Large 
particles are likely to become disentrained and impact on the throat. The 
aerosol cloud is then drawn through successively smaller jets and at 
progressively increasing velocities, projected towards the adjacent impaction 
stages. As the larger particles at any particular velocity have greater inertia 
they are unable to remain entrained in the diverging air stream, caused by the 
90 degree geometry between air-jet and collection plates and they impact on 
the plate. Smaller particles with a lower inertia remain in the air stream until 
their velocity increases and their inertia overwhelms entrainment. As the 
velocity of these smaller particles increases further down the impactor, the 
smaller particles begin to impact on the plates. Although the term impactor is 
reserved for instruments where particles impact on a dry impaction plate and 
the term impinger is used if the collection surface is liquid, the general 
principal of inertial impaction described above applies to both types of 
instruments.
A variety of impaction apparatus are available which include the twin stage 
impinger (TSI), multi-stage liquid impinger (MSLI), Marple-Miller impactor 
(MMI), next generation impactor (NGI), Micro-orifice uniform deposit 
impactor (MOUDI), Andersen cascade impactor (ACI) and Andersen viable 
sampler (AVS). Some of these apparatus are mentioned in more detail below.
The TSI comprises of a throat and two impingement chambers. Prior to testing 
7 ml of solvent is dispensed into the upper impingement chamber and 30 ml 
into the lower chamber. The TSI divides the emitted dose from an inhaler into 
respirable and non-respirable fractions. During testing the proportion of 
aerosolised particles which impact on the throat and in the upper chamber 
(collectively termed Stage 1) are considered the non-respirable dose, whilst the
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remaining particles which collect in the lower impingement chamber (Stage 2) 
are the respirable dose. After the test is complete, the drug collected in the 
lower impingement chamber is assayed and expressed as a respirable fraction 
of the delivered dose.
The TSI has value as a simple and inexpensive tool which offers the ability for 
rapid screening and quality assessment of aerosol products (Hallworth and 
Westmoreland 1987). However, although the TSI can characterise particles in 
terms of the non-respirable and respirable fraction, the apparatus is unable to 
provide particle size distribution data as more impaction stages are required.
Multi-stage cascade impaction apparatus such as the MSLI, NGI and ACI are 
extensively used for the in vitro determination of the aerosol particle size 
distribution and play an important role in product development, comparison of 
formulations and quality control of medicinal inhalers (Mitchell and Nagel
2003).
The MSLI comprises four impingement stages with cut-off diameters ranging 
from 1.7 to 13 pm. The MSLI can be used for determining the aerodynamic 
size distribution of particles aerosolised from pMDI, DPI and nebulisers 
(British Pharmacopoeia 2010b). Each stage of the MSLI, except the final filter 
stage, holds 20 ml of a suitable solvent termed the impaction medium. During 
testing, aerosolised particles will deposit on the impaction medium at various 
stages depending on their aerodynamic diameter based on the principle of 
inertia described earlier. The use of an impaction medium for particle 
collection is deemed advantageous as particle bounce and re-entrainment 
effects, often observed for particles impacting directly onto an impaction plate, 
are minimised (Ranz and Wong 1952). After the test is complete, the drug 
collected at the various stages can be assayed in order to determine the 
formulation particle size distribution profile.
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The NGI comprises three main parts, a bottom frame which holds the cup tray 
containing particle collection cups, the seal body which holds the nozzles with 
successively smaller diameters and the lid that contains the inter-stage 
passageways (British Pharmacopoeia 2010b). The NGI has seven impaction 
stages with the cut-off diameters ranging from 0.23 to 11 pm. During testing, 
aerosolised particles will deposit on the collection cups at various stages 
depending on their aerodynamic diameter. Deposited particles are then 
collected by adding approximately 10 ml of a suitable solvent to each of the 
collection plates.
An AC I is an alternative multi-stage cascade impaction apparatus to the MSLI 
and NGI. The ACI which comprises eight stages can provide a higher 
resolution (or increased number of stages) than both the TSI and MSLI to 
characterise the emitted aerosol and for this reason was the choice apparatus 
for use in this thesis (Marple et al 1998; Vein Oort and Truman 1998).
1.4.1 Andersen Cascade Impactor
The eight stage ACI, is a standard particle sizing device recognised in 
compendia (British Pharmacopoeia 2010b) and by regulatory authorities 
(EMEA 2002). Originally used to measure air-borne dust particles (Andersen 
1966), the ACI is now widely used to characterise the aerodynamic particle 
size distribution of particles and droplets emitted from inhalers.
The Westech Andersen-type Mark II non-viable cascade impactor comprises 
eight stages that are used for separating the spectrum of aerosolised particles 
into two categories above 5.8 pm aerodynamic diameter and six categories 
below 5.8 pm aerodynamic diameter. The eight stages of the compactor each 
contain multiple precision drilled orifices, the holes becoming successively 
smaller from Stage 0 to Stage 7. Each stage holds a removable stainless steel 
plate, the plates used in Stage 0 and Stage 1 having a hole in the centre. Below 
the eight stages is a final filter stage which is used to capture particles which 
have escaped impaction. The eight stages are held together in a stack by three
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spring clamps and sealed at each stage with rubber o-rings. A 90° aluminium 
USP-2 induction port (throat) is located at the top of the ACI and acts as an 
inlet to the device. The effective cut-off diameters for each stage of the ACI 
system are given in Table 1.1.
Table 1.1 Particle cut-off diameters using Mark II eight stage ACI at a flow rate of 
28.3 1/min adapted from Andersen (1985).
Stage
Effective cut-off 
diameter (pm)
0 9.0
1 5.8
2 4.7
3 3.3
4 2.1
5 1.1
6 0.7
7 0.4
The ACI is well suited for characterising aerosols emitted from pMDIs as it is 
an efficient size-separator of particles in the range of 9.0 pm to 0.4 pm (Table
1.1). Particles that impact on the metal plates, found at each stage, can be 
collected and assayed. Testing with the ACI allows for the mass and particle 
size distribution of the aerosolized drug to be determined directly through 
analysis o f each impaction stage.
Although ACIs are frequently used for in vitro particle size analysis, the data 
they generate can be limited when predicting in vivo deposition. Evidence that 
ACIs can be poor simulators of the respiratory tract has been presented by 
superimposing the collection efficiency curves for each stage of a ACI with 
that of the corresponding regions of the respiratory tract (Dunbar and Mitchell
2005). The results showed that the collection efficiency curves for the 
respiratory tract were relatively shallow compared to the ACI stages.
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Parameters such as FPF can, therefore, often overestimate the true percentage 
deposition in the respiratory tract (Newman 1998). The disparity between the 
two sets of data is due to a number of differences. The stages of an ACI are 
more size selective compared to the various regions of the lung. Additionally 
the 90° inlet throat typically used in an ACI has been criticised as failing to 
reflect the ‘complex geometry of the upper airways, which will have a 
significant “filtering” effect on the particles and droplet’ (Miller and Purrington 
1996; Newman 1998). Also ACIs do not simulate the temperature and relative 
humidity that exists in the respiratory tract. Both humidity and temperature are 
known to affect particle deposition, by influencing droplet growth and 
evaporation (Stein and Myrdal 2006). The differences in temperature and 
relative humidity between in vitro and in vivo models can therefore lead to 
inconsistency between the particle deposition data.
ACIs should not be considered as in vitro lung simulators for the 
aforementioned reasons. Nevertheless they can provide information on the size 
of particles based on their aerodynamic diameter which may be indicative of 
the likely deposition of particles in the lung. Additionally ACIs are a useful 
tool in product development where comparisons can be drawn between various 
devices and pMDI formulations’ deposition profiles (Smyth 2003).
1.4.2 Andersen Viable Sampler (AVS)
The A VS offers a possible alternative to the ACI to measure the aerodynamic 
particle diameter of biological aerosols. The six stage A VS was first developed 
in 1958 (Andersen 1958) and was originally designed to measure the 
concentration and particle size distribution of viable aerobic bacteria and fungi. 
As the A VS directly measures aerodynamic particle diameter it is therefore 
able to indicate the likely deposition of biological aerosols in the respiratory 
tract (Mitchell and Nagel 2003). For this reason, this in vitro model has been 
utilised in predicting and assessing the health hazard or infection potential of 
biological aerosols to humans (Wendt et al 1980; Weis et al 2002; Fennelly et 
al 2004).
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The A VS used for particle distribution analysis is available with either six or 
eight stages. The six stage A VS used in this thesis is constructed with six 
aluminium stages used for separating a spectrum of aerosolised particles. The 
sampler is often referred to as a multi-orifice impactor as each stage of the 
sampler contains 400 precision drilled orifices which are successively smaller 
from Stage 1 to Stage 6. Each stage holds a removable petri dish containing an 
impaction medium. The six stages are held together in a stack by three spring 
clamps and sealed at each stage with rubber o-rings. The effective cut-off 
diameters for each stage of the AVS are given in Table 1.2.
Table 1.2 Particle cut-off diameters using Andersen six stage viable sampler at a flow 
rate of 28.3 1/min adapted from Andersen (1958).
Stage
Effective cut-off 
diameter (pm)
1 7.00
2 4.70
3 3.30
4 2.10
5 1.10
6 0.65
To date the use of an AVS for characterising aerosolised particles emitted from 
an inhaler system has not been reported in published work. However the AVS 
offers a number of potential advantages for sizing biological particles such as 
aerosolised pDNA. As the viable sampler is based on particle impingement 
onto a liquid collection surface, it is ideal for collecting particles whilst 
minimising particle bounce and re-entrainment, effects which can be observed 
for particles impacting directly onto an impaction plate (Ranz and Wong 1952). 
Also judicious selection of the impaction media means that aerosolised 
particles can deposit directly into the media used to treat cells during cellular 
gene expression studies, minimising the possibility of sample loss through 
insufficient plate washing a possibility faced with the ACI. The AVS offers 
advantageous over alternative impingers as it comprises a larger number of
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collection stages than for example the TSI and MSLI, offering a higher 
resolution of particle characterisation. Additionally the total volume of 
impaction media used in the AVS (48 ml) is lower than that used in the MSLI 
(80 ml) which is crucial to prevent any dilution effect during quantification of 
deposited pDNA particles using cellular transfection methods.
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1.5 Scope of Thesis
Nebulisers and DPIs are currently the most used devices for aerosolising 
pDNA in pre-clinical and clinical studies. As limitations for both of these 
devices have been reported, the pMDI offers a potential alternative. The 
incorporation of pDNA into a pMDI system for pulmonary administration is a 
sparsely investigated area of research due to the inherent challenges of 
formulating and maintaining pDNA stability. A novel approach to preparing 
pMDI formulations proposed by Dickinson et al (2001) has been demonstrated 
to produce surfactant-coated nanoparticles suitable for incorporation into a 
pMDI system. As this formulation technology has only been proven with a low 
molecular weight drug, this thesis will aim to research the potential of 
developing the technology to formulate surfactant-coated pDNA particles 
suitable for incorporation into a pMDI system. Since the native structure of 
macromolecules is susceptible to damage during processing conditions, 
utilising the nanotechnology process will bring about new formulation 
challenges previously not faced when dealing with small molecular weight 
drugs. The work carried out in this thesis will attempt to address these 
challenges and investigate whether it is viable to aerosolise and deliver 
biologically active surfactant-coated pDNA particles via a pMDI with potential 
for pulmonary gene delivery.
These overall aims of the thesis will be addressed through the experimental 
work divided into the following chapters;
Chapter 2: This chapter will aim to validate, optimise and develop stages of the 
nanotechnology process using a model drug. Investigations will be carried out 
to develop an optimised surfactant microemulsion system based on HLB and 
HFA solubility to confer drug stability and dispersion in a pMDI system. The 
potential for achieving effective pulmonary delivery from the aerosolised 
pMDI formulation will be predicted using an in vitro cascade impaction model.
Chapter 3: The utility of the developed technology will be investigated for
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preparing surfactant-coated pDNA particles. Attempts to maximise pDNA 
integrity during processing through the use of lyoprotectants and freezing rates 
will be explored.
Chapter 4: The feasibility of incorporating surfactant-coated pDNA particles 
into a pMDI system to deliver biologically active pDNA following 
aerosolisation will be examined. The biological efficiency of the aerosolised 
pDNA formulation will be assessed by quantifying gene expression in an in 
vitro cellular model.
Chapter 5: As gene transfer vectors are commonly utilised to promote pDNA 
cellular transfection, this chapter will investigate the feasibility for 
incorporating a transfection agent into the pDNA pMDI formulation and will 
assess formulation stability during storage. Further to this, aerosolised particles 
will be characterised through aerodynamic particle size distribution profiles 
generated using an in vitro cascade impaction model.
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CHAPTER TWO 
Process Optimisation
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2.1 Introduction
A novel process for preparing hydrophilic drug nanoparticles, from small 
molecular weight drugs, suitable for dispersion in hydrofluoroalkane (HFA) 
propellant was originally outlined as a proof-of-principle by Dickinson et al 
(2001). The approach utilised a reverse microemulsion as a ‘template’ (Figure
2.1), where the hydrophilic drug, for example salbutamol sulphate (SS), was 
incorporated into the water phase of a water in oil (w/o) microemulsion. 
Reverse micelles containing the drug were subsequently reduced to solid 
surfactant-coated nanoparticles using lyophilisation, prior to pressure filling 
with HFA 134a propellant into a pMDI. In this chapter we aim to further 
optimise this process and evaluate its potential for achieving effective 
pulmonary drug delivery from pMDIs.
+ h2o
Surfactant
i — l
Dispersion 
in HFA
W/O
Reverse
micelle
Snap freezing
Lyophilisation
NANOPARTICLES
pMDI
Figure 2.1 Schematic illustration of the novel process involved in the formulation 
of a nanoparticulate pMDI.
2.1.1 W/O Microemulsion System
Microemulsions are typically regarded as ‘a system of water, oil and 
amphiphile which is a single optically isotropic and thermodynamically stable 
liquid solution’, as defined by Danielsson and Lindman (1981). Surfactants are 
amphiphilic as they are characteristically made up of two groups, the 
hydrophobic group (tail) and the hydrophilic group (head). When two 
immiscible liquids such as oil and water are added together, any surfactant
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present will reside at the oil/water interface due to its amphiphilic properties 
and will reduce the interfacial tension of the system. The orientation of the 
surfactant will optimise its solvation requirements and the free energy of the 
system overall (Attwood 2008).
Although both microemulsions and emulsions are dispersions of oil and water 
stabilised by an amphiphilic molecule, the two systems should not be confused. 
Microemulsions are only formed when the interfacial tension at the oil/water 
interface is brought to a very low level and the interfacial layer is kept highly 
flexible and fluid (Schulman et al 1959; Shinoda and Lindman 1987). These 
two conditions are usually met by a careful and precise choice of the 
microemulsion components and of their respective proportions. The surfactant 
plays a key role in forming stable microemulsions. If the surfactant molecule 
possesses the correct characteristics such as hydrophile-lipophile balance 
(HLB) (Griffin 1949) (mentioned in more detail on page 26) to match the 
relative oil and water substrates used, the surfactant will reside at the oil/water 
interface; causing a reduction in the interfacial tension to spontaneously form a 
thermodynamically stable microemulsion (Gillberg et al 1970). However in 
order to sufficiently minimise the interfacial tension and form a highly flexible 
stable system, co-surfactants are often used to augment the surfactant 
(Schurtenberger et al 1993). Polar organic liquids such as short chain alcohols 
are incorporated into the microemulsion to reside at the interfacial surfactant 
layer in order to stabilise and facilitate the dispersion of the surfactant along 
the oil-water interface (Shinoda et al 1991; M endoza et al 2009). The co­
surfactant also ensures that the interfacial film is flexible enough to deform 
readily around each droplet by intercalating between the surfactant molecules 
to decrease interactions associated with both the polar head group and the 
hydrocarbon chain (De Gennes and Taupin 1982).
Conversely emulsions are not thermodynamically stable and require a 
relatively large input of energy to form (Schulman and Cockbain 1940; Capek
2004). During dispersion of immiscible liquids, an input of energy, by for
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example mechanical agitation, will eventually cause one immiscible liquid to 
disperse (disperse phase) throughout the other (continuous phase) in the form 
of droplets. The surface free energy of the system, which is dependent on the 
interfacial area and the interfacial tension, is increased by the increase in the 
surface area produced during dispersion (Schulman and Cockbain 1940). If the 
surfactant used is unable to lower the interfacial tension to a degree where the 
system is stable, as in a microemulsion, the droplets will collide with one 
another and coalesce (Boyd et al 1972). Eventually the emulsion will bulk- 
phase separate in order to reduce the interfacial area between the immiscible 
liquids so that the system is in a state o f minimum free energy (Wennerstrom et 
al 1997). Prior to their phase separation, most emulsions will comprise droplets 
with diameters of 0.1-100 pm and are cloudy in appearance, whereas in 
microemulsions the droplet size of the disperse domain is much smaller 
(usually 5-140 nm) resulting in their transparent or translucent appearance 
(Saint Ruth et al 1995; Attwood 2008).
Whether a microemulsion forms an oil-in-water (o/w) or water-in-oil (w/o) 
micelle system is determined by a number of factors including the relative 
volumes of the microemulsion components and more importantly the nature of 
the surfactant. In general, o/w microemulsions are favoured when there is a 
smaller volume of oil than water and w/o systems are favoured in the presence 
of a smaller volume of water. In a system where the volumes of water and oil 
are equivalent, a bicontinuous microemulsion may result (illustrated in Figure 
2.2).
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Oil-in-water Bicontinuous Water-in-oil
microemulsion. microemulsion microemulsion.
Spherical m icelle Reversed m icelle
Figure 2.2 Schematic representation of the three common microemulsion systems 
adapted from Lawrence and Rees (2000). Black head groups ( ) indicate the
surfactant and white head groups ( ^ O  ) indicate the co-surfactant.
The type o f microemulsion system formed has been reported to be related to 
the surfactant hydrophile-lipophile balance (HLB) (Griffin 1949). The HLB is 
a value expressing the simultaneous attraction o f a surfactant for the water and 
oil phases. As surfactants are made up o f both hydrophilic and lipophilic 
regions, it is the balance of the size and strength o f these regions that is termed 
the HLB and assigned a numerical value between the range of 0 to 20 for non­
ionic surfactants. A surfactant that is lipophilic in character will have a low 
HLB and a surfactant that is more hydrophilic will have a high HLB. The 
Bancroft rule states that “The phase in which an emulsifier is more soluble 
constitutes the continuous phase” (Bancroft 1912). Therefore oil soluble 
surfactants which tend to have a low HLB will stabilise w/o systems and 
surfactants with a high HLB will stabilise o/w systems. Although both the HLB 
and Bancroft rule were originally formulated to explain surfactant behaviour in 
emulsions, the applicability o f these rules has also been demonstrated for use in 
determining the system formed in microemulsions (Shinoda et al 1991; 
Ruckenstein 1996).
In addition to HLB, the behaviour o f surfactants has also been rationalised in 
terms o f the critical packing parameter (CPP). The CPP relates to the ability of 
the surfactant to form particular aggregates governed by the geometry o f the 
surfactant (Israelachvilli et al 1976). The CPP can be calculated using the
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following equation:
CPP= v / I m o
Where v = volume of the hydrophobic portion of the surfactant; do =
optimal head group area; / = length of the surfactant hydrocarbon tail.
As the CPP is a measure of the preferred orientation adopted by a surfactant, 
surfactants with a CPP < 1 (larger head group area compared to the 
hydrophobic portion) have a tendency to form o/w microemulsions and a CPP 
> 1 (smaller head group area compared to the hydrophobic portion) have a 
tendency toward w/o microemulsion. Surfactants with a CPP = 1 have a 
tendency to form lamellar structures (Mitchell and Ninham 1981).
Both HLB and CPP can be used to predict the microemulsion system formed 
using the surfactant of choice, lecithin, for the work carried out in this thesis. 
Lecithins, are complex mixtures of phospholipids and fatty acids, but are 
composed mainly of the twin-tailed phospholipid phosphatidylcholine (Figure 
2.3). They are naturally occurring surfactants that form components of the cell 
membrane and are consumed as a normal part of diet. Lecithin is an ideal 
surfactant for this study in the sense that it is relatively non-toxic and has been 
approved for pulmonary administration (Fowler 2006). Although, as it is 
composed of a mixture of lipids there is a degree of batch to batch variation 
which could lead to potential differences in its ability to stabilise a 
microemulsion system (Attwood et al 1992).
Lecithin has a HLB of approximately 8 and favours the formation of w/o 
microemulsions (Griffin 1949; Shinoda et al 1991) which is one of the required 
features for the success of this proposed technology (Figure 2.1). However as 
the twin-tailed surfactant has a CPP close to 1, it tends to form highly rigid 
lamellar structures (Aboofazeli and Lawrence 1993). A co-surfactant such as 
propan-2-ol is often used to enhance the flexibility of the interfacial surfactant 
film, by reducing the interactions between the surfactant molecules (De Gennes 
and Taupin 1982), therefore promoting the formation of a w/o microemulsion.
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Figure 23  Schematic illustration of the chemical structure of 
phosphatidylcholine. Highlighting the hydrophilic head-group and hydrophobic tail- 
group.
The capacity of w/o microemulsions to act as drug carriers of water soluble 
molecules has been reported for a number of delivery routes including topical 
(Chen et al 2006) and ocular (Lv et al 2005; Chan et al 2007). Although the 
possibility for the formation of microemulsions prepared in HFAs for the 
pulmonary route has been explored (Patel et al 2003; Chokshi et al 2009), as 
yet no data has been published on the incorporation of drugs into these 
systems.
The technology proposed by Dickinson et al (2001) (Figure 2.1) utilises the 
microemulsions capability to incorporate water soluble medicament, and the 
nanometre size range of microemulsion droplets to generate surfactant-coated 
drug nanoparticles suitable for aerosolised delivery in pMDI. The use of 
microemulsions to form nanoparticles appropriate for pulmonary delivery is an 
uncluttered area of research with the potential for delivering macromolecules 
(Rogueda and Traini 2007b).
2.1.2 pMDI Formulation Excipients
During the production of surfactant-coated drug nanoparticles (Figure 2.1), 
apart from their role in generating microemulsions, surfactants also play an 
integral role in stabilising the pMDI dispersion. Due to their amphiphilic nature 
surfactants; minimise the adhesion of drug particles to canister walls, stabilise
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drug dispersions and prevent irreversible caking through sterically conferred 
repulsive forces between the surfactant tails which extend into the propellant 
(Vervaet and Byron 1999).
Suitable surfactant for pMDIs should not only have FDA approval of safety but 
also have a HLB that assures propellant compatibility. Selecting such a 
surfactant poses a formulation challenge as, to date, FDA approved surfactants 
are generally only compatible in chlorofluorocarbons (CFC) propellants. CFCs 
are however being phased out in response to concerns raised over their 
detrimental effects on the ozone layer (United Nations Environment 
Programme 2006). Due to this, hydrofluoroalkanes (HFA) propellants have 
been identified and used as an alternative to replace CFCs as they do not 
deplete ozone, are non-flammable and they are considered as non-toxic as the 
CFCs (Alexander and Libretto 1995; Donnell et al 1995). However, although 
they may seem to be a good alternative, HFAs are not a direct replacement for 
CFCs in pMDIs. HFAs are relatively polar compared to CFCs, and have 
insufficient capacity to solubilise low HLB surfactants traditionally used in 
CFC formulations (Blondino and Byron 1998; Vervaet and Byron 1999). As 
most o f the FDA-approved surfactants have a low HLB, such as lecithin and 
oleic acid, they can only be used effectively in HFA propellants containing an 
additional co-solvent excipient such as ethanol which facilitate their dissolution 
(Tzou et al 1997; Smyth 2003).
Apart from improving the solubility of surfactants, ethanol is also known to 
exert an effect on a pMDI formulation as a vapour pressure modifier (Gupta et 
al 2003; Stein and Myrdal 2006). The vapour pressure of a propellant is critical 
in influencing the performance of a pMDI in terms of the aerosol droplet 
velocity and the dose delivery characteristics (Moren 1978; Stein and Myrdal
2006). The presence of a less volatile solvent such as ethanol in a pMDI 
formulation can reduce the propellant vapour pressure to confer pMDI 
formulations which emit a slower velocity plume minimising particle 
impaction at the throat (Gabrio et al 1999). However, a careful balance is
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required as ethanol may cause excessive reduction in the vapour pressure 
resulting in larger droplets which evaporate slowly and tend to impact in the 
upper respiratory tract leading to a decrease in the respirable fraction (Steckel 
and Mtiller 1998; Smyth et al 2002).
The formulation technology previously outlined in this chapter (Figure 2.1) 
will be used to produce salbutamol sulphate (SS) nanoparticles. pMDI 
formulations incorporating these nanoparticles should confer smaller 
aerosolised particle sizes than commercially available SS pMDI which utilise 
micronised SS. In order to assess this, the aerodynamic particle size 
distribution of the novel formulation will be compared against commercial 
formulations Ventolin Evohaler® and Proventil® HFA. The Ventolin 
Evohaler® comprises SS suspended in HFA 134a propellant. Proventil® HFA 
comprises SS in a formulation containing oleic acid surfactant and ethanol co­
solvent.
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2.13 Specific Aims and Objectives of the Chapter
The aim of this chapter is to validate, optimise and develop stages of the 
nanotechnology process originally proposed by Dickinson et al (2001) to better 
understand its technological limitations and determine its potential for the 
effective pulmonary delivery of medicaments from pMDIs. Optimised 
parameters of the technology will be translated into later studies whereby the 
technology will be adapted for delivering pDNA to the lung using a pMDI.
The experimental objectives are to:
1. Use ternary phase diagrams to identify optimised constituent ratios to form 
stable isotropic microemulsions, with a maximum aqueous volume and 
minimum surfactant volume.
2. Incorporate salbutamol sulphate (SS), as a model drug, into surfactant- 
coated nanoparticles.
3. Develop washing procedures to remove excess surfactant from the 
surfactant-coated freeze-dried SS particles.
4. Characterise the engineered nanoparticles prior to incorporation into a 
pMDI and after aerosolisation from a pMDI, using scanning electron 
microscopy (SEM).
5. Quantify the ratio of SS and surfactant present in solvent washed freeze- 
dried SS particles using a high performance liquid chromatography (HPLC) 
assay method.
6. Characterise solvent-washed freeze-dried SS particle dispersion behaviour 
in pMDI canisters.
7. Determine deposition patterns of aerosolised solvent-washed freeze-dried 
SS particle pMDI formulations and compare with commercially available 
SS pMDI formulations.
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2.2 Materials and Methods
All reagents were used as received and were purchased from Fisher Scientific 
UK Ltd. (Loughborough, UK) unless otherwise stated.
Deionised water was obtained from an Elga reservoir (High Wycombe, UK). 
Iso-octane (2,2,4 trimethylpentane 99+ %) and Bamethane sulphate were 
purchased from Sigma-Aldrich Ltd. (Poole, UK). Micronised salbutamol 
sulphate (mean diameter of 50% particle population < 3.07 pm) was purchased 
from Micron Technologies Ltd. (Dartford, UK). Ventolin Evohaler® was 
purchased from AAH Hospital Service (Coventry, UK). Proventil® HFA was a 
generous gifts from 3M Healthcare Ltd. (Loughborough, UK). HFA 134a 
(Zephex 134a) was a generous gift from INEOS Fluor Ltd. (Runcorn, UK). 
Liquid nitrogen was purchased from BOC Gases Ltd. (Manchester, UK).
2.2.1 Optimisation of Microemulsion Formulation Parameters
Water-in-oil microemulsions were prepared at ambient temperatures using 
distilled water (aqueous phase), egg lecithin (~ 90%) in propan-2-ol (1:3 w/w) 
(stabilising surfactant system) and iso-octane (organic phase). Iso-octane was 
added to the surfactant: co-surfactant mixture in a 15 ml centrifuge tube and 
gently agitated using a vortex mixer. Distilled water was then pipetted into the 
centrifuge tube containing the surfactant-iso-octane mixture. The formulation 
was inverted five times to completely mix the components. Nineteen 
formulations were investigated with component proportions ranging from; 
surfactant system 36% to 71% (w/w), organic phase 7% to 41% (w/w) and 
aqueous phase 6% to 32% (w/w). The water content was sequentially increased 
to determine the phase boundary between a clear micellar (isotropic) phase and 
an opaque (non-isotropic) multiphase system. Samples that were potentially 
isotropic were visually inspected at 10 min and 24 hr, after the final water 
addition, to ensure that equilibrium had been fully established. Any visual 
changes over this period were noted. A pseudotemary phase diagram was 
constructed to show the phase boundary and identify optimum microemulsion 
formulation constituent ratios.
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2.2.2 Preparation of Nanoparticles
As the preparation of pDNA is a labour intensive and relatively expensive 
process, these preliminary studies used commercially available salbutamol 
sulphate (SS) as an accessible and easily identifiable model drug.
Drug-loaded microemulsions were prepared as outlined in Section 2.2.1. SS, to 
produce a concentration previously successfully incorporated into a 
microemulsion system (Dickinson et al 2001), (17% w/v) was added to the 
aqueous phase and agitated using a vortex mixer to form a solution prior to 
addition into the surfactant-iso-octane mixture of an optimised microemulsion 
system. The centrifuge tubes containing SS-loaded microemulsions were 
sealed with perforated Parafilm and snap-frozen by submersion in liquid 
nitrogen. Snap-frozen microemulsions were placed into a tray filled with dry 
ice in order to maintain their solid state, ensuring sublimation rather than 
melting occurred, and lyophilised for 24 hr using a Heto Drywinner freeze- 
drier (Heto-Holten, Alleroed, Denmark) with the condenser chamber set at 
-110°C.
2.23 Microscopic Characterisation of SS Nanoparticles
Excess surfactant in the microemulsion and resulting particulates could 
potentially cause particle aggregation, hinder surface morphology 
characterisation of resulting particles and potentially adversely affect 
particulate dispersibility and physical stability in a pMDI. Methods were 
therefore developed to remove excess surfactant from the formulation.
Method One
A sequential wash method, adapted from Dickinson et al (2001) was used to 
remove excess surfactant from the freeze-dried SS formulation. 300 pi of iso­
octane or propan-2-ol was pipetted into microcentrifuge tubes containing 
lyophilised microemulsions (0.5 g). The samples were centrifuged at 
13,000 rpm for 10 min using a Sanyo MSE Micro Centaur microcentrifuge 
(Sanyo Electric Co., Ltd., Hertfordshire, UK). The resulting supernatant was
33
Chapter Two
gently removed using a pipette ensuring minimal disturbance of the pellet. The 
pellet was resuspended with either 300 pi iso-octane or propan-2-ol and 
recentrifuged. This wash cycle was repeated a total of six times. In order to 
remove residual solvent, microcentrifuge tubes containing washed lyophilised 
SS were sealed with perforated Parafilm, snap-frozen by submersion in liquid 
nitrogen and lyophilised for 24 hr using a Heto Drywinner freeze-drier (Heto- 
Holten, Alleroed, Denmark) with the condenser chamber set at -110°C.
The extent o f removal of excess surfactant from the iso-octane washed samples 
was compared against propan-2-ol washed samples by visual assessment using 
scanning electron microscopy (SEM).
Solvent-washed SS formulations were placed onto double-sided carbon tape 
mounted on SEM aluminium stubs using a microspatula. Samples were sputter 
coated with gold (gold sputter coater, EM Scope, Kent, UK), to form a thin 
conductive layer, before being viewed using a Philips XL-200 Scanning 
Electron Microscope (TEI Company, Eindhoven, The Netherlands).
Method Two
As in Method One 300 pi of iso-octane or propan-2-ol was pipetted into 
microcentrifiige tubes containing lyophilised microemulsions (0.5 g). At this 
stage an additional vortexing step was incorporated into the wash cycle. 
Samples were gently agitated using a vortex mixer for 5 min in an attempt to 
maximise dispersion of excess surfactant into the solvent. Post-vortexing, 
samples were then centrifuged to form a pellet which was subsequently 
resuspended with 300 pi iso-octane or propan-2-ol as outlined in wash Method 
One. This wash cycle was repeated a total of six times. Samples were then 
prepared for freeze-drying and visualised using SEM as outlined in Method 
One.
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2.2.4 HPLC Assay to Quantity SS
A HPLC assay was used to quantify SS present in a specific quantity of the 
sol vent-washed freeze-dried SS sample and thus determine the SS: surfactant 
ratio. Sol vent-washed freeze-dried SS particles were assessed for SS: surfactant 
ratio using a calibration curve constructed from data generated from HPLC 
assays using known dilutions of micronised SS.
Preparation of Standard Solutions:
Internal Standard
A fresh stock of internal standard (IS) solution was prepared consisting of 
bamethane in methanol 400 ml, made up to 1000 ml with de-ionised water to a 
final concentration of 8 fig/ml. The internal standard was used to prepare a 
series of micronised SS dilutions from which a calibration curve would be 
generated.
A reference internal standard was also prepared containing equal 
concentrations of SS and bamethane (8 pg/ml). The reference internal standard 
was periodically injected during HPLC assays to ensure the assay remained 
consistent.
Mobile phase
A fresh stock of mobile phase was prepared consisting of 1-heptane sulphonic 
acid 0.83 mg/ml in deionised water to form an aqueous buffer. The aqueous 
buffer solution was adjusted to pH 3.2 using drop-wise additions of glacial 
acetic acid. Methanol was mixed into the aqueous buffer at a 40:60% v/v 
methanol: buffer ratio. The mobile phase was then filtered though a 0.2 pm 
Whatman® nylon membrane filter (Whatman International Ltd., Maidstone, 
UK).
A calibration curve was constructed from micronised SS diluted in 10 ml IS to 
form a series of final concentrations ranging from 0.2-1 mg/ml. Samples were 
analysed using a HPLC system model p 2000 pump, AS 3000 autosampler, UV
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2000 detector and Chem Quest® 4.1 software (Thermo Electron Corporation, 
Altrincham, UK) under the assay conditions outlined in Table 2.1, using a 
Genesis C l8 chromatography column 120 A 4 um 15 cm x 4.6 mm (Grace 
Vydac, Illinois, USA).
Solvent-washed freeze-dried SS was diluted in 10 ml IS to form a final 
concentration of 1 mg/ml and assayed using the same HPLC method as the 
micronised SS (Table 2.1). The concentration of SS in the sample of solvent- 
washed freeze-dried SS particles was calculated by using the linear equation 
generated from the calibration curve.
Table 2.1 Chromatographic conditions for the analysis of SS.
Condition Parameter
Flow rate of mobile phase 1 ml/min
Injection volume 100 pi
UV Wavelength 278 nm
Retention time: SS 6 min
Bamethane 10 min
2.2.5 Production of SS pMDI Formulations
A quantity of solvent-washed lyophilised SS particles, sufficient to deliver 
100 pg of salbutamol, ex-valve (including a 10% overage to compensate for 
potential SS losses that could occur through factors such as drug adherence to 
the canister) was added directly to fluorinated ethylene propylene (FEP) coated 
aluminium canisters (3M Drug Delivery Systems, Loughborough, UK) and 
dispersed in absolute ethanol a co-solvent (8% v/v) using a vortex mixer. 
Spraymiser™ 50 pi retention valves (3M Drug Delivery Systems, 
Loughborough, UK) were crimped onto the aluminium canisters and 6 ml HFA 
134a was pressure filled through the valve using a Pamasol® semi-automatic 
filling and crimping machine model P2005/2 (Pamasol Willi M&der AG, 
Pfhffikon SZ, Switzerland). The formulation was dispersed in the propellant by 
vortexing the canister for 5 min. The dose of SS expelled per actuation from
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the washed SS formulation was selected to permit comparison with marketed 
SS formulations (Ventolin Evohaler® and Proventil® HFA) during the 
impactor studies (Section 2.2.6).
Washed SS formulations were also prepared in plastic polyethylene 
terephthalate (PET) pMDI vials (3M Drug Delivery Systems, Loughborough, 
UK), for visual assessment of physical stability and dispersion homogeneity. 
pMDI vials were stored at room temperature with visual observation at 1 min 
and 1 month.
2.2.6 Assessment of SS pMDI Formulations
Aerodynamic Particle Size Distribution profiles were generated for three SS 
formulations; the washed SS formulation (as above), Ventolin Evohaler® and 
Proventil® HFA so that a comparison of the novel pMDI formulation could be 
made with commercially available pMDIs.
Aerosol performance of the three formulations was assessed using an eight 
stage non-viable Andersen-type cascade impactor (ACI) (Westech Instrument 
Services Ltd., Bedfordshire, UK) fitted with a 90° aluminium USP-2 induction 
port (throat), to act as an inlet to the device, and operated at 28.3 1/min. As 
impaction results may be affected by variations in temperature, operator 
technique and the impactor used (Stein 1999) these studies were carried out in 
a 20°C temperature controlled room, using the same apparatus and a standard 
operating procedure. The ACI stainless steel collection plates were evenly 
spray-coated with 2% v/v polyethylene glycol (PEG) in acetone to reduce 
particle bounce and re-entrainment. Once coated the plates were carefully 
placed into the stages of the ACI using tweezers. A Whatman® glass 
microfiber filter (Whatman International Ltd., Maidstone, UK) was placed into 
the filter holder.
Prior to testing, each canister was initially primed by actuating five shots to 
waste using an actuator with a 0.25 mm orifice diameter of (3M Drug Delivery
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Systems, Loughborough, UK). The initial priming actuations were required to 
eliminate the low dose first-spray effect (Cyr et al 1991). Canisters were also 
assessed for valve functionality issues such as blockages. Valve functionality 
was monitored by calculating the canister shot weight from weight 
measurements taken of canisters before and after testing.
During priming and testing pMDIs were shaken for 5 sec between actuations, 
as specified in compendia procedures (British Pharmacopoeia 2010b). Once 
primed, each inhaler was weighed and fixed into the testing position using a 
rubber mouthpiece attached to the throat of the ACI. The vacuum pump was 
then turned on and the canister was depressed and held for 5 sec. Two 
actuations were delivered from each canister, and three canisters of each 
formulation were used for this assessment (n = 3). Following actuation, the 
canisters were then re-weighed. The number of actuations used in this 
assessment were minimised as close to the patient dose as possible as 
recommended by the European agency for the evaluation of medicinal products 
(EMEA 2002). Flow through the ACI was maintained for an additional 30 sec 
following the final actuation.
Once the pMDI formulation had been actuated the ACI was disassembled and 
the amount of SS was recovered quantitatively from the components of the 
ACI using a washing step. The collection plates and filter were each placed in 
separate sterile petri dishes and washed with 10 ml of IS (prepared in Section
2.2.4) using a pipette. The actuator and inlet stage (inlet and Stage 0) were each 
washed in 25 ml IS and the throat was washed in 50 ml of IS. The differences 
in the volumes of IS used was accounted for when quantifying the SS 
recovered from the various points of ACI. Each piece of apparatus was 
vortexed, using a minishaker, in its corresponding volume of IS to ensure 
impacted SS had been effectively removed from the apparatus. Washings were 
then placed into 2 ml mini vials and sealed with a septa and screw lid. A 
Minisart® single use filter unit (0.2 pm) non-pyrogenic (Sartorius Stedim UK 
Ltd., Surrey, UK) attached to a syringe was used to remove the washings from
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the filter stage. This was to ensure that washings were free from any fibres 
picked up from the filter. The washings were then assessed for SS 
concentration by the HPLC-UV method outlined in Section 2.2.4.
Several parameters were derived from the ACI deposition data and used to 
quantify inhaler performance;
The emitted dose (ED) (pg) is the total amount of drug collected from all the 
parts of the impactor (Throat and Stages), excluding the amount recovered in 
the actuator, from one shot of the pMDI.
The fine particle fraction (FPF) (%) is the ratio of the aerosolised fine particle 
mass to the total mass of drug recovered from the various parts of the ACI 
excluding the actuator. The FPF is defined as the fraction of particles of an 
aerosol with an aerodynamic diameter less 5.8 pm (particles deposited on 
Stage 2 and below of the ACI). This ratio is often used as a guide to 
understanding the portion of the aerosolised drug that is likely to reach the lung 
(the respirable portion).
Extra fine particle fraction (EPF) (%) is the ratio of the aerosolised extra fine 
particle mass to the total mass of drug recovered from the various parts of the 
ACI (ex-actuator). The EPF is defined as the fraction of particles of an aerosol 
with an aerodynamic diameter less 1.1 pm (particles deposited on Stage 6 and 
below of the ACI).
Mass Median Aerodynamic Diameter (MMAD) (pm) is a statistical measure of 
central tendency of the particle size distribution of aerosolised particles emitted 
from an inhaler. The MMAD denotes the diameter that divides the particle size 
distribution into two halves with respect to mass. Of the total mass of particles 
found on the impactor plates, 50% resides with particles above and below the 
MMAD. Most orally inhaled pharmaceutical aerosols have a MMAD of 
between 1 and 5 pm (Hickey 1993).
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Geometric Standard Deviation (GSD): In addition to the MMAD, the GSD is a 
useful measure as it is a single parameter that quantifies the spread of the 
aerosol particle size distribution. In a logarithmic-normal (log-normal) 
distribution, the GSD is the measure of the polydispersity of the aerosol 
(Gonda 2000). An ideal monodisperse formulation should therefore have a 
GSD of 1, however as it is virtually impossible to prepare mondisperse 
aerosols a GSD of 1.2 is generally considered the limit above which an aerosol 
would be classed as polydisperse (Gonda 2000).
The MMAD and GSD can be calculated using the following method which
Timutilises an Excel spreadsheet. Probit values, determined from the particle 
deposition cumulative percentage undersize can be plotted against the log 
effective cut-off diameters (ECD) of the ACI stages. A probit value of 5 
corresponds to the cumulative percentage undersize of 50%, probit values of 4 
and 6 correspond to 15.87% and 84.13% respectively. Linear regression can be 
applied to the resulting line using the points plotted between the probit value of 
4 and 6 . The MMAD and GSD can be calculated using the straight line 
equation generated. The log ECD is calculated at the probit value of 5 using the 
straight line equation. The inverse of the log ECD value results in the MMAD. 
The GSD is then calculated by dividing the inverse of log ECD calculated from 
the probit value 6 (cumulative percentage undersize 84%) by the MMAD.
2.2.6.1 Microscopic Characterisation of Aerosolised SS Formulation
The solvent-washed SS pMDI formulation was actuated 60 times into a 
Volumatic™ spacer (Allen and Hanburys, Middlesex, UK) connected to an 
ACI operating at 28.3 l/min. Double sided carbon tape was attached at various 
points on the wall of the spacer and the plates in the ACI using tweezers. 
Particles that had deposited on the carbon tape, were mounted onto SEM 
aluminium stubs and sputter coated with gold (gold sputter coater, EM Scope, 
Kent, UK) before being viewed using a Philips XL-200 Scanning Electron 
Microscope (TEI Company, Eindhoven, The Netherlands).
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2.2.7 Statistical Analysis
Statistical analysis was carried out using a statistical package, SPSS 16®. One­
way analysis of variance (ANOVA) was followed by a Duncan’s multiple 
range test, to compare multiple groups, with significant differences indicated 
by p values <0.05. Results are summarised as mean ± sd.
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2.3 Results
2.3.1 O ptim isation o f  M icroem ulsion Form ulation Param eters
Initial studies aimed to identify optimised constituent ratios that form stable 
isotropic w/o microemulsions (Figure 2.4). Generally microemulsions to the 
right o f the phase boundary formed stable monophasic systems (Figure 2.5) 
which had a surfactant to water ratio o f approximately 2.0 and greater (Figure
2.4). Microemulsions to the left o f the phase boundary formed unstable 
biphasic systems (Figure 2.5) with a surfactant to water ratio below 2.0. Stable 
microemulsion systems with the lowest surfactant to water ratio were deemed 
as optimal from a drug loading and surfactant content perspective. The 
optimum microemulsion (identified by the arrow in Figure 2.4) with the lowest 
surfactant to water ratio comprised water phase: surfactant: organic phase, 
26:52:22 w/w/w.
0/100
Optimum
microemulsion
% Water (w/w) 40 60 % Surfactant (w/w)
70
100/0 10 20 30 40 50 60 70 80 90 100/0
% Organic phase (w/w)
Figure 2.4 Pseudoternary phase diagram of lecithin: Propan-2-ol (1:3 (w/w))/ iso­
octane/ water at room temperature. ( •  ) indicates a stable microemulsion. ( O )
indicates phase separation. The black line (----- ) indicates the phase boundary. ( E...J )
indicates anticipated boundaries for w/o microemulsion.
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Figure 2.5 displays a typical stable monophasic microemulsion system and an 
unstable biphasic system. The stable microemulsion is isotropic, with the 
water, oil and amphiphile dispersed throughout the whole system. Conversely 
the unstable system displays phase separation between the oil and the water.
Figure 2.5 Photographs of stable and unstable biphasic microemulsion systems.
2.3.2 M icroscop ic C haracterisation o f  SS N anoparticles
SEM was utilised to characterise SS particles following one o f two wash 
methods to ascertain the most efficient method for removing excess surfactant.
Method One
In wash Method One, either iso-octane or propan-2-ol was used to remove 
excess surfactant from the freeze-dried surfactant-coated SS formulation 
(Section 2.2.3).
There were no distinct particles visible from the SEM images taken o f the SS 
particles washed using iso-octane (Figure 2.6). The SEM images revealed a 
continuous matrix with no clear particle outlines within the matrix at either 
magnification used (Figure 2.6A or B).
Stable
Isotropic
Microerm i >
Unstable
Biphasic
system
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Figure 2.6 Scanning electron micrographs of the freeze-dried SS microemulsion 
formulation washed in iso-octane using Method One. Scale bar = 50 pm (A) and 5
pm (B).
SEM images o f surfactant-coated SS particles washed using propan-2-ol 
revealed the presence o f aggregated structures (Figure 2.7). Although distinct 
particles cannot be viewed in either micrograph (Figure 2.7A and Figure 2.7B), 
the lack o f any visible continuous matrix indicates that some o f the excess 
surfactant has been removed. Micrograph Figure 2.7B displays a 
heterogeneous population with structures ranging in size but predominantly 
smaller than 5 pm.
Figure 2.7 Scanning electron micrographs of the freeze-dried SS microemulsion 
formulation washed in propan-2-ol using Method One. Scale bar = 50 pm (A) and
5 pm (B).
Method Two
Wash Method Two, (Section 2.2.3) was based on wash Method One but 
incorporated an additional vortexing step prior to centrifugation in an attempt
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to optimise surfactant removal.
Figure 2.8A reveals a general population o f particle clusters residing on an 
amorphous surface. On closer inspection. Figure 2.8B reveals an amorphous 
matrix interspersed with aggregates made up o f a heterogeneous particle 
population. Particles appear asymmetric in shape and although particles vary in 
size the majority are smaller than 5 pm.
Figure 2.8 Scanning electron micrographs of the freeze-dried SS microemulsion 
formulation washed in iso-octane using Method Two. Scale bar = 50 pm (A) and 5
pm (B).
Figure 2.9A displays an extensive population o f particle clusters. Closer 
inspection o f the particle population (Figure 2.9B) generally revealed particles 
with a plate-like appearance. Although particles appear aggregated and variable 
in size, all particles were less than 5 pm.
Figure 2.9 Scanning electron micrographs of the freeze-dried SS microemulsion 
formulation washed in propan-2-ol using Method Two. Scale bar = 50 pm (A) and
5 pm (B).
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2 3 3  HPLC Assay to Quantify SS
A calibration curve was generated from HPLC data using the area under the 
curve (AUC) ratios between known concentration of SS and bamethane 
internal standard (Figure 2.10).
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Figure 2.10 Calibration curve for the quantification of SS (linear equation: y = 
158.49x+ 5.7816, R2 = 0.9963). Data are presented as mean ± sd; n = 3.
The R is a measure of the accuracy of the goodness of fit of the line to the 
plotted data points. An R2 > 0.90 is generally considered a good fit, as the R2 
generated from this calibration curve was 0.9963 the linear equation was taken 
as valid for calculating the concentration of SS present in a known quantity of 
solvent-washed freeze-dried SS (Figure 2.10).
The final amount of SS present in 1.00 mg of solvent-washed freeze-dried SS 
was 0.82 ± 0.05 mg; therefore the SS:surfactant ratio was O.8.O.2. This data 
demonstrates that, even after the solvent wash, surfactant still remained which 
accounted for approximately 1/5 of the solvent-washed freeze-dried SS 
formulation mass. However, as the SS to surfactant ratio used during the 
production of the microemulsion was 1.0:2.94, the wash procedure resulted in a 
10-fold reduction in the surfactant content.
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2.3.4 A ssessm ent o f  SS pM DI Form ulations
Visual observations of the washed SS particulate formulation, in transparent 
PET pMDI vials, provided a simple indication to the physical stability o f the 
formulation.
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Figure 2.11 Sedimentation behaviour of washed SS pMDI formulations. HFA
134a is used as propellant with absolute ethanol as a co-solvent. Images and 
sedimentation ratios were taken during 60 sec and after 1 month o f producing the 
formulation.
The addition of HFA 134a propellant to the SS formulation led to the 
formation of an opaque dispersion with particles suspended throughout the 
propellant where the sediment volume was equal to that of the propellant 
(Figure 2.11 photograph A). Within 20 sec the suspension had begun to 
sediment (Figure 2.11 photographs B and C), visual observations showed an 
inelegant (non-homogenous) formulation. At 60 sec (Figure 2.11 photograph 
D) the SS formulation had almost completely sedimented, with few visible 
suspended particles, leaving a distinct boundary between a larger volume of 
supernatant and the sediment. After this point there was no further visible 
change in the sedimentation height for up to 1 month after pMDI formulation 
production, as the sedimentation ratio appeared to plateau at 0.27 (Figure 2.11
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photograph E). Up to a period o f 1 month, suspended particles were still 
visible, although most particles had formed loose sedimented floccules which 
were easily dispersed by one inversion o f the PET vial.
2.3.4.1 A ssessm ent o f  SS D eposition Follow ing A erosolisation from  a 
pM DI
To enable comparison o f aerosol deposition characteristics between the novel 
washed SS formulation and commercially available pMDIs the aerodynamic 
particle size distribution profiles o f Ventolin Evohaler®, Proventil® HFA and 
the washed SS formulation were determined using an ACI method (Section 
2.2.6).
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Figure 2.12 Comparison of aerodynamic particle size distribution of two 
commercially available SS inhalers and a novel SS formulation. Thr: throat. Inlet 
stage: inlet and Stage 0, SI to S7: Stages 1 to 7, Fil: final filter. Data are presented as 
mean ± sd; n = 3, each individual measurement is the sum o f two actuations.
Figure 2.12 highlights how the deposition pattern o f aerosolised particles 
within the impactor can differ for different formulations. Although all o f the SS 
formulations generally display a bimodal mass distribution of particles
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following aerosolisation, a difference between the mass of deposited SS 
between the three formulations using equivalent doses can be observed. 
Deposition data generated from the Ventolin Evohaler® displayed a relatively 
large deposition of SS in the throat, with a secondary peak on Stages 4 and 5. 
The mass distribution of deposited particles for the Proventil® HFA 
formulation followed a similar pattern to the Ventolin Evohaler but with a 
decreased throat deposition and an increased deposition on Stages 4 and 5. The 
novel washed SS formulation displayed a primary deposition of particles at the 
throat and inlet stages, similar in total to the throat deposition from Ventolin 
Evohaler® with a secondary peak at Stage 5 which was greater than that for 
either Ventolin Evohaler® or Proventil® HFA. Indeed the novel formulation 
had greatest deposition at Stages 5, 6 and 7 of the impactor, indicative of a 
significant proportion of smaller aerosolised particles.
The MMAD is a statistical measure of central tendency of the particle size 
distribution on impaction plates of the ACI. The difference in MMAD between 
the three formulations is highlighted in Figure 2.13. The aerosol emitted from 
the washed SS formulation resulted in particles with a significantly lower 
(p< 0.05) MMAD (1.90 ± 0.06 pm) than particles emitted from the Ventolin 
Evohaler® (2.32 ± 0.06 pm) but statistically comparable (p> 0.05) to 
Proventil® HFA (2.00 ±0.10 pm).
A significant difference (p<0.05) between the FPF5.8 of all three 
formulations was found (Figure 2.13). The washed SS formulation resulted in a 
FPFj g jim (ex-actuator) of (45.0 ± 2.58%) which was significantly higher than 
that measured for Ventolin Evohaler® (27.7 ± 4.07%) but lower than for 
Proventil® HFA (56.6 ± 6.89%).
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Figure 2.13 A comparison of fine particle fraction (FPF^gex-actuator) and 
mass median aerodynamic diameter (MMAD) between two commercially 
available SS inhalers and a novel SS formulation. Data are presented as mean ± sd; 
n = 3. Bar represents no significant MMAD difference {p>0.05).
The geometric standard deviation (GSD) measures the spread of the particle 
size distribution within the ACI (Table 2.2). The actuated washed SS 
formulation produced an aerosolised particle population with a significantly 
greater degree of polydispersity (2.76 ± 0.15) compared to Ventolin Evohaler 
(2.06 ±0.12) and Proventil HFA (1.77 ± 0.11).
Extra fine particle fraction (EPFj i nm) measures the fraction of particles 
depositing on and below Stage 6 of the ACI. The washed SS formulation 
showed a significantly higher EPF (13.8 ± 1.66% p< 0.05) compared to both 
the Proventil® HFA (8.76 ± 1.68%) and Ventolin Evohaler® (4.83 ± 0.99%) 
(Table 2.2).
The mean emitted dose (ED) was calculated from the cumulative particle 
deposition in the ACI (Throat and Stages). The dose of SS emitted into the ACI
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from the washed SS formulation revealed a relatively high relative standard 
deviation (RSD) (102.52 ± 31.75%) (Table 2.2). Although the sample number 
was n = 3, the high RSD was a result of one of the washed SS formulation 
canisters tested emitting a lower SS dose (65.90 pg) compared to the other two 
canisters (128.16 pg and 113.50 pg).
Table 2.2 Comparison of aerosol characteristics, using geometric standard deviation 
(GSD), Extra fine particle fraction (EPF) and emitted dose (ED) per actuation, 
between two commercially available SS inhalers and a novel SS formulation. Data are 
presented as mean ± sd/ % rsd; n = 3.
Formulation GSD EPFi., nm (%) 
(ex-actuator)
ED
per actuation (pg) 
(± % rsd)
(ex- actuator)
Ventolin Evohaler® 2.06 ± 0.12 4.83 ± 0.99 91.24 ±5.96%
Proventil® HFA 1.77 ±0.11 8.76 ± 1.68 87.01 ± 6.90%
Washed SS 2.76 ±0.15 13.8 ± 1.66 102.52 ±31.75%
23.4.2 Microscopic Characterisation of Aerosolised SS Formulation
SEM images taken of SS particles aerosolised from the washed SS pMDI 
formulation and collected using an ACI showed the presence of SS aggregates 
(Figure 2.14). The micrographs in Figure 2.14A to D indicate the presence of 
an amorphous population of particles. Particles deposited on Stage 5 (Figure 
2.14A and Figure 2.14B) revealed amorphous bridged structures, whereas 
particles deposited on Stage 6 (Figure 2.14C and Figure 2.14D) revealed a 
continuous matrix interspersed with protrusions of amorphous structures with 
an agglomerated appearance. Although particle size was variable, all particles 
were less than 10 pm. Microscopic observations showed that ACI Stages 5 
(Figure 2.14A and Figure 2.14B) and Stage 6 (Figure 2.14C and Figure 2.14D) 
with cut-off diameters of 1.1 pm and 0.7 pm respectively had the greatest 
particle deposition. This potentially indicates that the majority of the 
aerosolised particles were within the respirable size range. However, SEM 
images (Figure 2.14B and Figure 2.14D) revealed the presence of particles
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deposited on Stages 5 and 6 that were larger than the quoted cut-off diameters.
Figure 2.14 Scanning electron micrographs of a solvent-washed freeze-dried 
pMDI formulation containing SS collected at Stage 5 (A and B) and 6 (C and D) 
of an ACI. Scale bar = 50 pm (A and C) or 10 pm (B and D).
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2.4 Discussion
2.4.1 Optimisation of Microemulsion Formulation Parameters
In order to maximise the loading capacity of a water-soluble therapeutic 
molecule such as SS, an optimum w/o microemulsion should consist of a large 
aqueous phase and a small volume of surfactant.
In this study an optimum microemulsion was found to have a surfactant to 
water ratio of approximately 2.0. At this ratio, the concentration of surfactant 
was sufficient to reduce the interfacial tension at the oil/water interface to form 
a stable, isotropic, monophasic microemulsion (Schulman et al 1959; Shinoda 
and Lindman 1987). Attempts to reduce the surfactant to water ratio below 2.0 
by increasing the quantity of water or decreasing the quantity of surfactant 
resulted in an unstable biphasic system. The reason for this being that there was 
insufficient surfactant at the oil-water interface, which can lead to an increase 
in the interfacial tension, causing the collapse of the microemulsion resulting in 
a phase separation (Gillberg et al 1970).
Having said this, Dickinson et al (2001) who used the same microemulsion 
components as this study reported stable systems with surfactant to water ratios 
as low as 1.5. The difference between the surfactant to water ratio reported and 
the ratio quoted in this study could be attributed to impurities in the egg 
lecithin (which was quoted as approximately 90% pure by the manufacturer) or 
unreported variations in the microemulsion preparation conditions (Attwood et 
al 1992; Cilek et al 2006).
2.4.2 Microscopic Characterisation of SS Nanoparticles
Microscopic characterisation of freeze-dried SS particles, having undergone 
Wash Method One (Section 2.2.3) with iso-octane, revealed insufficient 
removal of excess surfactant which hindered surface morphology 
characterisation and potentially caused particle aggregation. A typical feature 
of a microemulsion is the submicron size of the disperse domains (Schulman et 
al 1959; Saint Ruth et al 1995). This is advantageous as freeze-drying a drug
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solubilised in the disperse phase of a microemulsion can lead to the formation 
of surfactant-coated nanoparticles, a feature exploited by Dickinson et al 
(2001). However, stabilising such a microemulsion system requires a relatively 
large quantity of surfactant due to the large interfacial area between the 
disperse phase and the continuous phase (Shinoda et al 1991; Zarur et al 2000), 
which explains the microscopic observation of excess surfactant coating the 
lyophilised SS particles. The excess surfactant invariably required to formulate 
a stable microemulsion system, in addition to hindering particle 
characterisation, could also potentially adversely affect particulate 
dispersibility and physical stability of the formulation in a pMDI due to the 
poor solubility of surfactants in HFA propellants (Blondino and Byron 1998) a 
feature further explored in Section 2.4.3.
Visual inspection using SEM of the freeze-dried SS particles after solvent 
washing using Method One (Section 2.2.3) revealed differences in the extent of 
surfactant removal between the two solvents. The presence of a continuous 
matrix, which may be the sticky surfactant system, and the lack of any visible 
distinct SS particles (Figure 2.6) exemplifies that 6 wash cycles using iso­
octane (Method One) is not sufficient in removing excess surfactant for 
successful particle visualisation.
Replacing the iso-octane solvent with propan-2-ol which has a higher dipole 
moment and confers lower lipophilicity than iso-octane resulted in SEM 
micrographs with more discrete structures without the coverage of a continuous 
matrix (Figure 2.7). The apparent differences in the appearance of iso-octane 
and propan-2 -ol washed particles demonstrates the superiority of propan-2-ol 
in removing excess surfactant after 6 wash cycles compared to the iso-octane 
solvent. The rationale for this increased surfactant removal is dependent upon 
the chemistry of the two solvents. Propan-2-ol is composed of a polar hydroxyl 
group which can interact with the polar head group of the surfactant, whilst the 
non-polar hydrocarbon portion of the alcohol can interact with the hydrophobic 
tail group of the surfactant (Fowler 2006). As iso-octane is composed solely of
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non-polar hydrocarbons it can only interact with the hydrophobic portion of the 
surfactant. This increased interaction conferred by the alcohol propan-2-ol 
explains its increased efficiency, and use in the past, in surfactant removal 
compared to the lipophilic iso-octane solvent (Lang and Tuel 2004; Nyambura 
et al 2009b). However, as these particles were still highly aggregated a 
secondary wash method, wash Method Two (Section 2.2.3), was developed in 
an attempt to optimise removal of excess surfactant.
Wash Method Two involved the addition of a vortexing step to dramatically 
increase shear and enhance surfactant removal. In contrast to previous 
micrographs generated from SS particles washed using iso-octane which 
revealed a continuous matrix without any discrete particles (Figure 2.6), the 
addition of a vortexing step revealed that some of the excess surfactant had 
been successfully removed to reveal an amorphous matrix (the sticky surfactant 
system) interspersed with an aggregated particle population (Figure 2.8). This 
increased removal of surfactant using vortexing was also observed when 
comparing SS particles washed in propan-2-ol, although to a lesser extent than 
with iso-octane.
General observations of the micrographs revealed that the best method to 
remove excess surfactant from the freeze-dried SS particles utilised propan-2- 
ol as the solvent and Wash Method Two, i.e. sample vortexing. This method 
resulted in the greatest visibility of SS particles than any other solvent method 
combination. However, in all micrographs particles remained aggregated which 
could adversely affect the deposition profiles of these particles during particle 
characterisation of aerosolised particles (Berry et al 2004; Traini et al 2007) 
further discussed in Section 2.4.3.1.
Although the technology explored was originally reported to generate particles 
o f the nanoparticle size range (Dickinson et al 2001), SEMs revealed that such 
particles were not detected. A possible reason for this may due to the observed 
aggregation caused by the presence of a sticky surfactant. Nevertheless the
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particles generated from the developed technology was a significant 
advancement, as previous reports of lyophilised powders have often shown 
particles with diameters unsuitable for pulmonary delivery and generally 
require further processing using a milling step prior to incorporation into an 
inhaler (Seville et al 2002; Shoyele and Cawthome 2006). It is generally 
acknowledged that particles require an aerodynamic diameter < 5 pm to allow 
efficient penetration and deposition in the peripheral pulmonary regions 
(Hickey 1993). Solvent-washed lyophilised particles, although not in the 
nanoparticle size range, are still in the respirable size range for deposition in 
the bronchiolar and alveolar region.
2.43 Assessment of SS pMDI Formulations
Visual observation of solvent-washed SS formulations loaded into PET vials 
was used to determine gross visual changes in the properties of the dispersion. 
Solvent-washing the surfactant-coated SS particles removed excess surfactant 
to produce an off-white powder which initially dispersed in the propellant- 
cosolvent mixture. Sedimentation of the particles began to occur after 20 sec 
and was complete by 60 sec but the sedimented particles were readily 
redispersed by one inversion of the vial confirming the presence of loose 
floccules which showed no signs of caking following 1 month’s storage. The 
presence of surfactant excipient coating the drug particles may have stabilised 
the drug dispersion to prevent any irreversible sedimenting. Surfactants are 
often incorporated into suspension formulations to decrease the drug 
interparticle attractive forces through sterically conferred repulsive forces 
between the surfactant tails which extend into the propellant (Hickey et al 
1988; Vervaet and Byron 1999).
Observations of the dispersibility of the flocculated system indicate that 
particle aggregation of the formulation was suitably controlled within the 
1 month time span. The lack of solubility of the hydrophobic surfactant lecithin 
in HFA 134a propellant resulting in aggregation is well documented and 
commonly requires the use of a co-solvent in commercial formulations
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(Blondino and Byron 1998). The observations of a dispersed system suggest 
that the quantity of surfactant in the solvent-washed formulation fell within the 
range of that which can be solubilised into the propellant with the aid of 
ethanol as co-solvent (8% v/v).
A flocculated system is deemed advantageous, rather than for example a 
deflocculated system, as it is readily re-dispersible upon sedimentation. Rapid 
sedimentation, conferred from a flocculated system, can however often lead to 
poor dose reproducibility (Byron 1994, 1997). Dose reproducibility was one of 
the parameters measured during the assessment of the SS formulation aerosol 
performance (Section 2.3.4.1).
2.43.1 Assessment of SS Deposition Following Aerosolisation from a 
pMDI
Emitted dose reproducibility was measured as one of the means for assessing 
aerosolised formulation performance. Poor emitted dose reproducibility 
translating into a high RSD value (± 32.55%) was observed for the washed SS 
formulation. To put this data into context, compendial guidelines (British 
Pharmacopoeia 2010a) state that the emitted dose for 9 out of 10 canisters 
should be within ± 25% in order to assume uniformity of dose. Possible 
reasons for the poor dose reproducibility include the presence of a rapidly 
sedimenting formulation (Byron 1994) observed during the assessment of the 
formulation in PET vials (Section 2.3.4). As there was only a small delay 
between shaking the formulation and actuation of the formulation, it is perhaps 
more likely that the erratic dosing was caused by partial actuator blockage due 
to the presence of aggregated particles (Traini et al 2007).
Closer inspection of the ED data generated from each canister revealed that the 
poor RSD was due to one canister emitting a relatively small dose in relation to 
the 100 pg salbutamol sulphate target dose (from the mouthpiece). A possible 
reason for this could be due to a faulty valve. Additionally, the valve and 
actuators used for the commercial formulations have been carefully optimised.
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As the valve and actuators used for the washed SS formulations have yet to be 
optimised they are therefore prone to the possibility of for example actuator 
blockage if the actuator orifice is too small (Ecanow et al 1986; Dalby and 
Byron 1988). This could explain the low emitted dose in one of the washed SS 
canister resulting in a relatively high RSD compared to values generated from 
the commercial formulations.
Aerosol deposition profiles generated using an ACI illustrated the difference in 
aerosol performance between the SS formulations, both bespoke and 
commercially available. Both the Ventolin Evohaler® and Proventil® HFA 
formulations displayed a broad mean mass SS particle deposition peak at Stage 
4 and 5. The novel washed SS formulation, however, displayed a deposition 
profile skewed towards the smaller particle size range relative to the 
commercial formulations. This said, the washed SS formulation displayed an 
increased ACI inlet particle deposition, a phenomenon also reported by 
Dickinson et al (2001).
There are a number of possible reasons for this increased ACI inlet particle 
deposition. The presence of aggregated particles, observed during microscopic 
particle characterisation (Section 2.3.2), which are not broken up through the 
shearing forces of aerosolisation may have led to the observed impaction in the 
upper stage of the ACI (Berry et al 2004; Traini et al 2007). Conversely 
particle aggregation may have occurred post-aerosolisation. Gonda (1985) 
reported that in concentrated non-aqueous suspension formulations there is 
often more than one particle in a single aerosolised propellant droplet. Due to 
this, after droplet evaporation, the particles tend to aggregate resulting in a 
particle distribution which does not match the original size distribution of the 
particles. Also the presence of surfactant in the washed SS formulation may 
have caused particle deposition in the upper stages of the ACI including the 
inlet stage (Dalby and Byron 1988; Hickey et al 1988). During aerosolisation, 
surfactant has a tendency to associate at the droplet-air interface, as surfactant 
is non-volatile the presence of surfactant can retard propellant evaporation
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resulting in larger droplets and consequently an increased deposition in the 
upper stages of the ACI (Snead and Zung 1968; Otani and Wang 1984).
Apart from the inlet stage, the washed SS formulation deposition profile 
revealed a larger mass of particles deposited at the lower stages of the ACI 
(Stages 5 to 7) which suggests the presence of smaller and more dispersible 
particles compared to the two commercially available formulations. 
Compendially recognised parameters such as the MMAD, GSD and FPF 
(British Pharmacopoeia 2010b), were used as a means to quantify aerosol 
performance and draw statistically significant conclusions between the aerosols 
emitted from the three pMDI formulations.
It is generally acknowledged that an aerosol with a MMAD of between 1 and 
5 pm is acceptable for pulmonary delivery (Hickey 1993). The MMAD for all 
three formulations was found to be within this respirable range. However, both 
the novel washed SS and Proventil® HFA formulations generated a 
significantly smaller MMAD and significantly higher percentage of particles 
within the respirable size range (FPF5.8 nm) compared to the Ventolin 
Evohaler®. Although there is little published literature on the performance of 
the Ventolin Evohaler® and Proventil® HFA formulations, the data generated 
in this chapter is generally typical of a previous report (Harris et al 2006).
The washed SS particles had been carefully manufactured in an attempt to 
produce nanoparticles using the nanotechnology process (Figure 2.1). 
Although, as explained earlier, nanoparticles were not observed (Section 2.2.3) 
the technology may have produced smaller particles than those used in the 
commercial formulations. This may have been reflected in the smaller MMAD 
and larger FPF5 g generated from the aerosolised particles emitted by the 
washed SS compared to the Ventolin Evohaler®. In addition to this the washed 
SS formulation generated aerosolised particles with significantly greater 
EPF 11 Mm than both the commercially available SS formulations. In a 
suspension formulation, the aerosolised drug output cannot be smaller than the
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original particles used to prepare the formulation (Gonda 1985; Berry et al 
2004). The aforementioned data was therefore able to confirm that the 
technology used to generate the novel washed SS particles had successfully 
produced particles with a smaller aerodynamic diameter than both the Ventolin 
Evohaler® (washed SS formulation demonstrated superior MMAD, FPF5 8 
and EPF 11 Mm) and Proventil® HFA (washed SS formulation demonstrated 
superior EPF 1.1 ^m)- Additionally the FPF5.8 standard deviation generated 
from the washed SS formulation was less variable than for the commercially 
available formulations. As the experimental technique used to generate this 
data was standardised throughout aerosol testing, this difference in variability 
was most likely a feature of the formulations used. The lower FPF5 8 
variability for the washed SS formulation could allude to the consistent 
performance of this formulation however as the sample number was small 
(n = 3) such results cannot be taken as conclusive.
Factors other than the particle manufacturing process may have also played a 
part in the significantly superior data profiles achieved from the aerosolised 
washed SS formulation. Formulation excipients such as surfactant, present in 
both the washed SS (lecithin) and Proventil® HFA (oleic acid) but not the 
Ventolin Evohaler®, may have played a role in reducing the MMAD of 
particles emitted from pMDI when compared to a formulation containing no 
surfactant. As salbutamol sulphate is well known for its cohesive nature, 
surfactants incorporated in pMDI formulations can play an integral role in 
stabilising the drug dispersion, and preventing particle aggregation (Hickey et 
al 1988; Vervaet and Byron 1999), which may be a possible reason for their 
ability to maintain a reduced MMAD.
Ethanol is often used as a co-solvent to improve the solubility of surfactants in 
HFA based formulations (Tzou et al 1997; Smyth 2003) and was used as an 
excipient in both the Proventil® HFA and washed SS formulations. Ethanol is 
also known to exert its effect as a vapour pressure modifier (Gupta et al 2003; 
Stein and Myrdal 2006). The vapour pressure of a propellant is critical in
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influencing the performance of a pMDI in terms of the aerosol droplet velocity 
and the dose delivery characteristics (Moren 1978; Stein and Myrdal 2006). 
The reduction of the propellant vapour pressure by the addition of a less 
volatile solvent such as ethanol will cause the aerosolised formulation to exit 
the atomisation nozzle at a reduced speed and can consequently minimise 
impaction in the throat (Gabrio et al 1999). Reduced vapour pressure is a 
possible rationale as to why aerosolisation of both SS formulations containing 
ethanol, Proventil® HFA and washed SS, resulted in a reduced impaction at 
the ACI throat and generated significantly larger FPF5 8 nm than the Ventolin 
Evohaler®. Although the washed SS formulation did display a deposition of 
particles at the throat and inlet stages similar in total to the throat deposition 
from Ventolin Evohaler®, this is likely to be a feature of the presence of 
particle aggregation (explained earlier) rather than the vapour pressure.
The Ventolin Evohaler® formulation has been reported to generate a larger 
spray plume force upon actuation, 95.4 mN, compared to Proventil® HFA, 
29.3 mN (Gabrio et al 1999). As the Ventolin Evohaler® formulation does not 
contain ethanol, the relatively higher vapour pressure caused the aerosolised 
Ventolin Evohaler® droplets to exit the atomisation nozzle at high speeds 
leading to increased ACI throat deposition observed in the deposition profiles. 
An increased impaction at the upper stages of the ACI would consequently 
reduce the mass of particles reaching the lower stages leading to the reduced 
FPFs.gum observed.
Although the aerosolised particles emitted from the washed SS formulation had 
a MMAD that was lower than the Ventolin Evohaler® and comparable to the 
Proventil® HFA, the GSD is another important parameter that should be 
considered. The GSD measures the spread of the particle size distribution. 
Although all formulations were observed to generate polydisperse aerosols 
(GSD > 1.2) the actuated washed SS formulation had the greatest degree of 
polydispersity when compared to the two commercial SS formulations. An 
increased GSD can have detrimental effects on the respirable fraction of
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aerosolised drug particles although this was not seen with the washed SS 
formulation.
2.43.2 Microscopic Characterisation of Aerosolised SS Formulation
Visual observations of ACI plates showed the largest deposition of drug 
particles on Stages 5 and 6. This observation was supported by the 
aerodynamic particle size distribution profiles (Figure 2.12), which indicated 
that a relatively large degree of aerosolised particles were within the respirable 
size fraction and deposited at the lower stages of the ACI.
Scanning electron microscopy of the aerosolised, washed SS formulation 
deposited on Stage 5 revealed amorphous bridged structures (possibly 
surfactant-coated SS particles). Stage 6 SEMs revealed a continuous matrix 
(which may be the sticky surfactant system) interspersed with protrusions of a 
heterogeneous population (possibly the surfactant-coated SS particles).
Although micrographs showed particle deposition at Stage 5 and 6 of the ACI 
(cut-off diameter 1.1 pm and 0.7 respectively), the observed larger particle 
dimensions suggest that particle agglomeration was still prevalent. Whilst 
particles were solvent-washed to remove excess surfactant, the presence of the 
surfactant, even at a minimal quantity, may have caused the particles to 
agglomerate as they impacted on the ACI plate. It is also possible that sample 
heating during SEM processing and analysis may have caused particle 
agglomeration. As discrete particles could not be seen from the SEM images, 
the 60 actuations of the formulation into the ACI could have resulted in particle 
overload on the ACI stages, another significant reason as to why particle 
agglomeration may have been observed. The difference in appearance between 
the particles deposited on Stages 5 and 6 could be a feature of the larger mass 
of SS depositing on Stage 5 (Figure 2.12), causing a greater degree of ACI 
stage overload resulting in more agglomeration than on Stage 6. Further 
characterisation of discrete particles may have been possible at higher 
magnifications. However, due to the magnifying limitations of the SEM the
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particles could not be viewed at higher magnifications without a significant 
loss in the image resolution.
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2.5 Conclusion
This chapter aimed to further test and develop the nanotechnology process 
proposed by Dickinson et al (2001) and evaluate its potential for achieving 
effective pulmonary drug delivery from pMDIs.
Optimum microemulsions, comprising water phase: surfactant: organic phase 
26:52:22 w/w/w, were lyophilised in the presence of SS to confer surfactant- 
coated SS particles. Particle characterisation using SEM and quantification 
using HPLC assays revealed that the developed washing procedure served to 
successfully remove some of the excess surfactant from the SS particles with a 
10-fold reduction in surfactant content. However, the SS particles remained 
aggregated, rendering sizing of discrete particles difficult.
Incorporation of solvent-washed SS particles into a pMDI revealed an easily 
dispersed flocculated system that, upon aerosolisation, displayed deposition 
profiles skewed towards the smaller particle size range relative to commercial 
SS formulations. Aerodynamic particle size data confirmed that the developed 
nanotechnology process had generated smaller SS particles than the 
commercially available formulations. These studies highlight the potential for 
the use of this novel low-energy microemulsion process technology in 
delivering macromolecules to the lower respiratory tract.
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CHAPTER THREE 
Preparation of pDNA Particles
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3.1 Introduction
The previous chapter focussed on developing a process (Figure 2.1) used to 
generate particles for incorporation into pMDI systems using small molecular 
weight drugs. This chapter will concentrate on advancing this technology to 
incorporate macromolecules and assessing the suitability of the technology for 
such use. As the native structure of macromolecules is susceptible to damage 
during processing conditions, applying the technology to pDNA will introduce 
new formulation challenges previously not faced when dealing with small 
molecular weight drugs. Some of these challenges and other strategies which 
have been investigated to overcome them are included in this introduction.
The novel process used for preparing pDNA particles in this project included a 
freeze-drying step. Freeze-drying consists of two major steps, freezing of the 
pDNA microemulsion and drying of the frozen solid under a vacuum. 
Although freeze-drying is particularly suited to formulating thermolabile drugs 
(Anchordoquy et al 1997; Chemg et al 1997; Talsma et al 1997), as solvents 
are eliminated by applying pressures as well as temperature, the process itself 
can often induce destabilising stresses for the pDNA. Both the pDNA 
formulation and the design of the freeze-drying process play an important role 
in pDNA stabilisation.
Maintenance of pDNA biological function is dependent upon preserving its 
native structure after the freeze-drying process. As the structure and 
conformational states of DNA are critically dependent on the hydration level, 
the removal of water as either ice (during the freezing stage) or gas (during the 
drying stage) can cause pDNA to concentrate, consequently promoting 
aggregation (Anchordoquy et al 1997; Allison and Anchordoquy 2000) and 
pDNA degradation (Poxon and Hughes 2000). Previous studies on lyophilised 
pDNA have demonstrated that preservation of pDNA integrity and prevention 
of aggregation are critical in maintaining pDNA function, assessed through 
maintenance of the plasmid supercoiled conformation (Ando et al 1999) and 
transfection rates (Anchordoquy et al 1997; Allison and Anchordoquy 2000) 
respectively. Two accepted methods for reducing pDNA degradation are by
66
Chapter Three
controlling the rate of freezing and by incorporating a lyoprotectant into the 
pDNA formulation.
pDNA function (damage) can be affected by the rate of cooling during the 
freeze-drying process (Anchordoquy et al 1998). The time between the start of 
the freezing process and the point at which the product is frozen is critical 
(Woelders and Chaveiro 2004). Rapid freezing of macromolecules by liquid 
nitrogen has been shown to minimise damage when compared to slow freezing 
(Anchordoquy et al 1998; Heller et al 1999). The reason for this being that as 
the freezing process begins the aqueous media in which the macromolecule is 
suspended begins to crystallise into ice. During this freezing process, the 
unfrozen fraction of the media progressively reduces. As the macromolecule 
resides in the unfrozen fraction, the progressive reduction of this fraction 
causes the macromolecule to concentrate into a small area eventually leading to 
macromolecule aggregation (Anchordoquy et al 1998). Contrary to rapid 
freezing, the process of slow freezing allows macromolecules such as pDNA 
sufficient time to diffuse away from the ice crystals causing the pDNA to 
aggregate in the progressively reduced unfrozen fraction.
The use o f sugar excipients has proven to be critical in maintaining 
macromolecule function during both the freezing and drying stages (Talsma et 
al 1997; Carpenter and Crowe 1988a; Poxon and Hughes 2000). The 
mechanism by which excipients exert their protective effect on pDNA has yet 
to be clearly elucidated, although several mechanisms have been put forward. 
Two mechanisms, which are by no means exclusive, are explained below.
Vitrification is a process of converting a material into a glass-like amorphous 
solid. The process of vitrification is dependent on glass transition temperature 
(Tg), which is the temperature below which an amorphous material is in a 
glassy state and above which it is a viscous liquid. This process of glass 
formation has been proposed as responsible for the stabilisation of 
macromolecules during freeze-drying (Franks et al 1991). Macromolecules 
trapped in a glassy matrix, i.e. vitrified, during freezing will have limited
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mobility so that the rates of reactions, including macromolecule unfolding, 
aggregation and chemical degradation, are reduced relative to the rates which 
can occur in a rubber state (Levine and Slade 1992). Sugars have been found to 
cause glass formation (Crowe et al 1994). Rapid freezing of a sample in the 
presence of a sugar is therefore found to maintain pDNA integrity as the pDNA 
would not have sufficient time to aggregate before glass formation occurs 
(Zelphati et al 1998).
The shortcomings of vitrification as a mechanism to explain the protection 
conferred by sugars is exemplified when looking at dextran and trehalose. 
Dextran exists as a glass at a higher temperature than trehalose. Although 
dextran is capable of causing glass formation which should, according to the 
vitrification hypothesis, confer greater stability of macromolecules than 
trehalose, the converse has been found to be true (Crowe et al 1994; Allison et 
al 1999). This example highlights that although an important mechanism, 
vitrification alone is insufficient in preventing loss of macromolecule function 
during freeze-drying (Crowe et al 1994).
The replacement of hydrogen bonding between water and macromolecules 
such as protein, by that of sugar and protein, known as the “water replacement 
hypothesis” is considered to be a key factor by which sugars stabilise 
macromolecules during freeze-drying (Carpenter and Crowe 1988b, 1989). 
Protection conferred through hydrogen bonding would therefore indicate that 
the sugar moiety plays a critical role (Carpenter et al 1987). Sugars, such as the 
disaccharides sucrose and trehalose which posses a greater number of hydroxyl 
groups than monosacharrides such as glucose should and do result in 
conferring greater macromolecule stability (Carpenter et al 1987; Allison and 
Anchordoquy 2000).
Although the degree of structural protection conferred by sugars correlates with 
the extent of hydrogen bonding between sugar and protein, the excipient 
molecular size must also be taken into account. Potential steric hindrance due 
to the molecular size has been reported to dictate the hydrogen bonding
68
Chapter Three
capacity of sugars (Allison et al 1999). Dextran, for example, a relatively large 
complex branched polysaccharide is testament to this. Although dextran has 
many hydroxyl groups, its size results in its inability to hydrogen bond 
adequately to the protein. This steric hindrance results in its failure to inhibit 
dehydration-induced protein unfolding (Crowe et al 1994; Allison et al 1999).
3.1.1 Plasm id EGFP-N1
The pEGFP-N 1 reporter plasmid was selected as an appropriate candidate gene 
for incorporation into pDNA particles. pEGFP-N 1 contains the commonly used 
reporter gene enhanced green fluorescent protein (EGFP). EGFP is a mutant 
variant o f green fluorescent protein gene (GFP) native to the bioluminescent 
jellyfish Aequorea Victoria (Prasher et al 1992). GFP was first identified as a 
marker for gene expression by Chalfie et al (1994). The GFP gene codes for 
the GFP protein which exhibits green fluorescence when exposed to blue light. 
The ability o f GFP to fluoresce in cells without the need for exogenous 
substrates makes it an ideal marker for gene expression in living cells, an 
important requirement for the scope of this project.
pEGFP-N 1 has several important sites critical to its function and identification 
indicated on Figure 3.1.
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Figure 3.1 Schematic diagram  of plasmid enhanced green fluorescent protein 
construct. Adapted from Clontech (1999).
69
Chapter Three
The EGFP transgene utilises a cells transcription and translation apparatus to 
biosynthesise the EGFP protein marker. The human cytomegalovirus (CMV) 
promoter provides for efficient expression of the transgene in mammalian cells 
through binding with transcription factors during the initiation of gene 
transcription. The multiple cloning site (MCS) located on the N terminus of the 
EGFP gene contains restriction sites that only occur once within a given 
plasmid. The MCS plays an important role in plasmid identification during 
restriction digest assays.
The kanamycin/ neomycin resistant gene confers host resistance to kanamycin 
and neomycin antibiotics. This gene therefore permits selection of pEGFP-N 1 
transformed bacteria host cells during plasmid propagation. The pUC origin is 
the origin at which DNA replication is initiated. As the pDNA will replicate 
within the host cell independently of the host cell’s own replication cycle, the 
pUC origin determines the number of copies of the plasmid which can be 
made, i.e. the vector copy number, in each host cell.
pDNA can exist as three main conformations, supercoiled, nicked circular/ 
open circular and linear. Processing pDNA can lead to degradation of its native 
structure. Although linear DNA forms have also been found to be transfection 
competent (Chancham and Hughes 2001; von Groll et al 2006) most published 
literature supports the opinion that pDNA supercoiled structure should be 
retained to optimise cellular transfection efficiency (Chemg et al 1999; Even- 
Chen and Barenholz 2000; Remaut et al 2006) and to comply with regulatory 
requirements on product quality (Arulmuthu et al 2007). In order to assess 
pDNA structural integrity, pDNA samples are typically analysed using 
ethidium bromide (EtBr) agarose gel electrophoresis.
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3.1.2 Specific Aims and Objectives of the Chapter
The overall aim of this chapter is to research the potential for developing a 
nanotechnology process, originally used for small molecular weight drugs 
(Dickinson et al 2001), to prepare surfactant-coated pDNA particles. The 
development of this technology to prepare macromolecule particles will 
invariably face new challenges due to the susceptibility of the macromolecule 
native structure to damage during processing.
The primary aim of this chapter is to develop an approach to optimise retention 
of pDNA integrity by investigating the use of lyoprotectants and freezing rates. 
This chapter will also aim to compare the freeze-drying procedure with spray- 
drying, another process widely used in forming pDNA particles for pulmonary 
delivery (Seville et al 2002; Li et al 2005a). Subsequent aims of this chapter 
are to investigate the transferability of the wash procedure developed in the 
previous chapter to remove excess surfactant from pDNA particles without 
reducing pDNA integrity.
The experimental objectives are to:
1. Amplify and purify pEGFP-N 1 from DH5a Escherichia coli (E. coli) and 
confirm pEGFP-N 1 identity and integrity through the use of restriction 
endonucleases and ethidium bromide agarose gel electrophoresis.
2. Optimise pDNA integrity during freeze-drying by investigating the effect of 
freezing rate and the lyoprotection conferred by various sugar excipients.
3. Identify the optimum pDNA concentration incorporated into the aqueous 
phase of a microemulsion.
4. Compare the effectiveness of freeze-drying and spray-drying as methods to 
produce pDNA particles from pDNA incorporated microemulsions.
5. Remove excess surfactant from the surfactant-coated pDNA particles using 
washing procedures.
6. Verify pDNA stability in solvent-washed pDNA particles through 
maintenance of the supercoiled fraction.
7. Characterise the engineered nanoparticles using SEM and particle sizing 
techniques.
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3.2 Materials and Methods
All reagents were used as received and were purchased from Fisher Scientific 
UK Ltd. (Loughborough, UK) unless otherwise stated.
Deionised water was obtained from an Elga reservoir (High Wycombe, UK). 
Iso-octane (2,2,4 trimethylpentane 99+ %), Luria agar (Miller’s LB agar), 
Luria broth, Not /, lOx buffer SH, sucrose 99+ %, D-lactose monohydrate and 
D- (+)-glucose 99.5% minimum were purchased from Sigma-Aldrich Ltd. 
(Poole, UK). D-Trehalose anhydrous 99% was purchased from ACROS 
Organics (Geel, Belgium). Agarose (LE analytical grade) EcoR /, lOx buffer H 
and Wizard® DNA Clean-Up System product A7280 were purchased from 
Promega Ltd. (Southampton, UK). 2-Log DNA ladder (0.1-10.0 kb) 
1000 pg/ml was purchased from New England Biolabs (Hertfordshire, UK). 
Library efficiency® DH5a™ competent cells kit containing pUC19 and super 
optimal broth with catabolite repression medium (SOC), kanamycin 
(100 mg/ml) and ampicillin (100 mg/ml) were purchased from Invitrogen Ltd. 
(Paisley, UK). pEGFP-N 1 (4.7 kb) reporter pDNA was purchased from 
Clontech Laboratories Inc. (Palo Alto, USA). 5x coloured loading buffer blue 
was purchased from Bioline Ltd. (London, UK). Qiagen Plasmid Mega Kit® 
was purchased from Qiagen Ltd. (Crawley, UK). Liquid nitrogen was 
purchased from BOC Gases Ltd. (Manchester, UK).
3.2.1 Bacterial Transformation
Bacterial transformation is a process whereby foreign pDNA is introduced into 
a bacterial vector to amplify the quantity of pDNA.
All apparatus were sterilised or purchased as sterile prior to use.
Transformation:
The process of transformation (as outlined in the Invitrogen protocol, 
(Invitrogen 2003) involved transforming the DH5a strain of Escherichia coli 
(E. coli) bacteria with pEGFP-N 1, using kanamycin to ensure selective growth 
of transformed bacteria (Figure 3.1).
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Library efficiency® DH5a™ competent cells were gently thawed to 4°C after 
which 100 pi of the competent cell suspension was aliquoted into a pre-chilled 
polypropylene tube (Falcon® 2059 Becton, Dickinson Biosciences, Oxford, 
UK). For the transformation, 1 pi of pEGFP-Nl (10 ng/pl) in Tris-EDTA 
buffer (Tris-Cl, EDTA) (TE buffer) pH 8.0 was pipetted into the tube, mixed 
gently and then placed on ice for 30 min. Competent cells were heat shocked 
by placing in a water bath set at 42°C for 45 sec, after which the cells were 
immediately returned to ice for a further 2 min. At that point 900 pi of room 
temperature sterile SOC medium was pipetted into the heat shocked cell 
suspension. The tube was capped and incubated in an orbital shaker (100 rpm 
and 37°C) for 1 hr. The cell suspension mixture was then diluted with 250 pi of 
sterile Luria broth (2.5% w/v).
A sterile Luria agar plate was prepared by adding 25 pi of kanamycin 
(100 mg/ml) to 25 ml of autoclaved Luria agar in deionised water (4% w/v). 
The inoculated Luria agar was gently poured into a plastic petri dish in the 
presence of a Bunsen burner flame. Once the agar had set, 100 pi of the diluted 
cell suspension mixture was pipetted onto the plate and spread over the surface 
of the agar using a sterile cell spreader. The agar plate was then covered with a 
lid, inverted and incubated for 16 to 18 hr in a humidified incubator (37°C/ 5%
co2).
During the process of bacterial transformation three controls were also 
prepared alongside the pEGFP-N 1 transformed E. coli. The controls were used 
as a way o f validating the bacterial transformation process.
Control A (positive control):
A Luria agar (4% w/v) plate containing no antibiotic was streaked with 100 pi 
of the heat shocked DH5a E. coli cells transformed with pEGFP-N 1 (prepared 
as above). The agar plate was then covered with a lid, inverted and incubated 
for 16 to 18 hr in a humidified incubator (37°C/ 5% C 02).
This agar plate should serve as a positive control, bacterial colonies should be
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visible in order to demonstrate that the heat shock process has not resulted in 
cell death.
Control B (positive control):
A Luria agar (4% w/v) plate containing 25 pi of ampicillin (100 mg/ml) and
31.3 pi of X-gal (40 mg/ml) was prepared in the presence of a Bunsen burner 
flame.
DH5a competent cells were gently thawed as above and 100 pi was aliquoted 
into a pre-chilled polypropylene tube using a pipette. pUC19 was used as the 
control plasmid, 5 pi (10 pg/pl) of which was pipetted into the competent cell 
suspension. The sides of the polypropylene tube were then gently tapped to 
ensure sufficient mix of the cells with the plasmid. The cells were then heat 
shocked and incubated in the orbital shaker using the procedure outlined above. 
The reaction mixture was diluted by pipetting 9 ml of Luria broth (2.5% w/v) 
and 100 pi was spread onto the surface of the ampicillin-X-gal impregnated 
Luria agar gel plate. The agar plate was then covered with a lid, inverted and 
incubated for 16 to 18 hr in a humidified incubator (37°C/ 5% CO2).
pUC 19 is a plasmid vector containing the lacZ gene coding for P-galactosidase. 
In the presence of X-gal, the substrate is cleaved by p-galactosidase to yield a 
blue product. Control B acts as a visual marker used to identify E. coli cells 
successfully transformed with pUC19.
Control C (negative control):
A sterile Luria agar (4% w/v) plate prepared using 25 pi of kanamycin 
(4% w/v) was streaked with non-transformed DH5a E. coli cells using a sterile 
inoculation loop. The agar plate was then covered with a lid, inverted and 
incubated for 16 to 18 hr in a humidified incubator (37°C/ 5% CO2).
This agar plate should serve as a negative control in which bacterial growth 
should be inhibited by the antibiotic.
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Propagation:
E. coli bacteria successfully transformed using pEGFP-N 1 was propagated for 
further experimental use.
A McCartney bottle was prepared containing 10 ml of sterile Luria broth 
(2.5% w/v) and 10 pi of kanamycin (100 mg/ml) in the presence of a Bunsen 
burner flame. A single colony of the pEGFP-N 1 transformed E. coli was 
removed from the agar plate and placed into the McCartney bottle using a 
sterile inoculation loop. The McCartney bottle was then covered using a 
loosely screwed cap and incubated in an orbital shaker (100 rpm and 37°C) for 
16 to 24 hr.
Storage:
A sterile pipette was used to remove 50 pi of incubated bacterial culture from 
the McCartney bottle and placed into a pre-chilled microcentrifuge tube. An 
equal volume of glycerol in deionised water (30% v/v) was pipetted into the 
microcentrifuge tube and mixed gently by tapping the sides of the tube. The 
microcentrifuge tube containing the glycerol-cell mix was immersed in an 
ethanol-dry ice bath for 5 min and then stored in -80°C for future use.
3.2.2 pDNA Amplification and Purification
Preparation of Luria agar plate:
A Luria agar plate containing 25 ml sterile Luria agar (4% w/v) in water and 
25 pi kanamycin (100 mg/ml) was prepared using the methods described in 
Section 3.2.1 (Bacterial Transformation). DH5a E. coli glycerol stocks of 
pEGFP-N 1, prepared in Section 3.2.1, were gently thawed on ice after removal 
from -80°C storage and streaked over the surface of the agar plate using a 
sterile inoculation loop in the presence of a Bunsen burner flame. The agar 
plate was then covered with a lid, inverted and incubated for 16 to 24 hr in a 
humidified incubator (37°C/ 5% CO2).
Amplification of pDNA:
A McCartney bottle was prepared containing 5 ml of sterile Luria broth
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(2.5% w/v) and 5 pi of kanamycin (100 mg/ml) in the presence of a Bunsen 
burner flame. A single colony of the pEGFP-N 1 transformed E. coli was 
removed from the agar plate and placed into the McCartney bottle using a 
sterile inoculation loop. The McCartney bottle was then covered using a 
loosely screwed cap and incubated in an orbital shaker (300 rpm and 37°C) for 
8 hr.
After the initial propagation, 1 ml of the bacterial suspension was sub-cultured 
into 500 ml conical flasks each containing 125 ml of sterile Luria broth 
(2.5% w/v) and 125 pi of kanamycin (100 mg/ml). The tops of the flasks were 
covered with foil; flasks were then incubated in an orbital shaker (300 rpm and 
37°C) for 16 hr. The bacterial cultures were split equally between two 250 ml 
Sorvall® polypropylene centrifuge bottles (Sorvall®, North Carolina, USA) 
and centrifuged at 6000 x g for 15 min (4°C).
Purification of pDNA:
pEGFP-N 1 was harvested and purified using Qiagen Plasmid Mega Kit®. The 
process, detailed in the Qiagen® plasmid purification handbook (Qiagen® 
2005), briefly involved lysing the bacteria, complexing and discarding cell 
debris and chromosomal DNA (cDNA), adsorbing the pDNA onto the column, 
washing through impurities (degraded RNA) and eluting the pDNA. Propan-2- 
ol and ethanol were then used to precipitate the pDNA resulting in pure pDNA. 
Finally the pDNA precipitated pellets were dissolved in 1 ml of warmed TE 
buffer pH 8.0 and stored in a sterile eppendorf.
Samples were removed at set stages of the purification procedure in order to 
monitor the procedure on an analytical level (Qiagen® 2005). Samples were 
analysed using gel electrophoresis (Section 3.2.3.1).
3.23 Assessment of pDNA Quality
3.2.3.1 Gel Electrophoresis -  Analysis of pDNA Purification Procedure
Samples removed during the purification of pDNA (Section 3.2.2) were 
analysed as a means of assessing the purification procedure.
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A 1% (w/v) agarose gel was prepared by boiling 1 g of agarose in 100 ml of lx 
Tris-borate EDTA buffer (Tris-Borate, EDTA) (TBE buffer) pH 8.0 until the 
agarose was fully dissolved. The solution was then left to cool at room 
temperature. Once the solution had cooled to approximately 55°C, 80 pi of 
EtBr solution (a fluorescent probe) was added to the agarose solution. The 
solution was swirled to ensure a sufficient mix and was then poured into an 
electrophoresis plate containing an 8-well comb. Once the gel had solidified, it 
was placed into an electrophoresis tank and submerged under lx TBE buffer.
Aliquots of 15 pi were removed from each of the four samples taken 
throughout the purification procedure (Section 3.2.2) and made up to 20 pi 
using 5x coloured loading buffer blue. A sample of the purified pDNA diluted 
to 2 pg/ 15 pi using TE buffer pH 8.0 was also prepared and made up to 20 pi 
using 5x coloured loading buffer blue. A 20 pi aliquot of each sample was then 
carefully pipetted into the wells of the agarose gel.
The gel was developed for 30 min at 200 volts using an electrophoresis power 
supply and analysed using Molecular Analyst® software and Bio-Rad Gel Doc 
1000 (Bio-Rad Laboratories Ltd., Hertfordshire, UK).
3.23.2 Determination of pDNA Yield and Purity
pDNA concentration was determined by the UV absorbance at 260 nm using 
an Eppendorf Biophotometer (Eppendorf Ltd., Cambridge, UK). An aliquot of 
pDNA stock solution was diluted x50 using TE buffer pH 8.0 and transferred 
to an Eppendorf Uvette® (Eppendorf Ltd., Cambridge, UK). The diluted 
aliquot was analysed for double stranded DNA (dsDNA) concentration. The 
purity o f the dsDNA was calculated from the absorbance ratios given at
A260/A280-
33.3.3 pEGFP-N 1 Restriction Enzyme Double Digest -  Determination of 
Plasmid Identity
A restriction enzyme double digest was used to confirm pDNA identity with 
the aid of a restriction map of pEGFP-N 1 (Figure 3.2).
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Figure 3.2 Restriction map and multiple cloning site of pEG FP-N l. Adapted from 
Clontech (1999).
pDNA was incubated with EcoR I andJ Not I restriction enzymes for a single 
digest and a double digest (Table 3.1).
Table 3.1 Single digest and double digest components.
Component Single digest Single digest Double digest
Restriction enzyme EcoR I Not I EcoR I & Not I
0.5 pi 0.5 pi 2 x 0.5 pi
Digest buffer 1 Ox buffer H lOx buffer SH 1 Ox buffer H
2 pi 2 pi 2 pl
pEGFP-N 1 2 p g 2 p g 2 pg
Sterile water up to 20 pi up to 20 pi up to 20 pl
Typically, 2 pi o f lOx digest buffer was pipetted into a sterile microcentrifuge 
tube containing autoclaved water (to a final volume of 20 pi). To this solution
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2 jig of pDNA was introduced, followed by the addition of 0.5 pl of the 
restriction enzyme. The tube was gently mixed and incubated at 37°C for 2 hr. 
Three digestions were performed (Table 3.1), the first containing EcoR I  as the 
restriction enzyme, the second containing Not I  as the restriction enzyme with 
the third being a double digest using both restriction enzymes.
After the incubation period, aliquots of 15 pl from each digest mix were made 
up to 20 pl with 5x coloured loading buffer. A sample of the purified pDNA 
diluted to 2 pg/15  pl using TE buffer pH 8.0 was also prepared and made up to 
20 pl using 5x coloured loading buffer blue. The 20 pl aliquots of each sample 
were then carefully pipetted into the wells of an EtBr agarose gel (prepared as 
in Section 3.2.3.1). A DNA 2-log ladder was also pipetted into a well (no 
dilution was required). The gel was developed for 2 hr at 150 volts using an 
electrophoresis power supply and analysed using Molecular Analyst® software 
and Bio-Rad Gel Doc 1000 (Bio-Rad Laboratories Ltd., Hertfordshire, UK).
3.2.4 Investigating the Effect of Lyoprotectant and Freezing Rate on 
Lyophilised pDNA
Prior to forming surfactant-coated pDNA particles, an initial pilot study was 
performed to investigate optimal lyoprotectants and rates of freezing for 
retaining pDNA integrity during lyophilisation.
Investigating Alternative Lvoprotectants
Six sugars were investigated for pDNA lyoprotection; disaccharides; sucrose, 
lactose, maltose and trehalose; a monosaccharide glucose and a sugar alcohol 
mannitol. pDNA (50 pg) was added to six freeze-drying vials (Fisher Scientific 
Ltd., Loughborough, UK) containing 5 ml of deionised water and sugar 
3% (w/v) which was deemed a sufficient lyoprotectant concentration to 
maintain pDNA integrity (Chemg et al 1997; Seville et al 2002; Li et al 
2005a). A seventh vial containing 50 pg of pDNA in 5 ml of deionised water 
(sugar was excluded) was prepared as a negative control. All seven vials were 
gently vortexed to ensure a good mix before being frozen using one of two 
freezing rates (below) prior to lyophilisation.
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Investigating Alternative Freezing Rates
In order to identify any effect freezing rate may have on the integrity of pDNA 
through freeze-drying, vials containing pDNA and the various sugars (prepared 
above) were frozen using one of two methods:
Rapid Freezing: pDNA samples were snap-frozen by submerging vials in 
liquid nitrogen prior to lyophilisation.
Controlled Freezing: Samples were frozen using a cryopreservation technique 
typically used in freezing and storing cells. pDNA samples were placed in a 
polystyrene container and frozen at -20°C for 2 hr, and then placed into deep 
freeze at -80°C for 16 hr. Samples were then submerged in liquid nitrogen 
prior to lyophilisation.
All frozen samples were subsequently lyophilised for 24 hr using the Heto 
Drywinner freeze-drier (Heto-Holten, Alleroed, Denmark) with the condenser 
chamber set at -110°C.
Freeze-dried pDNA samples were diluted to a final concentration of 
2 pg/ 15 pl using TE buffer pH 8.0 and made up to 20 pl using 5x coloured 
loading buffer blue. A control sample of the unprocessed pDNA diluted to 
2 pg/ 15 pl using TE buffer was also prepared and mixed with gel-loading dye. 
The 20 pl aliquots of each sample were then carefully pipetted into the wells of 
a 1% (w/v) agarose gel containing EtBr (Section 3.2.3.1). The gel was 
developed for 30 min at 200 volts using an electrophoresis power supply and 
analysed using Molecular Analyst® software and Bio-Rad Gel Doc 1000 (Bio- 
Rad Laboratories Ltd., Hertfordshire, UK).
3.2.5 Preparation of pDNA Particles
Microemulsions of previously optimised constituent ratios were prepared as 
outlined in Section 2.2.1. pDNA was added to the aqueous phase (26% w/w of 
microemulsion) containing sucrose (3% w/v) as lyoprotectant and agitated 
using a vortex mixer to form a solution prior to addition into the surfactant
80
Chapter Three
(lecithin: propan-2-ol (1:3)) (52% w/w of microemulsion) and iso-octane 
(22% w/w of microemulsion) mixture. Various pDNA concentrations were 
investigated in order to establish the maximum quantity of pDNA that could be 
successfully incorporated into a microemulsion.
Optimised pDNA microemulsions were subjected to one of two drying 
methods to form pDNA particles.
Freeze-Drvine
Pre-weighed centrifuge tubes containing pDNA loaded microemulsions were 
sealed with perforated Parafilm and snap-frozen by submersion in liquid 
nitrogen. Snap-frozen microemulsions were placed into a tray filled with dry 
ice in order to maintain their solid state, ensuring sublimation rather than 
melting occurred, and lyophilised for 24 hr using a Heto Drywinner freeze- 
drier (Heto-Holten, Alleroed, Denmark) with the condenser chamber set at 
-110°C. After the drying procedure, centrifuge tubes were re-weighed to 
determine percentage yield.
Spray-Drying
Centrifuge tubes containing pDNA loaded microemulsions were placed under 
the feed hose of a Biichi B-191 mini spray dryer (Btichi Labortechnik, Flawil, 
Switzerland). The spray dryer was operated under the following conditions; 
inlet temperature 120°C; spray flow rate 600 1/hr; aspirator 100%; pump 20%. 
These conditions resulted in an outlet temperature of 80°C. Spray-dried 
particles were removed from the collection vessel using a spatula. The 
recovered formulation was weighed to determine percentage yield.
3.2.6 Analysis of pDNA Particles
3.2.6.1 Integrity of pDNA Particles
Agarose gel electrophoresis, with EtBr staining, was used to determine the 
physical integrity of the processed pEGFP-N 1. Following the microemulsion 
and drying stages, surfactant from the freeze-dried and spray-dried surfactant- 
coated pEGFP-N 1 particles was removed using a Wizard® DNA Clean-Up kit.
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This was deemed necessary as excess surfactant in the microemulsion and 
resulting particulates could hinder the pDNA migration across the agarose gel.
Sample Preparation Using a Wizard® DNA Clean-Up System 
An in-depth protocol for surfactant clean up is available on the Promega (2006) 
web site. The sample was taken through a three stage process: binding, 
washing and elution briefly explained below.
Binding Stage: 28 mg of surfactant-coated pDNA particles were weighed out 
into a microcentrifuge tube containing 1 ml Wizard® DNA Clean-Up resin and 
mixed by inversion. The resin/ pDNA mix was pipetted into a syringe barrel 
which was attached to a minicolumn. A syringe plunger was then used to 
slowly push the resin/DNA mix into the minicolumn.
Washing Stage: 2 ml of propan-2-ol was pipetted into the syringe barrel and 
slowly pushed through the minicolumn using a plunger. The minicolumn was 
then transferred to a microcentrifuge tube and centrifuged at 13,000 rpm for 
2 min using a Sanyo MSE Micro Centaur microcentrifuge (Sanyo Electric Co., 
Ltd., Hertfordshire, UK) to dry the resin.
Elution Stage: 50 pi of pre-warmed de-ionised water (65-70°C) was pipetted 
into the minicolumn and left for 1 min. The minicolumn was then transferred to 
a new microcentrifuge tube and centrifuged as before for 20 sec. Centrifugation 
at this stage eluted the bound pDNA.
Aliquots of 15 pi eluted pDNA and a control sample of the unprocessed pDNA 
(2 pg/ 15 pi) were made up to 20 pi with 5x coloured loading buffer and ran 
through an EtBr agarose gel as previously outlined in Section 3.2.3.1.
3.2.6.2 Microscopic Characterisation of pDNA particles
Excess surfactant in the microemulsion and resulting particulates could 
potentially cause particle aggregation and hinder surface morphology 
characterisation. For this reason a solvent-wash procedure was utilised to
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remove excess surfactant from the surfactant-coated pDNA particles. Freeze- 
dried surfactant-coated pDNA particles (500 mg) and spray-dried surfactant- 
coated pDNA particles (9 mg) were solvent-washed using the optimised 
sequential wash Method Two using propan-2-ol (outlined in Chapter 2, Section 
2.2.3).
Solvent-washed pDNA formulations were sputter coated with gold (gold 
sputter coater, EM Scope, Kent, UK) and viewed using a Philips XL-200 
Scanning Electron Microscope (TEI Company, Eindhoven, The Netherlands) 
(previously outlined in Section 2.2.3).
3.2.63 Integrity of Solvent-Washed pDNA Particles
Following the microemulsion and solvent removal stages, surfactant from the 
lyophilised surfactant-coated pEGFP-N 1 (28 mg) and solvent-washed pEGFP- 
N1 (0.8 mg) was removed using a Wizard® DNA Clean-Up System (Section 
3.2.6.1). Aliquots of 15 pi eluted pDNA and a control sample of the 
unprocessed pDNA (2 pg/ 15 pi) were made up to 20 pi with 5x coloured 
loading buffer and ran through an EtBr agarose gel as previously outlined in 
Section 3.2.3.1.
3.2.6.4 Measurement of Particle Size
The mean diameter of the solvent-washed pDNA particles was determined by 
photon correlation spectroscopy using a Coulter® N4 Plus (Coulter Electronics 
Ltd., Luton, UK). Particles of lyophilised pEGFP-Nl (2 mg) were dispersed in 
iso-octane (5 ml) and agitated using a vortex mixer for ~ 3 min. Samples were 
transferred into a clear sided disposable cuvette, which was sealed using 
Parafilm to prevent evaporation. Measurements were expressed using the 
unimodal size distribution model and repeated six times.
83
Chapter Three
3 J  Results
33.1 Bacterial T ransformation
pEGFP-Nl was introduced into a bacterial vector using the process of bacterial 
transformation. In order to assure that the transformation was successful, three 
controls were also prepared. Agar plate A streaked with pEGFP-Nl 
transformed DH5a E. coli cells without the presence of antibiotic shows an 
abundant growth of bacterial colonies (Figure 3.3A). The appearance of 
colonies acted as a marker to indicate that heat shocking did not result in total 
cell death. Agar plate B which was streaked with DH5a E. coli transformed 
with pUC19 in the presence of ampicillin and X-gal, reveals the presence of 
discreet blue colonies. For visual purposes the blue colonies were highlighted 
on the figure using circles (Figure 3.3B). The blue colonies observed on plate 
B were the result of X-gal cleaved by p-galactosidase an enzyme coded for by 
the lacZ gene contained within the plasmid vector, which acted as a visual 
marker to confirm that the process resulted in cells successfully transformed 
with pUC19. Agar plate C streaked with non-transformed DH5a E. coli cells in 
the presence of kanamycin reveals a blank plate, showing no bacterial colonies. 
The absence of colonies is due to antibiotic induced cell death. Agar plate D 
which was streaked with pEGFP-Nl transformed DH5a E. coli cells in the 
presence of kanamycin reveals multiple discrete colonies. These colonies were 
a result of successfully transformed bacteria with pEGFP-Nl as untransformed 
bacteria would succumb to antibiotic induced cell selection.
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Figure 3.3 Photographs taken of treated Luria agar plates during bacterial 
transformation. A: Control A plate containing no antibiotic, streaked with pEGFP- 
N1 transformed DH5a E. coli cells. B: Control B plate containing ampicillin and X- 
gal, streaked with pUC19 transformed DH5a E. coli cells. The circles indicate the 
presence o f blue colonies. C: Control C plate containing kanamycin, streaked with 
non-transformed DH5a E. coli cells. D: agar plate containing kanamycin streaked with 
pEGFP-Nl transformed DH5a E. coli cells.
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3.3.2 Assessment of pDNA Quality
3.3.2.1 Gel Electrophoresis -  Analysis of pDNA Purification Procedure
The success o f the plasmid purification procedure was monitored on an 
analytical gel (Figure 3.4).
Degraded
RNA
Figure 3.4 A typical agarose gel analysis of the pEGFP-Nl purification 
procedure. Sample (1) cleared bacterial lysate. Sample (2) pDNA supernatant flow 
through column. (3) buffer wash through column. Sample (4) column eluate 
containing pure pDNA sample. Sample (5) stock pDNA. The arrows indicate 
degraded RNA.
The original bacterial lysate (lane 1, Figure 3.4) contained supercoiled and 
open circular pDNA as well as a small band of degraded RNA (visible as a 
faint band at the top of the lane highlighted by an arrow). The pDNA 
supernatant flow through column and the buffer wash used to remove 
contaminants from the pDNA bound column (lanes 2 and 3 respectively, 
Figure 3.4) show no bands, indicating that there was no pDNA flow through 
the column and that the pDNA remained bound to the column during the wash 
step o f the purification procedure. The absence of pDNA bands during these 
two stages revealed that there was no excessive loss of pDNA which could 
result in a low yield. The column eluate (lane 4, Figure 3.4) contained pure 
pDNA as well as a faint band at the top of the lane indicating a small band of 
degraded RNA. Both the eluate and the purified pDNA (lane 4 and 5 
respectively, Figure 3.4) had three bands present in the DNA profile. The 
presence o f the intense supercoiled band in the samples containing pDNA
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(lanes 1,4 and 5) verify that the pDNA remained intact throughout the 
procedure. The results shown here confirm the efficiency of the techniques 
used and are representative of the many batches of pDNA produced throughout 
the time course of the project.
33.2.2 Determination of pDNA Yield and Purity
Purified pDNA was routinely quantified by UV-vis spectrophotometric 
analysis using an Eppendorf Biophotometer. Typical pDNA yields ranged from 
2 mg to 3.5 mg which was within the expected range for high copy plasmids 
(Qiagen® 2005). The pDNA absorbance 260/280 ratio was typically in the region 
of 1.8 indicating the samples were free from salt and protein contamination 
with 100% purity.
3 3 .2 3  pEGFP-Nl Restriction Enzyme Double Digest -  Determination of 
Plasmid Identity
A restriction enzyme double digest was carried out to confirm the identity of 
the amplified and purified pDNA (Section 3.2.2). As indicated on the pEGFP- 
N1 restriction map (Figure 3.2), there is one specific restriction site for each 
restriction enzyme; EcoR I  and Not I. Incubation with each of these enzymes 
caused the linearization of the plasmid at a single site visualised in lanes 
labelled EcoR I  and Not I  (Figure 3.5). The bands in each of these two lanes 
correspond to the linearised form of pEGFP-Nl made up of 4,700 base pairs, 
which is confirmed by the 2-log ladder (Figure 3.5). The last lane on the gel is 
the result of the double digest using both restriction enzymes EcoR I  and Not /. 
The difference between the EcoR I  and Not I  restriction site on the plasmid 
map (Figure 3.2), is approximately 770 base pairs. This linear piece is 
visualised at the top of the lane (Fragment 1, Digest x2, Figure 3.5) confirmed 
with reference to the 2-log ladder. The larger second band, approximately 
3,930 base pairs (Fragment 2), produced by the double digest is visible at the 
expected range for pEGFP-Nl.
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Figure 3.5 A ty pical gel electrophoresis image of pEGFP-Nl after a single and 
double digest. Ladder: 2-log ladder. pDNA: pure pDNA. EcoR I: single digest of 
pDNA by EcoR I  restriction enzyme. Not /: single digest of pDNA by Not I  restriction 
enzyme. Digest x2: double digest of pDNA using both EcoR 1 and Not /.
3.3.3 Investigating the Effect of Lyoprotectant and Freezing Rate on 
Lyophilised pDNA
Comparisons were made between the physical integrity of pDNA lyophilised in 
the presence of various lyoprotectants and freezing rates in order to optimise 
pDNA retained integrity post-lyophilisation. The integrity of the tertiary 
structure o f pEGFP-Nl post-lyophilisation can be determined by the presence 
of a supercoiled band in line with that shown by the unprocessed pEGFP-Nl. 
Figure 3.6 and Figure 3.7 show the supercoiled signal band relating to pEGFP- 
N1 lyophilised in the presence o f various lyoprotectants and freeze-dried using 
the rapid freezing and controlled freezing methods respectively (Section 3.2.4). 
In all but one case, pEGFP-Nl lyophilised using mannitol as the lyoprotectant, 
the integrity o f pEGFP-Nl was clearly maintained throughout processing with 
maintenance o f the supercoiled band. A partial reduction in pDNA signal 
intensity was, however, observed when comparing the supercoiled bands of the 
processed pDNA samples to the unprocessed positive control. pDNA 
lyophilised in the presence of mannitol (lane ‘Man’, Figure 3.6 and Figure 3.7) 
appeared to migrate at a slower rate than unprocessed pDNA (+ve Control,
I— Fragment 2
— Fragment 1
LadTlcr pDNA EcoR! N o tI  Digest \2
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Figure 3.6 and Figure 3.7). In respect to the pDNA freeze-dried using the fast 
freezing method without the presence of a lyoprotectant (-ve Control, Figure 
3.6) the supercoiled band, although present, shows a partial reduction in the 
signal intensity. pDNA frozen using the controlled freezing method and 
lyophilised without the presence of a lyoprotectant (-ve Control, Figure 3.7) 
displays a supercoiled band with a signal intensity equivalent with that emitted 
from unprocessed pDNA (+ve Control, Figure 3.7).
Rapid Freezing
+ve
Control
Lae Mai
Control
Figure 3.6 Gel electrophoresis image of pEGFP-Nl after rapid freezing and 
lyophilisation in the presence of various lyoprotectants. +ve Control: unprocessed 
pDNA, Sue: sucrose, Lac: Lactose. Mai: maltose, Man: mannitol, Tre: trehalose, 
Glu: glucose, -v e  Control: pDNA freeze-dried without a lyoprotectant. (n = 1) (SC: 
supercoiled fraction).
C ontrolled Freezing
+ve Sue ' Lae 
C'ontrol Control
Figure 3.7 Gel electrophoresis image of pEGFP-Nl after controlled freezing and 
lyophilisation in the presence of various lyoprotectants. +ve Control: unprocessed 
pDNA, Sue: sucrose, Lac: Lactose. Mai: maltose, Man: mannitol, Tre: trehalose, 
Glu: glucose, -v e  Control: pDNA freeze-dried without a lyoprotectant. (n = 1) (SC: 
supercoiled fraction).
Semi-quantitative signal analysis was used to compare fluorescence emission
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(Figure 3.8). The percentage of fluorescence attributable to the supercoiled 
fraction of pDNA that was maintained post-lyophilisation (Figure 3.8) was 
calculated by comparing the intensity of the supercoiled band from the 
processed pDNA samples against that of the unprocessed pDNA. The 
fluorescence emitted from the supercoiled band of the unprocessed pDNA in 
this analysis (+ve Control, Figure 3.6 and Figure 3.7) was taken as 100%.
The percentage of fluorescence maintained by the pDNA supercoiled fraction 
was reduced in all pDNA samples that had undergone the lyophilisation 
process (Figure 3.8).
Rapid Freezing:
pDNA lyophilised in the presence of sucrose and maltose maintained the 
highest percentage of supercoiled signal intensity of all the lyoprotectant 
samples (70% and 75% respectively). Mannitol performed the poorest as a 
pDNA lyoprotectant, the percentage fluorescence emitted from the supercoiled 
band was taken to be 0% (lane ‘Man’, Figure 3.8) as the top most band from 
this sample did not migrate as far as the supercoiled band from the unprocessed 
pDNA (Figure 3.6). In most cases the presence of a lyoprotectant maintained 
either the same (lactose 48%) or a higher percentage of fluorescence emitted 
from the supercoiled fraction than pDNA lyophilised without the presence of a 
lyoprotectant (48%).
Controlled Freezing:
The highest percentage of supercoiled fluorescence that was maintained using 
the controlled freezing method was achieved when maltose or trehalose were 
used as lyoprotectants (79% and 86% respectively). The worst performing 
lyoprotectant once again was found to be mannitol (0% pDNA supercoiled 
fluorescence maintained). The relative percentage of signal intensity afforded 
by supercoiled pDNA lyophilised without the presence of a lyoprotectant was 
higher (89%) than for any pDNA samples lyophilised in the presence of a 
lyoprotectant.
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Figure 3.8 A comparison of pDNA lyoprotection conferred using sugars and 
freezing rates. The values represent a semi-quantitative analysis of the ratio of 
fluorescence emitted from the supercoiled band of lyophilised pDNA compared to 
unprocessed pDNA. Sue: sucrose, Lac: Lactose. Mai: maltose, Man: mannitol, Tre: 
trehalose, Glu: glucose, -ve Control: pDNA freeze-dried without a lyoprotectant. (n 
= 1).
33.4  Preparation of pDNA Particles
Visual observation revealed that pDNA incorporated into the aqueous phase of 
an optimised microemulsion (Section 2.2.1) at concentrations above 
approximately 0.048% (w/v) resulted in a biphasic microemulsion (Table 3.2). 
The incorporation of pDNA at concentrations of 0.048% (w/v) and below 
produced isotropic microemulsions.
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Table 3.2 Investigating the maximum quantity of pDNA that can be successfully 
incorporated into the aqueous phase of an optimised microemulsion system (n = 3).
pEGFP-Nl 
(% w/v)
Observation
0.096
Cloudy microemulsion with a biphasic system
forming 10 min after pDNA addition
0.048 Isotropic microemulsion
0.028 Isotropic microemulsion
33.5 Investigating the Effect of Freeze-Drying versus Spray-Drying 
During pDNA Processing
Solvent and water present in pDNA microemulsions was removed using either 
freeze-drying or spray-drying resulting in the production of surfactant-coated 
pDNA particles (Table 3.3). The surfactant-coated pDNA particles produced 
from either method had an amorphous yellow appearance and a sticky texture. 
pDNA particles were almost completely recovered after undergoing the freeze- 
drying process 94 ± 5% (mean ± sd; n = 3) (Table 3.3). Product recovery after 
spray-drying was lower at 20 ± 10%.
Table 3.3 Percentage yield of surfactant-coated pDNA particles recovered from the 
freeze-drying and spray-drying process (mean ± sd; n = 3).
Process Yield (%) Observed product
Freeze-drying 94 ±5
Yellow surfactant with 
a sticky texture
Spray-drying 20 ± 10
Yellow surfactant with 
a sticky texture
33.5.1 Integrity of pDNA Particles
The integrity of pDNA was assessed following drying and removal of the 
surfactant (Section 3.2.6.1). Figure 3.9 shows the fluorescent pDNA signal, 
prior to and post freeze-drying or spray-drying. The integrity of pEGFP-Nl, as 
evidenced by similar band intensity for supercoiled fraction, was maintained 
through either drying process.
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Figure 3.9 A ty pical gel electrophoresis image of pEGFP-Nl after freeze-drying 
and spray-drying. Control: unprocessed pEGFP-Nl, FD: Freeze-dried pEGFP-Nl, 
SD: Spray-dried pEGFP-Nl. The percentage values represent a semi-quantitative 
analysis o f the ratio o f fluorescence emitted from the supercoiled band compared to 
the total pDNA. All percentages are mean of n = 3 (SC: supercoiled fraction).
A semi-quantitative signal analysis was used to compare the fluorescence 
emission between the samples. The percentage supercoiled fluorescence was 
calculated by comparing the intensity of the supercoiled band against the 
fluorescence emitted from the total pDNA signal. The supercoiled band of 
unprocessed pDNA contributed 88 ± 7% (mean ± sd; n = 3) of emitted 
fluorescence from the total pDNA (Control, Figure 3.9). Once the pEGFP-Nl 
had been incorporated into a microemulsion and freeze-dried, fluorescence 
from the supercoiled fraction was reduced to 81 ± 12% (FD, Figure 3.9). 
Removing solvent from pDNA incorporated in a microemulsion using the 
spray-drying process caused a reduction in the supercoiled fraction to 78 ± 
19% o f the total fluorescence emitted from the whole pDNA (SD, Figure 3.9).
3.3.5.2 Microscopic Characterisation of pDNA particles
SEM was utilised to characterise any differences between the pDNA 
formulations dried using one o f the two methods, freeze-drying or spray- 
drying.
Freeze-Dried:
SEM images o f unwashed surfactant-coated freeze-dried pDNA particles 
revealed a continuous matrix with no visible particle outline (Figure 3.10).
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Figure 3.10 Scanning electron micrograph of unwashed surfactant-coated freeze- 
dried pDNA formulation containing lecithin, pEGFP-Nl and sucrose. Scale bar = 
200 pm.
Excess surfactant was removed from the lyophilised pDNA samples using a 
developed wash method which utilised propan-2-ol solvent and repeated 
vortexing and centrifugation cycles (outlined in Section 2.2.3) (Figure 3.11). 
SEM images of washed samples (Figure 3.11 A) conferred aggregates of 
pDNA-lyoprotectant particles. Figure 3.1 IB shows the presence o f a 
heterogeneous, in both size and shape, population made up of near spherical 
and cuboidal particles. Although particle sizes vary, all particles are generally 
less than 10 pm in size.
Figure 3.11 Scanning electron micrographs of solvent-washed freeze-dried pDNA 
formulation containing pEGFP-Nl and sucrose. Scale bar = 50 pm (A) and 10 pm
(B).
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Spray-dried:
SEM images, of unwashed surfactant-coated spray-dried pDNA particles, 
revealed a continuous matrix with no clear particle outline visible (Figure 
3.12).
Figure 3.12 Scanning electron micrograph of unwashed surfactant-coated spray- 
dried pDNA formulation containing lecithin, pEGFP-Nl and sucrose. Scale bar = 
200 pm.
As earlier a wash method utilising propan-2-ol solvent (Section 2.2.3) was used 
to remove excess surfactant from the spray-dried pDNA samples (Figure 3.13). 
SEM images of solvent-washed spray-dried pDNA particles (Figure 3.13A) 
revealed a general population of particle clusters residing in a continuous 
matrix. On closer inspection, Figure 3.13B revealed the continuous matrix 
interspersed with a heterogeneous particle population comprising of angular 
particles. Although the particle size is variable visible particles are smaller than 
10 pm.
Figure 3.13 Scanning electron micrographs of solvent-washed spray-dried pDNA 
formulation containing pEGFP-Nl and sucrose. Scale bar = 50 pm (A) and 10 pm
(B).
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3.3.6 A nalysis o f  Solvent-W ashed pD NA Particles 
3.3.6.1 Integrity7 o f Solvent-W ashed pD N A  Particles
The integrity o f pDNA following processing was assessed using Figure 3.14. 
Figure 14 shows the supercoiled signal band relating to pEGFP-Nl, prior to 
and following freeze-drying and solvent-wash cycles. The integrity of pEGFP- 
N1 was maintained through processing, although a partial reduction in pDNA 
signal intensity was observed.
Before After A fter freeze-
freeze- freeze- drying & 
drying drying solvent-w ash  
Figure 3.14 A typical gel electrophoresis image of pEGFP-Nl before and after 
freeze-drying and solvent-washes. The percentage values represent a semi- 
quantitative analysis of the ratio of fluorescence emitted from the supercoiled band 
compared to the total pDNA. All percentages are mean of n = 3 (SC: supercoiled 
fraction).
The fluorescence emitted from pDNA samples was compared using semi- 
quantitative signal analysis. The percentage supercoiled fluorescence was 
calculated by comparing the intensity of the supercoiled band against the 
fluorescence emitted from the corresponding whole pDNA. The supercoiled 
band of unprocessed pDNA contributed 88 ± 7% (mean ± sd; n = 3) o f emitted 
fluorescence from the total pDNA (Figure 3.14). Once the pEGFP-Nl had been 
incorporated into a microemulsion and freeze-dried, fluorescence from the 
supercoiled fraction was reduced to 81 ± 12% and then further reduced to
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76 ± 14% of the total after solvent-wash.
33.6.2 Measurement of Particle Size
Particle size analysis using photon correlation spectroscopy was performed on 
solvent-washed lyophilised particles. Analysis revealed particles with a mean 
diameter of 1.9 ± 0.8 pm (mean ± sd; n = 6). The average particle size 
distribution shown by the polydispersity index was 1.0 indicating a 
polydisperse population of particles.
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3.4 Discussion
3.4.1 Choice of lyoprotectant
Ethidium bromide (EtBr) gel electrophoresis and semi-quantitative signal 
analysis were used to assess the physical integrity of processed pDNA and 
compare the supercoiled fluorescence emission respectively. The disaccharides 
sucrose and maltose (during rapid freezing) and trehalose (during controlled 
freezing) conferred the greatest pDNA stability (70%, 75% and 86% 
fluorescence maintained from the supercoiled fraction respectively). The 
superiority o f disaccharides in maintaining macromolecule stability during 
freeze-drying has been reported due to their ability to promote glass formation 
(Crowe et al 1994) and by substituting water by hydrogen bonding with the 
macromolecule (Carpenter et al 1987; Carpenter and Crowe 1989).
The monosaccharide glucose maintained a lower pDNA supercoiled fraction 
than most o f the disaccharides. Glucose is known to have a lower glass 
transition temperature and a fewer number of hydroxyl groups for hydrogen 
bonding than the disaccharides which could be a feasible reason for its poorer 
performance in maintaining pDNA integrity (Carpenter et al 1987; Allison and 
Anchordoquy 2000).
Mannitol, in particular, was found least effective at maintaining pDNA 
supercoiled fraction during freeze-drying. Gel electrophoresis images, for both 
rapid and controlled freezing, reveal that the migration of the top most band 
was slower than the supercoiled band of the unprocessed pDNA. This led to the 
belief that the pDNA freeze-dried in the presence of mannitol had 
predominantly degraded into its linearised and nicked open circular 
conformations. This increased pDNA degradation maybe attributable to the 
tendency for mannitol to crystallize during freeze-drying (Izutsu et al 1993). 
Excipients that crystallize rather than remain amorphous during freeze-drying, 
tend to separate from the macromolecule causing the macromolecule to 
concentrate in the uncrystallised fraction (Izutsu et al 1993; Allison and 
Anchordoquy 2000). This concentration effect causes the macromolecule to 
aggregate and consequently have reduced biological activity (Anchordoquy et
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al 1997). The use of mannitol may have augmented pDNA degradation, which 
could explain the reason why a clear pDNA supercoiled fraction was not 
observed on the electrophoresis gels.
Comparisons between sugar induced pDNA protection during freeze-drying, 
using either rapid or controlled freezing, conferred no major differences 
between the freezing methods. Semi-quantitative signal analysis of pDNA 
processed without a lyoprotectant, however, revealed that an increased 
supercoiled fraction was maintained in controlled freezing conditions (89%) 
compared to rapid freezing conditions (48%). These results are contrary to the 
published literature which indicates the converse to be true as rapid freezing 
should be more efficient at minimising pDNA aggregation and therefore 
degradation (Anchordoquy et al 1998; Heller et al 1999).
The increased degradation of pDNA subjected to rapid freezing without a 
lyoprotectant compared to controlled freezing could however be explained by a 
cryolysis mechanism (Lyscov and Moshkovsky 1969). Lyscov and 
Moshkovsky (1969) described a mechanism of DNA degradation (cryolysis) 
that resulted from the formation of cracks within the ice during freezing. These 
cracks and therefore DNA degradation was shown to be more prevalent in 
rapidly cooled samples. This mechanism of cryolysis also offers an explanation 
as to why there were no major differences in the extent of pDNA degradation 
between the two freezing rates in the presence of a lyoprotectant. Glass 
formation caused by the addition of a sugar may have inhibited the cracking 
that is implicated in the DNA degradation during rapid freezing (Lyscov and 
Moshkovsky 1969; Franks et al 1991).
The data generated in this study revealed that during controlled freezing, a 
larger supercoiled pDNA signal was conferred from the pDNA sample 
processed without a sugar (89%) compared to with a disaccharide (trehalose 
86%). This is contrary to the data generated for the pDNA frozen using rapid 
freezing methods and published data, where pDNA processed in the absence of 
a sugar has been reported to result in an increased degradation (Ando et al
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1999; Allison and Anchordoquy 2000). Although a maintenance of up to 75% 
of pDNA supercoiled fraction post freezing-drying without a lyoprotectant has 
been reported, the use of a lyoprotectant has always been of benefit (Ando et al 
1999). Considering the limitations of this study, as these sets of experiments 
were not repeated (n = 1), any significant conclusions should not be drawn. 
The results however do provide an insight into the applicability of rapid 
freezing and the disaccharides sucrose, in maintaining pDNA stability which 
was confirmed by published data (Carpenter and Crowe 1989; Crowe et al 
1994; Allison and Anchordoquy 2000). As this study revealed that rapid 
freezing pDNA in the presence of sucrose during freeze-drying was able to 
sufficiently maintain pDNA stability, this method was utilised for preparing 
surfactant-coated pDNA particles for subsequent studies in this thesis.
3.4.2 Preparation of pDNA Particles
Varying quantities of pDNA were incorporated into the aqueous phase of an 
optimised microemulsion system comprising water phase: surfactant: organic 
phase 26:52:22 w/w/w (Section 2.3.1). Investigations revealed that 
incorporating pDNA up to a concentration of 0.048% (w/v) resulted in an 
isotropic system, indicating that the microemulsion had retained its stability. 
Increasing the pDNA concentration above 0.048% (w/v) resulted in a biphasic 
system, indicating that the microemulsion stability had been compromised. 
These results infer that the presence of the pDNA may have changed the 
microemulsion characteristics. To date there is a limited amount of work 
investigating how the presence of a drug affects microemulsion phase 
behaviour. However, the general consensus is that on addition of the 
hydrophilic drug, initially the microemulsion droplet size may reduce as the 
drug interacts with the hydrophilic portion of the surfactant (Lawrence and 
Rees 2000). However, further addition of the drug results in an increase in the 
droplet size (Park and Kim 1999). As the surfactant interacts with an increasing 
concentration of hydrophilic drug, this could alter the surfactant characteristics 
leading to changes in its ability to stabilise the system (Kelley and McClements 
2003). It is therefore possible that as the droplet size increases, eventually the 
interfacial area will increase beyond the surfactants capability to maintain a
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stable microemulsion, causing the system to phase separate.
3.4.2.1 Investigating the Effect of Freeze-Drying versus Spray-Drying 
During pDNA Processing
A comparative study between freeze-drying and spray-drying was carried out 
in order to determine the effectiveness of the drying method. The method of 
freeze-drying was compared to spray-drying as both have proved to be 
effective methods to prepare pDNA particles whilst maintaining pDNA 
integrity for lipid:protamine:pDNA (LPD) dry powders (Seville et al 2002; Li 
et al 2005a; Colonna et al 2008). The drying processes have not however, been 
evaluated in terms of their ability to form pDNA particles from microemulsion 
formulations.
In this comparative study the recovered percentage yield of the pDNA 
formulation was considered an important parameter. The reason for this was 
that each formulated microemulsion could only contain a maximum of
0.048% (w/v) pDNA in the aqueous phase whilst maintaining a stable isotropic 
state. Therefore, a low recovery of the pDNA particle formulation post-drying 
would result in a high wastage of pDNA that is relatively expensive and labour 
intensive to prepare. This would be detrimental from a large scale 
manufacturing perspective as well was for the progression of this project.
The recovered yields revealed a relatively large difference between the freeze- 
drying (94 ± 5%) and spray-drying process (20 ± 10%). The relatively high 
yield of recovered surfactant-coated pDNA particles from the freeze-dried 
procedure was to be expected as the formulation was dried in situ within its 
collection vessel (Liao et al 2004; Maitani et al 2008). Recovery from the 
spray-dried formulation however was deemed more difficult as the product was 
atomised and carried to the collection vessel using air flow. Typical yields of 
spray-dried samples are in the range of 40% to 70% (Maa et al 1998; Nguyen 
et al 2004; Li and Birchall 2006). This low yield is related to the fact that often 
small quantities of samples are spray-dried using relatively large spray-driers 
causing an increase in the possibility of sample loss throughout the apparatus.
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In comparison to these reported typical yields, the quantity of pDNA 
formulation recovered in this study using spray-drying was exceptionally low. 
A possible reason for this was that as the pDNA particles were coated in 
surfactant which had a sticky texture, these particles had a tendency to stick to 
the various parts of spray-drying apparatus leading to a reduced sample 
recovery in the collection vessel. The low yield conferred from the spray- 
drying process is also a problem typically seen with cohesive powders for the 
same reason mentioned (Li et al 2005b; Li and Birchall 2006).
DNA integrity, assessed by gel electrophoresis, was studied following the 
drying of pDNA incorporated microemulsions using either freeze-drying or 
spray-drying methods. pDNA samples were analysed for their transfection 
competent supercoiled fraction as degradation of this fraction may have 
detrimental effects on the transfection efficiency of the pDNA (Chemg et al 
1999; Chancham and Hughes 2001). Analysis of the unprocessed pDNA 
(control, Figure 3.9) indicated that 88% (± 7%) was in the supercoiled form 
which is within the expected range (80-90%) for small-scale, freshly made 
pDNA preparations (Middaugh et al 1998). Further analysis of freeze-dried 
and spray-dried preparations, showed a reduction in the supercoiled fraction (to 
approximately 81 (± 12%) and 78 (± 19%) respectively). This reduction may 
have possible adverse implications on the pDNA gene expression efficiency as, 
although linear DNA forms have been found to be transfection competent 
(Chancham and Hughes 2001; von Groll et al 2006), most published literature 
supports the opinion that pDNA supercoiled structure should be retained to 
optimise cellular transfection efficiency (Chemg et al 1999; Remaut et al 
2006) and to comply with regulatory requirements on product quality 
(Arulmuthu et al 2007). However, in comparison to published reports, the 
results in this study infer that the process of either freeze-drying or spray- 
drying the pDNA-loaded microemulsion had a comparatively small adverse 
effect on the supercoiled form. The relatively small change in supercoiled 
fraction observed through processing is similar to that previously observed for 
freeze-dried and spray-dried lipid:protamine:pDNA (LPD) dry powders for 
inhalation prepared in the presence of a lyoprotectant (Seville et al 2002; Li et
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al 2005a).
Freeze-dried pDNA samples were expected to retain their supercoiled fraction 
as the method works on the principle of sublimation using low temperatures 
and reduced pressures and is therefore suited to preparing thermolabile 
powders (Maitani et al 2008; Prego et al 2010). However, the relatively small 
reduction in the supercoiled fraction detected post spray-drying could initially 
be deemed as surprising, as spray-drying has demonstrated degradation of 
thermolabile macromolecules through shear-induced and thermal stress 
(Mumenthaler et al 1994; St&hl et al 2002). The reason for this degradation is 
related to the fact that DNA denaturation is reported to occur at temperatures as 
low as 65°C (Lasic and Templeton 1996; Blake and Delcourt 1998). The 
elevated temperatures involved in the spray-drying procedure (inlet 
temperature 120°C, outlet temperature of 80°C) are therefore able to adversely 
affect the pDNA integrity. This said, the pDNA sample temperature may have 
remained significantly less than the drying air due to evaporative cooling and 
the final product may have been protected from overheating by its rapid 
removal from the drying zone (Johnson 1997). Also the presence of a 
lyoprotectant such as sucrose has been reported to aid in macromolecule 
preservation during spray-drying as a thermal and dehydration stress stabiliser 
(Tzannis and Prestrelski 1999; Colonna et al 2008).
The dimensions and surface morphology of processed pDNA particles were 
visualised using SEM. Microscopic characterisation of dried pDNA- 
lyoprotectant incorporated microemulsions revealed a continuous matrix, 
which may be the sticky surfactant system, covering the particles. A relatively 
high concentration of surfactant is required to stabilise microemulsion systems 
due to the large interfacial area between the disperse phase and the continuous 
phase (Shinoda et al 1991; Zarur et al 2000). However, the large quantity of 
surfactant used at the microemulsion stage leads to an excess of surfactant 
covering the pDNA particles resulting in the observed hindered surface 
morphology characterisation.
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A solvent-wash technique developed in the previous chapter (Section 2.2.3) 
was used to remove the excess surfactant in order to visualise particles as the 
shape and size of the dried particles might differ depending on the drying 
condition used. Spray-drying for instance offers the potential to produce 
particles that are homogenous and smaller in size due to the atomisation and 
evaporation methods used during this process (Maa et al 1997; Seville et al 
2002). These features, however, may not be observed in this study as the use of 
a microemulsion template should dictate the size of the resulting particles 
(Dickinson et al 2001).
Solvent-washed freeze-dried particle formulations revealed a reduction of 
excess surfactant so that individual particles could be visualised. The SEM 
images revealed a heterogeneous particle population comprising angular 
particles, likely to be the sucrose lyoprotectant, and more rounded particles, 
possibly including surfactant-coated pEGFP-Nl particles. SEM images of 
solvent-washed spray-dried pDNA particles revealed a continuous matrix, 
possibly the surfactant system, interspersed with protrusions of a 
heterogeneous particle population comprising of angular particles, likely to be 
the pDNA particle formulation.
A stark difference between the freeze-dried and spray-dried SEM images was 
observed due to the presence of the surfactant continuous matrix in the latter 
image. The presence of surfactant in the spray-dried SEM images may have 
been due to the fact that the spray-dried sample was put through a smaller 
number of wash cycles (3 wash cycles) compared to the freeze-dried sample (6 
wash cycles). The reason for this being that a smaller quantity of the spray- 
dried sample was used in the solvent-wash, due to the low yield recovered 
Table 3.3, and so too many wash cycles may have resulted in total loss of the 
sample. The insufficient solvent-wash of spray-dried pDNA particles makes 
particle characterisation and any comparisons against the freeze-dried sample 
difficult. However, as the freeze-drying technique was found to successfully 
prepare transfection competent pDNA particles, and the solvent-wash 
procedure was able to remove some of the excess surfactant from the pDNA
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particles, repeating this study for the spray-dried particles was not deemed 
necessary.
3.43 Analysis of Solvent-Washed pDNA Particles
The relatively high concentration of surfactant required to formulate a stable 
microemulsion system, in addition to hindering particle characterisation 
(Section 3.3.5.2), could also potentially adversely affect pDNA cellular 
functionality (Duncan et al 1997), an issue investigated in later chapters, and 
formulation dispersibility and physical stability in a pMDI due to the poor 
solubility of surfactants in HFA propellants (Blondino and Byron 1998). 
Although SEMs of the sequentially washed freeze-dried samples was found to 
successfully remove some of the excess surfactant (Section 3.3.5.2), it is 
important to assess pDNA integrity following solvent-washing from a pDNA 
functionality perspective. As mentioned earlier, a reduction in the transfection 
competent supercoiled fraction may have detrimental effects on the 
transfection efficiency of the pDNA (Chemg et al 1999; Chancham and 
Hughes 2001).
Analysis of ffeeze-dried and freeze-dried then solvent-washed preparations, did 
show a small reduction in the supercoiled fraction (from 88% (± 7%) 
unprocessed pDNA to approximately 81% (± 12%) and 76% (± 14%) 
respectively). This data highlights a possible limitation of the developed 
technology and the need for further optimisation of the process in order to 
maintain pDNA integrity and maximise cellular transfection efficiency. This 
said, comparisons of these results with those previously published infer that the 
process of freeze-drying the pDNA-loaded microemulsion had a comparatively 
small adverse effect on the supercoiled form and that further processing, via 
sol vent-washing, was not particularly detrimental. The relatively small change 
in supercoiled fraction observed through processing, i.e. 88% to 76%, is similar 
to that previously observed for spray-dried lipid:protamine:pDNA (LPD) dry 
powders for inhalation prepared in the presence of a lyoprotectant (Seville et al 
2002; Li et al 2005a). These results were not particularly surprising as although 
there are no published reports on the effect of solvent-washing pDNA particles,
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solvent-washing protein particles to remove excess surfactant was found not to 
be detrimental (Nyambura et al 2009b).
Particle size analysis of solvent-washed lyophilised particles revealed particles 
with a mean diameter o f 1.9 ± 0.8 pm. Photon correlation spectroscopy data 
supports the SEM images of lyophilised solvent-washed pDNA particles, as the 
particle sizing technique verifies that particles are smaller than 10 pm. 
Although the technology explored in this thesis was originally reported to 
generate particles of the nanoparticle size range (Dickinson et al 2001), such 
discrete particles were not detected. A possible reason for the larger particle 
size could be due to the particles being aggregated, which is certainly observed 
in the SEM images (Section 3.3.5.2). Nevertheless the particles generated from 
the developed technology was a significant advancement, as previous reports 
of lyophilised powders have often shown particles with diameters unsuitable 
for pulmonary delivery and generally require further processing using a milling 
step prior to incorporation into an inhaler (Seville et al 2002; Shoyele and 
Cawthome 2006). It is generally acknowledged that particles require an 
aerodynamic diameter < 5 pm to allow efficient penetration and deposition in 
the peripheral pulmonary regions (Hickey 1993). Solvent-washed lyophilised 
particles, although not in the nanoparticle size range, are still in the respirable 
size range for deposition in the bronchiolar and alveolar region.
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3.5 Conclusion
This chapter aimed to further develop a nanotechnology process, previously 
used for small molecular weight drugs, and investigate its feasibility to 
formulate pDNA particles with the potential for incorporation into a pMDI.
Studies investigating the maintenance of pDNA integrity during freeze-drying 
demonstrated that pDNA freeze-dried in the presence of a disaccharide retained 
the supercoiled fraction which was confirmed by published data. Comparative 
studies between freeze-dried and spray-dried pDNA particles revealed that 
although in both cases the integrity of pDNA was maintained to a similar 
extent, freeze-drying was a more efficient process in terms of the recovered 
pDNA yield. Characterisation of solvent-washed freeze-dried pDNA particles, 
using SEM, and analysis of its retained integrity, using agarose gel 
electrophoresis, revealed that the developed washing procedure served to 
successfully remove some of the excess surfactant from the pDNA particles 
with a relatively small reduction in the pDNA integrity. Although the pDNA 
particles remained aggregated post-washing, particle sizing using photon 
correlation spectroscopy revealed pDNA particles were in the respirable size 
range for peripheral pulmonary deposition.
The data generated in this chapter highlight the feasibility of this developed 
technology, which utilises a low energy microemulsion lyophilisation process, 
to formulate pDNA particles with potential for incorporation into a pMDI 
system.
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CHAPTER FOUR 
Characterisation, Transfection 
and Cellular Toxicity of pDNA 
Delivered by pMDI
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4.1 Introduction
The former chapter demonstrated that pDNA integrity could be maintained 
after processing to form pDNA particles using the outlined technology. This 
chapter will attempt to investigate the feasibility of incorporating these pDNA 
particles into a pMDI system and assess the pDNA biological functionality, 
using in vitro cellular transfection studies. Such studies will provide evidence 
of retained stability from a gene expression perspective.
Published reports have demonstrated that cellular uptake of naked DNA in its 
native form remains relatively inefficient (Zabner et al 1997; Remaut et al 
2006). As a consequence, gene transfer vectors are employed in cellular 
transfection studies to promote cellular uptake and processing of the nucleic 
acid cargo (Remaut et al 2006; Davies et al 2008; Jiang et al 2008). Gene 
transfer vectors are generally split into two groups; viral gene vectors and non- 
viral gene vectors. Of the two, non-viral gene vectors are regarded to be the 
more clinically accepted form of vector from a safety perspective as they do 
not face the inherent safety and immunogenicity issues often associated with 
viral vectors (Thomas et al 2003; Li and Huang 2007). There are a number of 
non-viral gene vectors available including the polysaccharide chitosan (Guang 
Liu and De Yao 2002), polyethyleneimines (Densmore et al 2000) and 
dendrimers (Haensler and Szoka 1993; Jeong et al 2007). Also in this category 
of non-viral agents are cationic lipids and liposomes which have demonstrated 
proof-of-principle for gene transfer to the airway for almost two decades 
(Stribling et al 1992; Alton et al 1993; McDonald et al 1998).
4.1.1 Cationic Liposomes
Liposomes are structures composed of single or multiple concentric bilayers 
resulting from the assembly of amphiphilic molecules, such as phospholipids, 
in aqueous medium (Bangham and Home 1964; Schuber et al 1998). Cationic 
lipids, which may form liposomes in aqueous media, can be divided into three 
main sections, a hydrophobic lipid anchor group which interacts with the cell 
membrane, a linker group which is responsible for the lipids chemical stability
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and biodegradability and a positively charged head group which interacts with 
the plasmid and promotes condensation (Figure 4.1).
Feigner et al (1987) introduced the idea of using cationic liposomes as efficient 
pDNA carriers for intracellular delivery using N-[l-(2,3-dioleoyloxy) propyl]- 
N,N,N, trimethylammonium chloride (DOTMA). Since then other lipids such 
as 1,2 dioleoyloxypropyl-3 (trimethylammonium)- propane (DOTAP), 2,3 
dioley loxy-V- [2(sperminecarboxaminino)ethy 1]-V,V-dimethyl-1 
propanaminium (DOSPA) and cetyltrimethylammoniumbromide (CTAB) have 
been synthesised. Transfection studies in this chapter will focus on using 
DOTAP as this readily available lipid has been shown to be effective at 
delivering pDNA in vitro (Birchall et al 1999) and in vivo (Porteous et al 
1997). In addition DOTAP has been suggested to have reduced cell toxicity 
compared to other lipids, such as DOTMA. This is because, unlike DOTMA, 
DOTAP contains readily cleavable ester bonds, which link the cationic 
headgroup to the lipid anchor, facilitating its degradation in eukaryotic cells 
(Leventis and Silvius 1990; Pedroso de Lima et al 2001) (Figure 4.1).
Linker HeadgroupLipid Anchor
C H .
Figure 4.1 Schematic illustration of the chemical structure of 1,2 
dioleoyloxypropyl-3 (trimethylammonium)- propane methylsulphate (DOTAP).
Highlighting the hydrophilic head-group, linker region and hydrophobic lipid anchor.
4.1.1.1 Preparation of Cationic Liposomes
Several methods are available to prepare liposomes including, vortexing, 
sonication, and extrusion. These techniques are used to prepare small 
unilamellar vesicles (SUV), consisting of a single bilayer, from multilamellar 
vesicles (MLV) which consist of multiple concentric lipid bilayers. Liposomes
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in this project were prepared by extrusion as this method offers greater batch to 
batch reproducibility of vesicle size and size distribution than the other 
methods, due to the physical processing involved (Lapinski et al 2007). 
Briefly, the extrusion process involves a technique in which the lipid 
suspension, prepared by the hydration of a thin lipid film in an aqueous 
solution, is forced through a polycarbonate filter with a defined pore size. 
Extrusion causes the concentric layers of ML Vs to deform so that they can pass 
though the filter pore. As the ML Vs pass through the pores breaking and re­
sealing of the membranes occurs. If the liposome preparation is repeatedly 
cycled through the extrusion process a SUV population with a mean diameter 
that is comparable to the diameter of the filter pore can be produced (Hope et 
al 1985; Mayer et al 1986). The size of the liposome used to complex with the 
pDNA is important as it has been shown to affect resulting pDNA cell 
transfection (Templeton et al 1997). The extrusion of cationic liposomes 
through filters results in the conversion of MLV, which may be tens of microns 
in size, into SUV which may be only tens of nanometres in size. The overall 
increase in the surface area of the liposomes by extrusion results in more 
efficient complexing with the pDNA which is essential for transfection (Hope 
et al 1985; Templeton et al 1997).
4.1.1.2 Liposomal Gene Delivery
Due to the difference in electrostatic charge, cationic liposomes are able to 
interact with DNA to form deliverable complexes so as to promote pDNA 
transfection into cells (Feigner et al 1987; Gao and Huang 1995). The 
electrostatic interactions between the anionic phosphate backbone of pDNA 
molecules and the positively charged polar amino- head group of the cationic 
lipids result in the pDNA self-assembling with the lipid to form lipoplexes 
(lipid-DNA complexes) of condensed pDNA. The condensation of DNA, 
which involves a decrease in the volume occupied by a DNA molecule, is of 
immense biological importance as it serves as a platform for enhancing the 
cellular delivery of DNA and protection from degradation by nucleases 
(Bloomfield 1996; Crook et al 1996). The formation of lipoplexes with an
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overall positive charge facilitates the association of the lipoplex with the 
negatively charged cell membrane, and therefore entry of the complex into the 
cell primarily via the endocytotic route (Feigner et al 1987; Zabner et al 1995; 
Xu and Szoka 1996).
Although lipoplexes are widely used to transfect DNA into cells both in vitro 
and in vivo (Xu and Szoka 1996), lipoplexes that are microinjected directly into 
the nucleus do not induce high expression levels of the transgene (Zabner et al
1995). This implies that during the normal transfection process, plasmid DNA 
is released from the lipoplex before entering the nucleus (Xu and Szoka 1996). 
The mechanism by which DNA dissociates from the lipoplex is poorly 
understood, especially because there is a strong interaction between the 
cationic lipid and DNA (Gershon et al 1993).
Many researchers have found that destabilising the endosome membrane, by 
which the lipoplex enters the cell, plays a key role in catalysing DNA 
dissociation from its lipoplex and its subsequent release into the cytoplasm. 
When the cationic lipoplex comes into close contact with the negatively 
charged membrane of the endosome, the lipoplex fuses with the membrane 
causing membrane asymmetry to be lost resulting in its destabilisation 
(Stamatatos et al 1988; Bevers et al 1994). The destabilisation of the endosome 
membrane results in an influx of anionic lipids, which are located on the 
cytoplasmic face of the membrane, via a ‘flip-flop’ mechanism (Xu and Szoka
1996). The anionic lipids compete with the DNA for the cationic lipid, 
resulting in DNA displacement to form charge-neutralized ion pairs with the 
cationic lipids. The dissociated DNA is then permitted to enter the cell 
cytoplasm.
The cytoplasmic pDNA must then enter the cell nucleus for transcription to 
occur. In dividing cells pDNA entry into the nucleus is considered to occur 
predominantly during the cell mitosis stage during which the nuclear 
membrane disintegrates, allowing cytoplasmic pDNA entry into the nuclear
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compartment (Wilke et al 1996; Brunner et al 2000). However, in non-dividing 
cells pDNA entry into the nucleus of such cells is suggested to also be via 
transport through the nuclear pore complex which spans the nuclear envelope 
(Dowty et al 1995; Dean 1997).
4.1.2 Cell Culture of a Mammalian Cell Line
The A549 cell line, used for the cell culture experiments in this chapter, 
originates from human lung carcinoma cells of a 58 year old Caucasian male 
(Lieber et al 1976). The A549 cells are a continuous epithelial cell line. 
Continuous cell lines are transformed from primary cells by a series of 
mutational events resulting in their capacity to multiply indefinitely in vitro.
The use of in vitro cell culture models to assess pDNA transfection can be 
advantageous in the sense that in vitro experiments are generally more 
economical than in vivo, the usage of animals is reduced if preliminary proof- 
of-principle studies are carried out in vitro and in vitro studies can offer more 
rapid results with better experimental control (Forbes 2000). However in vitro 
models are often based on cells with two dimensional growth characteristics 
(A549 cells) which do not mimic the complex three-dimensional geometry of 
cell interactions in vivo. Additionally in vitro cells tend to display a more 
constant rate of growth than cells in vivo, and as gene transfer occurs 
predominantly during the mitotic stage a significant variation between pDNA 
transfection efficiency can often be observed between the two models (Wilke 
et al 1996). More specifically to inhalation therapy, the lungs possess 
numerous biological barriers and mechanisms which in vitro models do not 
possess. Examples of this include the mucus layer and the mucociliary 
escalator that contribute to the clearance of foreign particles and therefore 
hinder their ability to exert any therapeutic effect (Farr et al 1985; Barker et al 
1994; Weers et al 2009). In spite of this, A549 cells possess some of the 
morphological and biochemical features of the pulmonary alveolar type II cells 
typified by their endogenous ability to synthesise and secrete 
phosphatidylcholine, a constituent of lung surfactant (Lieber et al 1976; Smith
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1977).
The use of cell cultures in laboratory investigations requires prior knowledge 
of growth characteristics for the specific cell line. Growth studies which 
involve plotting a growth curve are an essential prerequisite for ensuring that 
transfection studies are carried out on cells which are at their most viable and 
uniform state (cells in their log phase) (Freshney 2000).
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4.1.3 Specific Aims and Objectives of the Chapter
The primary aim of this chapter is to report the potential for incorporating 
solvent-washed pDNA particles, prepared using methods developed in 
previous chapters, into a pMDI system. This chapter’s secondary aims are to 
detail whether it is viable to aerosolise and deliver these pDNA particles via a 
pMDI using a standard valve and actuator and preliminary assess any 
formulation toxicity issues.
The experimental objectives are to:
1. Culture A549 human lung epithelial cells and establish growth 
characteristics.
2. Prepare DOTAP liposomes via solvent evaporation and extrusion methods 
and characterise liposomes in terms of particle size.
3. Identify the optimum DOTAP:pDNA constituent ratio by quantifying 
transfection efficiency on A549 cells using flow cytometry.
4. Assess the transfection competency of lyophilised pDNA particulates 
(before loading into pMDI) on A549 cells using flow cytometry.
5. Characterise the aerosolised solvent-washed pDNA particles using SEM of 
particles deposited at various stages of the ACI.
6. Verify stability of pDNA particles post pMDI aerosolisation through 
maintenance of the supercoiled fraction.
7. Assess pDNA functionality following pMDI aerosolisation via gene 
expression efficiency in A549 cells.
8. Investigate cytotoxic effects of the aerosolised pDNA pMDI formulation on 
the A549 cell line.
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4.2 Materials and Methods
All reagents were used as received and were purchased from Fisher Scientific 
UK Ltd. (Loughborough, UK) unless otherwise stated.
Deionised water was obtained from an Elga reservoir (High Wycombe, UK). 
Phosphate buffered saline pH 7.4 (Mg2+ and Ca2+ free), trypan blue, 
Chloroform > 99.8% spectrophotometric grade and MTT-based assay kit were 
purchased from Sigma-Aldrich Ltd. (Poole, UK). Agarose (LE analytical 
grade) was purchased from Promega Ltd. (Southampton, UK). Dulbecco’s 
Modified Eagle’s Medium (DMEM), foetal bovine serum, penicillin G 
5000 units/ml, streptomycin sulphate 5000 fig/ml and trypsin-EDTA were 
purchased from Invitrogen Ltd. (Paisley, UK). 5x coloured loading buffer blue 
was purchased from Bioline Ltd. (London, UK). A549 mammalian cell line 
was purchased from ECACC (Salisbury, UK); 1,2- Dioleoyl- 3- 
Trimethylammonium propane (methyl sulphate salt) (DOTAP) was purchased 
from Avanti Polar Lipids Inc. (Alabama, USA). HFA 134a was a generous gift 
of INEOS Fluor Ltd. (Runcorn, UK). Brilliant Blue pMDIs were obtained 
courtesy of 3M Healthcare Ltd (Loughborough, UK).
4.2.1 Cell culture
Cell culture was carried out in a Class II laminar flow cabinet. The laminar 
flow cabinet and any cell culture equipment placed in the cabinet were sprayed 
with 70% (v/v) absolute ethanol in water prior to use. All media was sterile and 
pre-warmed to 37°C using a water bath to avoid any contamination and 
thermal damage to the cells respectively.
All cell investigations were performed using A549 human lung epithelial cells 
following at least two passages post-thawing. Cells were maintained as 
adherent monolayer cultures in 25 cm2 angled neck, cell culture flasks (T25) 
(Coming Costar Ltd., High Wycombe, UK) in 5 ml growth media (10% fetal 
bovine serum, 2% penicillin/streptomycin 5000 iu/ml and Dulbecco’s Modified 
Eagle’s Medium (DMEM) to 100%). Cells were stored in a humidified
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incubator at 37°C containing 5% CO2. Once the cell line was confluent (every 
72 hr) the growth media was removed using a pipette and washed twice with 
5 ml pre-warmed phosphate buffered saline (PBS pH 7.4). The adherent cells 
were then released enzymatically by incubating them (37°C/ 5% CO2) for 
5 min with 1ml trypsin-EDTA. After 5 min the flask containing the cells was 
gently tapped on the bench top to ensure all the cells were released from the 
surface of the flask. The cells were then re-suspended using 10 ml growth 
media, pipetted into a 50 ml centrifuge tube and centrifuged at 1000 rpm for 
5 min (20°C) using an Avanti J-20 XP Beckman Coulter centrifuge with J-14 
head (Beckman Coulter, London, UK). The resultant supernatant was gently 
removed from the centrifuged cells using a pipette, the pellet formed during 
centrifugation was re-suspended using 10 ml growth media. Pipetting action 
was used to disperse the cell pellet throughout the growth media ensuring a 
homogenous cell suspension. A 50 pi aliquot of the cell suspension was taken 
and a cell count using a neubauer double net ruling bright lined 
haemocytometer (Fisher Scientific Ltd., Loughborough, UK) was performed. 
A549 cells were reseeded at 1 x 106 cells/ T25 flask in 5 ml of growth media 
and returned to the humidified incubator (37°C/ 5% CO2).
Cells were counted using a haemocytometer and trypan blue dye. Trypan blue 
is a stain used to selectively colour dead cells with damaged plasma 
membranes as live cells with an intact cell membrane exclude the stain. During 
cell counting non-viable cells, stained blue, were excluded from the cell counts 
with the aid of the exclusion dye. An equal volume (50 pi) of 0.4% trypan blue 
was pipetted into an eppendorf tube containing the cell suspension and 
incubated (37°C/ 5% CO2) for 5 min.
A precision ground cover slip was pressed gently onto the top of the 
haemocytometer until Newton rings were visible. Approximately 10 pi of the 
incubated cell suspension was pipetted onto the haemocytometer at either end 
of the cover slip. Capillary action caused the cell suspension to be drawn into 
the haemocytometer counting chamber. The haemocytometer was then placed
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under a light microscope so that number of living cells present on the grids 
engraved on the haemocytometer could be counted.
The haemocytometer is made up of two counting chambers. Each counting 
chamber contains an engraved grid. The total volume of cell suspension found 
on each square is KT4 ml (Figure 4.2). The number of cells present in 1 ml of 
the cell suspension was therefore calculated using the following formula:
No o f cells per ml = (A verage No o f  cells counted in 1 square x 2) x 104
(Note: the number of cells counted was multiplied by a factor of two to allow 
for the dilution of cell suspension with trypan blue).
Area = 1 mm2 
Depth = 0.1 mm 
Volume = lxlO'4 ml
1 mm
; . . . . . . .
1 mm
Figure 4.2 Schematic drawing of one haemocytometer counting chamber.
4.2.2 A 549 Cell Growth Study
A549 cells prepared for the growth study were seeded into 24-well plates at a 
density of 4 x 104 cells/cm2 and submerged under 1 ml growth media. The 
seeding time was noted and cells were stored in a humidified incubator (37°C/ 
5% CO2). Cells were counted twice daily for a period of four days. During the 
growth study, cells were washed twice with 1 ml pre-warmed PBS pH 7.4, 
enzymatically released from the 24-well plate using 125 pi trypsin-EDTA and 
re-suspended in 875 pi growth media. The cell suspension was then prepared 
for counting using trypan blue as outlined earlier (Section 4.2.1). A growth 
curve was then plotted for the A549 cells in order to monitor cell growth over 
time.
118
Chapter Four
4.23 DOTAP Liposome Preparation
To prepare DOTAP liposomes, 10 mg of DOTAP was weighed into a 100 ml 
round bottom flask and 5 ml of chloroform was added to dissolve the lipid. 
Once the lipid was dissolved, the round bottom flask was securely attached to a 
rotary evaporator set at approximately 1 revolution per second under negative 
pressure and 37°C. Once the chloroform had evaporated, rotary evaporation 
was carried on for a further 90 min in an attempt to remove solvent residues 
and produce a thin lipid film. A 1 mg/ml solution of DOTAP was prepared by 
adding 10 ml pre-warmed (37°C) sterile water. The flask was agitated using a 
vortex mixer to remove the lipid film from the glass to produce a multilamellar 
liposome solution. The round bottom flask was incubated for 30 min in a water 
bath (37°C) to aid annealing of the liposomes.
An extrusion process was used to form unilamellar vesicles from the 
multilamellar DOTAP vesicles. DOTAP was pipetted slowly into the central
T W
chamber of an Extruder (Lipex Biomembranes Inc., Vancouver, Canada) 
and extruded through a 100 nm polycarbonate filter (Millipore, Watford, UK) 
using nitrogen pressure set between a 5-10 bar range. In order to obtain a 
vesicle population with a narrow size distribution the liposome suspension was 
cycled through the extrusion process a total of ten times (Hope et al 1985; 
Mayer et al 1986).
The mean diameter of liposomes was determined by photon correlation 
spectroscopy using a Coulter® N4 Plus (Coulter Electronics Ltd., Luton, UK). 
Liposomes (200 pi) were dispersed in sterile water (1800 pi). Samples were 
transferred into a clear sided disposable cuvette, which was sealed using 
Parafilm to prevent evaporation. Measurements were expressed using the 
unimodal size distribution model and repeated three times.
4.2.4 Optimising DOTAP: pDNA Ratio for Transfection Studies
Prior to assessing the transfection competency of lyophilised pDNA particles 
(Section 3.2.5), a pilot study was carried out to investigate the optimum
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DOTAP: pDNA ratio in order to maximise cell transfection.
DOTAP: pDNA complexes were prepared by adding 18 pg of unprocessed 
pEGFP-Nl to DMEM (up to 6 ml). Extruded DOTAP ranging from a DOTAP 
liposome: pDNA ratio of 4:1 w/w increasing in two unit increments up to 
12:1 w/w was slowly pipetted into the DMEM-pDNA solution. The various 
DOTAP liposome: pDNA ratio treatments were gently vortexed and then left 
to stand for 20 min to promote complexation.
Cellular transfection and gene expression performance was assessed in A549 
cells seeded into 24-well plates at a density of 4 x 104 cells/cm2 and cultured 
under the specified culture conditions (Section 4.2.1) for 48 hr (68% 
confluency) as determined by the cell growth study (Section 4.2.2). Cells 
contained in 6 wells of the 24-well plates were each subjected to treatment with 
either 1 ml DMEM alone or up to 1 ml DMEM containing DOTAP liposome: 
pDNA complexes ranging from 4:1 w/w to 12:1 w/w ratios. Cells were then 
returned to the humidified incubator (37°C/ 5% CO2) for 6 hr. After 6 hr the 
DMEM containing the treatments was removed, cells were washed once with 
1 ml pre-warmed PBS pH 7.4 and replenished with 1 ml growth media. Cells 
were then returned to the humidified incubator (37°C/ 5% CO2).
4.2.4.1 Analysis of Gene Expression
42 hr after treatment cells were surface rinsed twice with 1 ml cold PBS pH 7.4 
and trypsinised with 150 pi trypsin-EDTA solution. After 1 min the trypsin- 
EDTA was removed from the cells using a pipette and the cells were incubated 
(37°C/ 5% CO2) for 10 min. Cells were then resuspended in 600 pi growth 
media. The cell suspension was then transferred from the well into an 
appropriately labelled flow cytometry tube (Falcon® Becton, Dickinson 
Biosciences, Oxford, UK) and placed on ice prior to analysis. The percentage 
of cells displaying GFP-associated fluorescence (FL1-H) was quantified by 
flow cytometry (FACSCalibur™ system Becton, Dickinson Biosciences, 
Oxford, UK) with analysis by WinMDI™ Software (Joseph Trotter, The
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Scripps Institute, California, USA), as described previously (Seville et al 
2002). Untreated control cells were used to establish a ‘gated’ region which 
excluded the fluorescence detected due to the natural autofluorescence of cells. 
The percentage of EGFP positive cells (fluorescent cells) was measured from 
the cells in this established ‘gated’ region.
4.2.5 Assessing the Transfection Competency of Lyophilised pDNA 
Particulates
The biological functionality of lyophilised pDNA particles (Section 3.2.5) was 
assessed in A549 cells seeded into 24-well plates at a density of 
4 x 104 cells/cm2 and cultured under the specified culture conditions (Section 
4.2.1) to 68% confluency (cells were in their log phase).
Cells were subjected to one of seven treatments (Figure 4.3): (i) DMEM alone 
(no pDNA), (ii) unprocessed pEGFP-Nl (positive control), (iii) an unwashed 
formulation of lyophilised DNA-loaded particles, (iv) a solvent-washed variant 
of formulation (iii). In the case of (ii), (iii) and (iv) the formulations were 
added directly onto cells covered with (A) DMEM alone or (B) DMEM 
containing extruded DOTAP liposomes (Section 4.2.3). A549 cells, in each 
well of a 24-well plate, were treated with the equivalent of 5 pg pEGFP-Nl. In 
the case of cells treated in the presence of DOTAP, a 6:1 w/w DOTAP 
liposome: DNA ratio was used. All treatments were conducted in serum-free 
DMEM. Treated cells were stored in a humidified incubator (37°C/ 5% CO2). 
After a period of 6 hr, cells were washed once with 1 ml PBS, pH 7.4, 
replenished with 1 ml of growth media and returned to the humidified 
incubator (37°C/ 5% CO2).
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Figure 43 Diagrammatic representation of the production of samples for 
subsequent in vitro analysis.
The biological functionality of lyophilised pDNA particles was assessed 
qualitatively at 42 hr post-treatment, using fluorescent microscopy and 
quantitatively by flow cytometry (FACSCalibur™ system Becton, Dickinson 
Biosciences, Oxford, UK) with analysis by WinMDI™ Software (Joseph 
Trotter, The Scripps Institute, California, USA) (Section 4.2.4.1).
4.2.6 Production of pDNA pMDI Formulations
Two pMDI formulations were aerosolised and investigated for pEGFP-Nl 
biological functionality with the aim to determine whether you could detect 
gene expression based upon a loadable quantity. The first “unwashed” 
formulation used unwashed surfactant-coated, lyophilised pEGFP-Nl particles 
(25 mg, which was a quantity of formulation that would disperse in the 
propellant). The second “washed” formulation (16 mg) used the same batch of 
particles after solvent-washing to remove excess surfactant (the wash method 
was outlined Section 2.2.3). Particles were weighed directly into fluorinated 
ethylene propylene (FEP) coated aluminium canisters (3M Drug Delivery 
Systems, Loughborough, UK) and dispersed in absolute ethanol a co-solvent
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(0.5 ml) using a vortex mixer. Spraymiser™ 50 pi retention valves (3M Drug 
Delivery Systems, Loughborough, UK) were crimped onto the aluminium 
canisters and 6 ml HFA 134a was added using a Pamasol® semi-automatic 
filling and crimping machine model P2005/2 (Pamasol Willi M&der AG, 
Pf&ffikon SZ, Switzerland). Washed formulations were also prepared in plastic 
polyethylene terephthalate (PET) pMDI vials (3M Drug Delivery Systems, 
Loughborough, UK), for visual assessment of physical stability and dispersion 
homogeneity. pMDI vials were stored at room temperature with visual 
observation at 24 hr and 5 months.
4.2.7 Assessment of pDNA pMDI Formulations
4.2.7.1 Integrity of pDNA Particles Following Aerosolisation from a pMDI
Agarose gel electrophoresis, with EtBr staining, was used to determine the 
physical integrity of the processed pEGFP-Nl following aerosolisation from a 
pMDI system. Following the incorporation of the unwashed and washed 
processed pDNA into a pMDI formulation, the formulations were actuated 
onto glass slides with the equivalent of 2 pg aerosolised pEGFP-Nl. The 
pDNA formulation deposited on the glass slides was reconstituted with 15 pi 
of TE buffer pH 8.0 and made up to 20 pi with 5x coloured loading buffer. A 
control sample of the unprocessed pDNA diluted to 2 pg/ 15 pi using TE 
buffer was also prepared and made up to 20 pi using 5x coloured loading 
buffer blue. The 20 pi aliquots of each sample were then carefully pipetted into 
the wells of an EtBr agarose gel (gel preparation was carried out as outlined in 
Section 3.2.3.1). The gel was developed for 50 min at 200 volts and analysed 
using Molecular Analyst® software and Bio-Rad Gel Doc 1000 (Bio-Rad 
Laboratories Ltd., Hertfordshire, UK).
4.2.7.2 Aerosolised Delivery to Cell Culture Flask
Initial pilot studies, using pMDIs containing Brilliant Blue dye, were carried 
out to determine the most efficient orientation for delivery to cell culture 
medium (Figure 4.4). Brilliant Blue incorporated into a pMDI was primed by 
actuating five shots to waste using an actuator with a 0.5 mm orifice diameter
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(3M Drug Delivery Systems, Loughborough, UK). The Brilliant Blue pMDI 
was then actuated 5 times into a T25 cell culture flask, containing 6 ml of 
water, by either spraying vertically or horizontally (with regards to the plane of 
the aerosolised spray) (Figure 4.4). For actuations carried out by spraying 
vertically a hole was cut out from the top of a T25 flask using a hot copper pipe 
which had been fabricated into the dimensions of the actuator mouthpiece. 
Also during actuations from the vertical orientation, the metering chamber of 
the valve was allowed to fill in the upright position between actuations. 
Following visual observation, the coloured liquid at the bottom of the T25 flask 
was transferred into a UV quartz cuvette (Hellma Worldwide Precision Cells, 
Essex, UK) and assayed by UV absorbance at 629 nm. Data from the two 
actuation orientations were compared to a positive control. Control absorbance 
data was generated by actuating the Brilliant Blue pMDI into a conical flask 
containing 6 ml of water and swirling the water around the flask to collect the 
total emitted dye present in the flask.
The relative deposition efficiency of the Brilliant Blue dye actuated from the 
two orientations was calculated by comparing the UV absorbance data of 
deposited dye against that of the control. As the UV absorbance detected from 
control was a measure of the total emitted dye collected from the flask, the 
deposition efficiency for the control was taken as 100%.
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A) Sprayed Vertically
T25 Flask
Water
B) Sprayed Horizontally
Figure 4.4 Schematic representation of aerosolisation into a cell culture flask. A) 
Sprayed Vertically: pMDI actuated with the aerosol directed onto liquid; B) Sprayed 
Horizonatally: pMDI actuated with aerosolisation across the liquid.
4.2.7.3 Assessment of pDNA Functionality Following Aerosolisation from a 
pMDI
Biological functionality of pDNA actuated from the pMDI formulation was 
assessed in A549 cells seeded into T25 flasks with seeding densities previously 
outlined in Section 4.2.5.
Cells were subjected to the following treatments: (i) DMEM (negative control), 
(ii) an unwashed formulation of lyophilised DNA-loaded microemulsion 
incorporated into a pMDI, (iii) a solvent-washed variant of formulation (ii). In 
the case of (ii) and (iii) the formulations were actuated from pMDI canisters 
directly onto cells covered with (A) DMEM, and (B) DMEM containing 
extruded DOTAP liposomes (Section 4.2.3). Each T25 flask was treated with 
the equivalent of 15 pg aerosolised pEGFP-N 1. In the case of cells treated in 
the presence of DOTAP, a ratio of 6:1 w/w DOTAP: washed DNA was used, 
based on the assumption that 15 pg of pDNA would be successfully expelled
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from the pMDI. pMDIs were primed by firing five shots to waste using an 
actuator with a 0.5 mm orifice diameter (3M Drug Delivery Systems, 
Loughborough, UK). To reduce any cell death, due to aerosol cold freon effect, 
the T25 flasks were placed on pre-warmed saline infusion bags with 30 sec 
intervals between actuations. All treatments were conducted in serum-free 
DMEM. Treated cells were stored in a humidified incubator (37°C/ 5% CO2). 
After a period of 6 hr, cells were washed once with 5 ml PBS, pH 7.4, 
replenished with 5 ml of growth media and returned to the humidified 
incubator (37°C/ 5% CO2).
The biological functionality of lyophilised pDNA particles was assessed 
qualitatively at 42 hr post-treatment using fluorescent microscopy. Following 
microscopy, cells were surface rinsed twice with 5 ml cold PBS, trypsinised 
with 1 ml trypsin-EDTA solution and then resuspended in 6 ml growth media. 
Cells were assessed for fluorescence using flow cytometry (FACSCalibur™ 
system Becton, Dickinson Biosciences, Oxford, UK) with analysis by 
WinMDI™ Software (Joseph Trotter, The Scripps Institute, California, USA) 
(Section 4.2.4.1).
4.2.7 .4 Microscopic Characterisation of Particles
The solvent-washed pDNA pMDI formulation (Section 4.2.6) was actuated 80 
times into a Volumatic™ spacer (Allen and Hanburys, Middlesex, UK) 
connected to an ACI (Westech Instrument Services Ltd., Bedfordshire, UK) 
operating at 28.3 1/min. Double sided carbon tape was attached at various 
points on the wall of the spacer and the plates in the ACI using tweezers. 
Particles that had deposited on the carbon tape, post-actuation, were mounted 
onto SEM aluminium stubs and sputter coated with gold (gold sputter coater, 
EM Scope, Kent, UK) before being viewed using a Philips XL-200 Scanning 
Electron Microscope (TEI Company, Eindhoven, The Netherlands).
4.2.8 Cell Toxicity Assay
In vitro toxicity of treatments was assessed using the colorimetric 3-[4, 5 -
126
Chapter Four
dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide (MTT) based assay 
kit. In vitro cytotoxicity was determined by spectrophotometrically measuring 
the activity of living cells post-treatment via their mitochondrial activity.
Initially A549 cells were seeded into T25 flasks at a density of 
4 x 104 cells/cm2 and cultured under the specified culture conditions (Section 
4.2.1) to 68% confluency. Cells were surface-treated with: (i) DMEM, 
(negative control), (ii) Nine actuations of a solvent-washed pEGFP-Nl pMDI 
formulation (produced in Section 4.2.6) actuated into DMEM alone, (iii) Nine 
actuations of a solvent-washed pEGFP-Nl pMDI formulation actuated onto 
DMEM containing DOTAP, (iv) Nine actuations of placebo pMDI formulation 
containing 6 ml HFA 134a and absolute ethanol (8% v/v) actuated onto 
DMEM alone, (v) Nine actuations of placebo pMDI formulation containing 
6ml HFA 134a and absolute ethanol (8% v/v) actuated onto DMEM containing 
DOTAP, (vi) Eighty actuations of placebo pMDI formulation containing 6 ml 
HFA 134a and absolute ethanol (8% v/v) actuated onto DMEM containing 
DOTAP. In the case where pDNA loaded pMDI formulations were used, each 
T25 flask was treated with the equivalent of 15 pg aerosolised pEGFP-Nl. A 
quantity of 90 pg extruded DOTAP liposomes (1 mg/ml) (Section 4.2.3) (ratio 
of 6:1 w/w DOTAP: washed DNA) was used in all cases where cells were 
treated in the presence of DOTAP.
pMDIs were primed by firing five shots to waste using an actuator with a 
0.5 mm orifice diameter (3M Drug Delivery Systems, Loughborough, UK). To 
reduce any cell death, due to aerosol cold freon effect, the T25 flasks were 
placed on pre-warmed saline infusion bags with 30 sec intervals between 
actuations. All treatments were conducted in serum-free DMEM. Treated cells 
were stored in a humidified incubator (37°C/ 5% CO2). After a period of 6 hr, 
cells were washed once with 5 ml PBS pH 7.4, replenished with 5 ml of growth 
media and returned to the humidified incubator (37°C/ 5% CO2). 42 hr post­
treatment, cells were washed twice with 5 ml aliquots of cold PBS, then PBS 
was removed and 1 ml trypsin-EDTA added to the cell surface. After 1 min,
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the trypsin was removed from the wells and the T25 flasks stored in a 
humidified incubator at 37°C containing 5% CO2 for 10 min. After 10 min 
incubation, cells were re-suspended in 6 ml growth media.
Reconstituted MTT (5mg/ml PBS) was added at 10% of the 100 pi culture 
medium volume in a 96-well plate and agitated using a bench top shaker to 
ensure mix. Samples were incubated (37°C/ 5% CO2) for 4 hr after which the 
reconstituted MTT was removed using a syringe needle with care taken not to 
disturb the cells. Subsequently, formazan crystals were dissolved using 100 pi 
of MTT solubilisation solution. Cell culture samples were incubated (37°C/ 5% 
CO2) for a further 30 min and assayed by UV absorbance at 570 nm using a
T*\jISunrise microplate reader (Tecan Trading AG, Mannedorf, Switzerland). 
Background absorbance, measured at 690 nm, was subtracted from the 570 nm 
readings automatically using Magellan™ data reduction software (Tecan 
Trading AG, Mannedorf, Switzerland).
4.2.9 Statistical Analysis
Statistical analysis was carried out using a statistical package, SPSS 16®. One­
way analysis of variance (ANOVA) was followed by a Duncan’s multiple 
range test, to compare multiple groups, or Dunnett’s test, used to compare 
groups against a reference group with significant differences indicated by p- 
values <0.05 or <0.001. Results are summarised as mean ± sd.
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4 3  Results
4.3.1 A549 Cell Growth Study
The A549 cell growth curve was plotted as cell number against time so that a 
clear understanding of the state of cell growth at any given time could be 
gained (Figure 4.5). The growth curve generally followed a sigmoidal pattern 
of cell proliferation, where cell exponential growth (log phase) commenced 
after a 23 hr lag period. At 71 hr after cell seeding, the cells entered their 
plateau phase of cell growth followed by a decline in cell number.
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Figure 4.5 A549 cell growth curve with annotations of the cell growth phases
(mean n = 4).
4.3.2 Measurement of DOTAP Liposome Size
Liposome size analysis using photon correlation spectroscopy was routinely 
performed on extruded DOTAP liposomes prior to transfection studies. 
Analysis revealed liposomes had a mean diameter of 119.4 ± 23.2 nm (mean ± 
sd; n = 3). The average vesicle size distribution shown by the polydispersity 
index was 0.046 indicating a monodisperse suspension of particles.
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43 3  Optimising DOTAP: pDNA Ratio for Transfection Studies
Prior to experiments assessing the biological functionality of pDNA following 
processing into particles, a pilot study was carried out using flow cytometry to 
determine the most transfection efficient ratio of DOTAP: pDNA (Figure 4.6).
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Figure 4.6 Quantitative gene expression of pDNA particles using various ratios of 
DOTAP liposome: pDNA. A549 cells were surface-treated with Control: DMEM 
alone, 4:1, 6:1, 8:1,10:1,12:1 represented the w/w DOTAP liposome: pDNA ratios. 
Data are presented as mean ± sd; n = 3. The bars represent no significant difference 
between treatments (p>0.05).
Gene expression analysis (Figure 4.6) revealed no statistical increase in 
reporter gene expression when using 4:1 w/w DOTAP liposome: pDNA ratio 
(2.51 ± 0.87% (p>0.05)) compared to the control (0.99 ± 0.87%). However 
increasing the ratio to 6:1 w/w resulted in a significantly increased percentage 
of cells emitting GFP fluorescence (4.09 ± 0.30% (p<0.05)) compared to 
control. Figure 4.6 revealed that any further increase in the DOTAP liposome: 
pDNA ratio beyond 6:1 w/w to 8:1, 10:1 or 12:1 w/w did not confer any further 
significant increase in the percentage of cells emitting GFP fluorescence 
(4.59 ± 0.44%, 4.63 ± 1.90%, 5.72 ± 2.50% respectively (p>0.05)) when 
compared to the 6:1 w/w treatment.
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43.4 Assessing the Transfection Competency of Lyophilised pDNA 
Particulates
Figure 4.7 shows the result of an in vitro transfection experiment to assess the 
biological functionality of pDNA following processing into particles, but 
before loading into a pMDI canister and subsequent aerosolisation. DOTAP 
cationic lipid was added to selected cell culture flasks to form an electrostatic 
complex with the pDNA and enable cell transfection. A significant increase 
(p<0.001) in the percentage of fluorescent cells, attributed to expression of 
GFP, was observed when A549 cells were treated with unprocessed (positive 
control) pEGFP-Nl in the presence of DOTAP (14.49 ± 1.76%). The 
unwashed surfactant-coated pDNA particles did not mediate any gene 
expression, regardless of whether DOTAP was present (0.59 ± 0.11%) or not 
(0.67 ± 0.31%). Gene expression was however statistically comparable 
(p>0.05) to the positive control in DOTAP-supplemented samples that had 
undergone the washing procedure to remove excess surfactant 
(14.28 ± 1.82%). Formulations treated in the absence of DOTAP, showed no 
significant increase (p>0.05) in cell fluorescence against the negative control. 
Fluorescent microscopy inserts confirmed the presence of fluorescent protein 
in transfection-positive cells.
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Figure 4.7 Quantitative gene expression of pDNA particles. A549 Cells were 
surface-treated with (i) Control- DMEM alone, (ii) Unprocessed pEGFP-Nl into 
DMEM alone, (iii) Unprocessed pEGFP-Nl into DMEM containing DOTAP, (iv) 
Unwashed pEGFP-Nl particles into DMEM alone, (v) Unwashed pEGFP-Nl particles 
into DMEM containing DOTAP, (vi) Solvent-washed pEGFP-Nl particles into 
DMEM alone, (vii) Solvent-washed pEGFP-Nl particles into DMEM containing 
DOTAP.
Data are presented as mean ± sd; n = 6. ^denotes a significant difference from the 
control (pO.OOl).
Insert: Fluorescence microscopy image o f  A549 cells following treatment with (A) 
unprocessed pEGFP-Nl into media containing DOTAP, and (B) solvent-washed 
pEGFP-Nl formulation into media containing DOTAP.
4.3.5 Assessment of pDNA pMDI Formulations
4.3.5.1 Integrity of pDNA Particles Following Aerosolisation from a pMDI
Agarose gel electrophoresis with EtBr staining was used to assess the physical 
integrity o f processed pDNA actuated from a pMDI formulation. The integrity 
o f pEGFP-Nl post-aerosolisation cam be determined by the presence o f a 
supercoiled band that is in line with that shown by the unprocessed pEGFP-Nl 
(Figure 4.8). Figure 4.8 shows that the integrity of the washed pDNA 
formulation was maintained post-actuation from a pMDI with the maintenance 
o f the supercoiled fraction. The unwashed formulation however reveals a 
streaked band with the top most band not migrating as far as the unprocessed 
pDNA supercoiled band.
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Control Washed
Figure 4.8 Gel electrophoresis of unwashed and solvent-washed freeze-dried 
pEGFP-Nl particles actuated from a pMDI formulation. Control: unprocessed 
pEGFP-Nl, Unwashed: surfactant-coated pDNA pMDI formulation, Washed: 
solvent-washed pDNA pMDI formulation. The percentage values represent a semi- 
quantitative analysis o f the ratio o f fluorescence emitted from the supercoiled band 
compared to the total pDNA. (n = 1) (SC: supercoiled fraction).
A semi-quantitative signal analysis was used to compare the fluorescence 
emission from the supercoiled pDNA bands. The supercoiled band of 
unprocessed pDNA contributed 70% o f emitted fluorescence from the total 
pDNA (Control, Figure 4.8). Once the solvent-washed pDNA had been 
actuated from a pMDI system fluorescence from the supercoiled fraction was 
reduced to 66% (washed. Figure 4.8). A semi-quantitative analysis was not 
carried out on the unwashed actuated pDNA sample as a clear supercoiled band 
was not visible.
4.3.5.2 A erosol Delivery to Cell C ulture Flask
Prior to experiments assessing biological functionality of aerosolised pDNA 
particles, pilot studies using Brilliant Blue dye were performed to ascertain the 
most efficient orientation to actuate processed pDNA formulations to capture 
aerosol output onto adherent cells in vitro.
Visual observations revealed spraying vertically resulted in the majority o f the
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dye depositing in the water coating the bottom of the flask (Figure 4.9A). 
Spraying horizontally (Figure 4.9B) resulted in deposition o f dye at the neck of 
the flask as well as into the water at the bottom of the flask. A partial reduction 
in the dye intensity was observed when aerosolisation from the horizontal 
orientation was compared with that from the vertical orientation. The intensity 
o f colour was further analysed quantitatively in Figure 4.10.
B) Sprayed HorizontallyA) Sprayed Vertically
Deposited dye
Figure 4.9 A typical photograph taken of Brilliant Blue pMDI actuated into a cell 
culture flask. A) Sprayed Vertically: pMDI actuated with the aerosol directed onto 
liquid; B) Sprayed Horizontally: pMDI actuated with aerosolisation across the 
liquid.
Figure 4.10 shows the relative UV-vis absorbance of the liquid at the base of 
the flask following actuation o f the Brilliant Blue pMDI. The vertically sprayed 
pMDI gave a greater relative collection efficiency (78% of the actuated dye 
was deposited into the collection medium at the bottom of the flask) than 
horizontally spraying into a flask (19% deposition). Statistical analysis 
confirmed no significant reduction (p>0.05) in the concentration of deposited 
dye from the vertically sprayed pMDI (0.15 pig/6 ml ± 0.04 pg) compared to 
the control (0.19 ± 0.01 pg).
As a result o f this pilot study, pDNA loaded pMDI formulations were actuated 
onto A549 cells directly from above (vertically sprayed).
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Control Sprayed Sprayed
Vertically Horizontally
Figure 4.10 Relative deposition efficiency of Brilliant Blue when actuated from a 
pMDI in the vertical and horizontal orientation relative to the control. Control: 
positive control where the total pMDI emitted dose is collected, Sprayed Vertically: 
pMDI actuated with the aerosol directed onto liquid; Sprayed Horizontally: pMDI 
actuated with aerosolisation across the liquid. Data are presented as mean ± sd; n = 3. 
♦denotes a significant difference from the control (using one-way analysis of variance 
and Dunnett’s multiple range test p<0.05).
4 3 .5 3  Assessment of pDNA Functionality Following Aerosolisation from a 
pMDI
Flow cytometry was used to determine whether pEGFP-Nl remained 
biologically active subsequent to particle processing, propellant dispersion and 
aerosolisation from a pMDI (Figure 4.11). As previously, DOTAP cationic 
lipid was added to selected cell culture flasks to facilitate in vitro cell 
transfection. No increase in gene expression was observed for the unwashed 
aerosolised formulation (p>0.05) regardless of whether it was actuated in the 
presence (1.35 ± 0.33%) or absence (1.16 ± 0.94%) of DOTAP. Aerosolising 
the washed formulation onto cells in normal media also conferred no 
significant rise in the percentage of cells emitting GFP fluorescence 
(1.74 ± 0.67%, p>0.05). However, a significant increase in the percentage of 
cells expressing GFP (p<0.001) was apparent following aerosolisation of the 
washed pEGFP-Nl particulates into DOTAP containing media 
(24.75 ± 2.35%) compared with control cells (0.96 ± 0.30%).
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Fluorescence microscopy (Figure 4.11 insert) further confirmed gene 
expression in cells following aerosolisation o f the washed formulation onto 
cells in DOTAP-supplemented media.
Control Unwashed Unwashed Washed pDNAWashed pDNA 
pDNA pDNA particles particles +
particles particles* DOTAP
DOTAP
Figure 4.11 Quantitative gene expression of aerosolised pDNA particles. A549 
cells were surface-treated with (i) Control- DMEM alone, (ii) Unwashed pEGFP-Nl 
particles into DMEM alone, (iii) Unwashed pEGFP-Nl particles into DMEM 
containing DOTAP, (iv) Solvent-washed pEGFP-Nl particles into DMEM alone, (v) 
Solvent-washed pEGFP-Nl particles into DMEM containing DOTAP.
Data are presented as mean ± sd; n = 4. The bar represents no significant difference 
(p>0.05). Insert: Fluorescence microscopy image o f A549 cells following treatment 
with solvent-washed pEGFP-Nl formulation into media containing DOTAP.
4.3.5.4 V isual A ssessm ent o f W ashed lyophilised pDNA pM DI 
F orm ulations
Visual observations o f the washed pDNA particulate formulation, in 
transparent PET pMDI vials, provided a simple indication o f the gross physical 
stability o f the formulation in situ (Figure 12). When the surfactant-coated 
lyophilised pDNA particles were subjected to six cycles of the solvent-wash 
procedure, excess surfactant was removed to leave an off-white powder. Upon 
addition o f the washed pEGFP-Nl particles into a pMDI vial, initial 
observations showed that particles were suspended throughout the propellant 
ethanol mix. After a 24 hr period, suspended particles were still visible,
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although most particles had formed loose sedimented floccules at the base of 
the canister. These floccules were easily dispersed by one inversion o f the PET 
vial. Redispersible floccules were also observed after a storage period o f 5 
months.
24 hr 5 M onths0 hr
Figure 4.12 Photograph of PET pMDI vials containing solvent-washed freeze- 
dried pEGFP-Nl particles in HFA 134a propellant with absolute ethanol as a co­
solvent. Images were taken 0 hr, 24 hr and 5 months after producing the formulation 
stored at room temperature.
4.3.5.5 M icroscopic C haracterisation o f  Particles
SEM images o f material aerosolised from the pMDI formulation and collected 
on Stages 4 and 5 o f an ACI indicate the presence of a heterogeneous 
population o f particles comprising rounded and angular particle protrusions 
from a continuous matrix (Figure 4.13) Although variable in size, all o f these 
particle protrusions were less than 10 pm in diameter. Microscopic 
observations indicated that ACI Stages 4 (Figure 4.13A) and 5 (Figure 4.13B) 
with cut-off diameters o f 2.1 pm and 1.1 pm respectively contained the 
greatest number of particle protrusions, potentially indicating that the majority 
o f the aerosolised material is within the respirable size range. However, SEM 
images (Figure 4.13A and Figure 4.13B) also reveal the presence of particle 
protrusions larger than the quoted cut-off diameters.
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Figure 4.13A and 4.13B Scanning electron micrographs of a solvent-washed 
freeze-dried pMDI formulation containing pEGFP-Nl and sucrose collected at 
Stage 4 and 5 of an ACI. Scale bar = 10 pm.
4 .3 .6  Cell Toxicity Assay
The in vitro MTT toxicity assay, performed on A549 cells (Figure 4.14), 
showed no significant loss in cell viability (p>0.05) between blank, untreated 
cells and cells treated with the washed, aerosolised pDNA formulation. A 
significant reduction in cell viability (p<0.05) was however observed when 
DOTAP was added to the cell culture medium. The MTT assay was also used 
to ascertain the effect o f number o f actuations on cell viability. Statistical 
analysis showed a significant reduction (p<0.05) in cell viability when cells 
bathed in DMEM plus DOTAP were exposed to 80 compared to 9 actuations 
o f  8%v/v ethanol in HFA134a. This demonstrates the sensitivity o f the MTT 
assay and is likely due to the cold-freon effect o f repeated aerosolisations or 
increased exposure to ethanol.
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9 Actuations
9 Actuations
80 Actuations
Control Actuated Actuated Actuated Actuated Actuated 
pDNA pDNA+ Placebo Placebo + Placebo + 
DOTAP DOTAP DOTAP
Figure 4.14 Percentage cell viability of cells following aerosolisation of 
treatments. Cells were surface-treated with: (i) DMEM, (control cells; 100% 
viability), (ii) Nine actuations of a solvent-washed pEGFP-Nl pMDI formulation 
actuated into DMEM alone, (iii) Nine actuations of a solvent-washed pEGFP-Nl 
pMDI formulation actuated onto DMEM containing DOTAP, (iv) Nine actuations of 
placebo pMDI formulation containing HFA 134a and absolute ethanol actuated onto 
DMEM alone, (v) Nine actuations of placebo pMDI formulation containing HFA 134a 
and absolute ethanol actuated onto DMEM containing DOTAP, (vi) Eighty actuations 
of placebo pMDI formulation containing HFA 134a and absolute ethanol actuated 
onto DMEM containing DOTAP. Data are presented as mean ± sd; n = 3. ^denotes a 
significant difference from the control (p<0.05). ** denotes a significant difference 
from both the control and the treatment with nine actuations (p<0.05).
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4.4 Discussion
4.4.1 A549 Cell Growth Study
The cell growth study demonstrated that A549 cells followed a sigmoidal 
pattern of cell proliferation (Figure 4.5) (Davis 2002). Transfection studies 
were performed on cultures during the exponential log phase of cell growth as 
this is considered the optimal time to treat cells as transfection efficiency is 
increased in dividing cells due to the compromised cell membranes (Wilke et 
al 1996). Also the cell population in this phase is at its most uniform and cell 
viability is high (Freshney 2000). For this reason, knowledge of the A549 
growth curve played a critical role in the transfection studies carried out in this 
chapter. In addition, as the percentage cell confluency at any given time could 
be calculated from the growth curve, all transfection studies could be carried 
out at a predetermined cell confluency to facilitate consistency in results 
between investigations. Cells in this study were treated at 68% confluency, 
48 hr post seeding, as cells were in their log phase and this was considered an 
appropriate time period from an operational perspective.
4.4.2 Optimising DOTAP: pDNA Ratio for Transfection Studies
In the pilot study to determine the most transfection efficient DOTAP: pDNA 
ratio (Section 4.3.3), the data revealed that a 6:1 w/w ratio of DOTAP: pDNA 
was the minimum required to obtain a significant increase in the percentage of 
cells emitting GFP fluorescence compared to the control (Figure 4.6). This 
could be due to the fact that a 6:1 w/w ratio may contain an excess of lipid 
leading to the formation of complexes with an overall positive charge which is 
critical for efficient cell entry (Feigner et al 1987; Zabner et al 1995; Xu and 
Szoka 1996). Higher DOTAP: pDNA ratios, i.e. from 8:1, 10:1 and 12:1 w/w 
did not yield any further significant increase in the percentage of fluorescent 
cells. As lipid toxicity is concentration dependent, (Feigner et al 1987; 
Chiaramoni et al 2007) the lowest transfection efficient ratio of DOTAP: 
pDNA was used in order to minimise any cationic lipid induced cell toxicity. 
As DOTAP: pDNA ratios of 6:1 w/w delivered DNA to A549 cells at least as 
efficiently as did treatments containing higher proportions of cationic lipids,
140
Chapter Four
the 6:1 w/w ratio was deemed a suitable treatment ratio for the transfection 
studies (Section 4.2.5 and Section 4.2.7.3).
However, the percentages of cells expressing GFP fluorescence in this study 
are relatively low, for example a 6:1 w/w ratio conferred 4.59% gene 
expression. By comparison, Birchall et al (2000) reported GFP expression of 
approximately 29% in A549 cells treated with a 6:1 w/w DOTAP: pDNA ratio. 
Possible reasons for the reduced absolute levels observed could have been due 
to the quality of the lipid. As the DOTAP used in this study had been stored for 
a long period of time and was past its expiry date, the lipid used may not have 
been of sufficient quality. Nevertheless, this study was not repeated using 
newly purchased DOTAP. The reason for this being that the general trend 
observed in this study was reflective of published work, in the sense that gene 
expression increased with DOTAP: pDNA ratios up to approximately 6:1 w/w 
ratio after which expression levels tended to plateau (Birchall et al 2000). 
Although this study was not repeated, all subsequent studies conducted in this 
thesis were performed using newly purchased DOTAP.
4.43 Assessing the Transfection Competency of Lyophilised pDNA 
Particulates
Initial transfection results revealed no significant difference in the expression 
of reporter gene in cells treated with unprocessed pDNA and solvent-washed 
lyophilised pDNA (Figure 4.7). These data demonstrate the utility of the 
developed nanotechnology processes to deliver biologically active pDNA 
particles. The transfection data also highlight that a washing stage is essential 
to maintain pDNA functionality, by removing the excess surfactant, as treating 
the cells with pDNA particles coated in an excess of surfactant revealed no 
significant increase in the expression of the reporter gene compared to the 
control (Figure 4.7). This suggests that the excess of surfactant present in the 
unwashed samples may have reduced the formation of the electrostatic 
lipid:pDNA complex and/or affected interactions of the lipid:pDNA complex 
with the cell surface.
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Lecithin surfactant, used during processing the pDNA particles, is composed of 
various substances including anionic lipids. Given the charge of the surfactant, 
it is feasible that an excess of surfactant coating the pDNA particles may have 
electrostatically interacted with the DOTAP, preventing the lipid:DNA 
complexes from forming. Also as anionic lipids have been shown to have a 
strong ability to displace pDNA from cationic lipid:pDNA complexes (Xu and 
Szoka 1996), a reduction in transfection in the presence of surfactant may have 
been anticipated. Additionally, previous research has shown that anionic 
surfactants have the ability to reduce transfection efficiency by inducing 
release of DNA from cationic lipid:DNA complexes before it reaches the target 
cell (Duncan et al 1997; Tsan et al 1997).
4.4.4 Assessment of pDNA pMDI Formulations
DNA integrity, assessed by electrophoresis, was studied following 
incorporation of processed pDNA into a pMDI formulation and aerosolisation 
(Figure 4.8). Aerosolised pDNA was assessed for retention of the transfection 
competent supercoiled band, as most published literature supports the opinion 
that degradation of this fraction may have detrimental effects on the 
transfection efficiency of the pDNA (Chancham and Hughes 2001; Remaut et 
al 2006). Analysis of unprocessed pDNA indicated that 70% was in the 
supercoiled form, providing the baseline for subsequent samples. Analysis of 
the aerosolised solvent-washed pDNA particles showed a reduction in the 
supercoiled fraction to 66% (Figure 4.8). Placing this result in context with the 
extant literature in the pulmonary gene delivery field, previous research has 
demonstrated that jet nebulisation can result in much greater losses of pDNA 
with only 5 to 60% (Birchall et al 2000; Kleemann et al 2004; Lentz et al 
2005) o f supercoiled pDNA, of a similar size to that of pEGFP-Nl, being 
recoverable after nebulisation compared with non-nebulised control. Our 
results infer that the formulation processes of preparing, solvent-washing, 
incorporating into a co-solvent propellant mixture and aerosolising of the 
pDNA particulates had a comparatively small adverse effect on the tertiary 
structure o f the pDNA.
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Analysis o f the aerosolised unwashed pDNA pMDI formulation revealed a 
sample that did not migrate as far as the supercoiled fraction from the 
unprocessed pDNA (Figure 4.8). As sample migration during electrophoresis is 
size driven as well as charge driven, a possible reason for the reduced mobility 
of the surfactant-coated pDNA particles may have been due to the increase in 
the size or change in the net charge of the pDNA composite due to the 
surfactant coating.
Cellular transfection and gene expression studies, using aerosolised pDNA 
formulations were carried out by actuating treatments onto cells seeded in 
flasks. Treatments were actuated directly into cell seeded flasks as this 
technique would allow a closer simulation of in vivo delivery, rather than 
collection and then treatment of aerosolised pDNA on to cells (Stem et al 
1998). Guided by the results from a preliminary study using coloured dye 
(Figure 4.10), pDNA loaded pMDI formulations were actuated from above 
onto A549 cells seeded in a cell culture flask. Data from the transfection 
studies, using various aerosolised formulations, revealed that only the solvent- 
washed pDNA particles conferred a significant rise in the percentage of 
fluorescent cells in the presence of DOTAP Figure 4.11. This suggests that the 
solvent-washed pEGFP-Nl particulates remained functionally active following 
formulation processing, dispersion in propellant and aerosolisation from a 
pMDI. Statistical analysis showed no significant difference in the percentage of 
cells expressing GFP following treatment with the washed pEGFP-Nl 
formulation actuated onto cells without the presence of DOTAP compared with 
control cells. This data substantiates previous research that a transfection agent 
is essential in conferring efficient gene expression in vitro (Zabner et al 1995; 
Gao and Huang 1996; Remaut et al 2006), and acts as a control to confirm that 
the fluorescence detected during FACS analysis was indeed due to intact 
pEGFP-Nl transfecting cells with the aid of a transfection agent.
These in vitro cell culture studies establish that pDNA can be formulated to 
remain transfection competent when actuated from a pMDI. However whilst in
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vitro studies are necessary to demonstrate proof-of-concept, a clear 
understanding of the barriers encountered in vivo is required to progress this 
work towards clinical therapy. The lungs possess numerous biological barriers 
and mechanisms that all contribute to the clearance of foreign particles and 
therefore hinder their ability to exert any therapeutic effect. The presence of a 
mucus layer and the mucociliary escalator are crucial in trapping and removing 
foreign particles in the upper airways. Lung surfactant at the air-water interface 
not only causes macromolecule aggregation and thus promotes particle 
removal by macrophage engulfment, but has also been shown to interact with 
cationic lipid:pDNA complexes to reduce pDNA transfection (Duncan et al 
1997; Tsan et al 1997). Therefore if the lipid DNA treatment is administered 
separately, endogenous anionic surfactants have the potential for interacting 
with the DOTAP preventing the lipid:DNA complexes from forming in situ. In 
addition, due to the mechanism of gene transfer, the differences between cell 
proliferation rates in vitro and in vivo has revealed significant variation in 
pDNA transfection efficiency (Wilke et al 1996; Brunner et al 2000; Remaut et 
al 2006). Nevertheless, our data provides early proof-of-concept of this 
approach and more research through in vivo assessment is now warranted.
Visual observations of solvent-washed pDNA formulations in PET vials with 
time highlighted a number of points (Figure 4.12) Solvent-washing the 
surfactant-coated pDNA particles removed the excess surfactant to produce an 
off-white powder which initially dispersed in the propellant-cosolvent mixture. 
Sedimentation of the particles did occur after 24 hr but the sedimented particles 
were readily redispersed by one inversion of the vial confirming the presence 
of loose floccules. This flocculated system showed no signs of caking 
following storage at ambient temperatures for 5 months. Surfactants are often 
incorporated into suspensions to stabilise the drug dispersion by reducing the 
electrostatic charge of the drug. Observations of a dispersible flocculated 
system indicated that drug aggregation of the formulation was suitably 
controlled within the 5 month time span. The lack of solubility of hydrophobic 
surfactants (e.g. lecithin) in HFA 134a propellant is well documented
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(Blondino and Byron 1998; Vervaet and Byron 1999) and commonly requires 
the use of a co-solvent in commercial formulations. The observations of a 
dispersed system (Figure 4.12) suggested that the quantity of surfactant in the 
solvent-washed formulation fell within the range of that which could be 
solubilised into the propellant with the aid of ethanol as co-solvent (8% v/v).
Scanning electron microscopy of the aerosolised, solvent-washed pEGFP-Nl 
formulation revealed a continuous matrix (which may be the sticky surfactant 
system) interspersed with protrusions of a heterogeneous particle population 
comprising of angular particles (likely to be the sucrose lyoprotectant) and 
more rounded particles (possibly including surfactant-coated pEGFP-Nl 
particles) (Figure 4.13). Although micrographs showed that more of these 
particle protrusions were present at Stage 5 of the ACI (cut-off diameter 1.1 
pm), the observed larger particle dimensions suggest that particle 
agglomeration was prevalent. Whilst particles were solvent-washed to remove 
excess surfactant, the presence of the surfactant, even at a minimal quantity, 
may have caused the particles to agglomerate as they impacted on the ACI 
plate. Additionally as the formulation was actuated into the ACI a total of 80 
times, particle overload on the ACI stages could have resulted, another 
significant reason as to why particle agglomeration may have been observed. It 
is also possible that sample heating during SEM processing and analysis may 
have caused particle agglomeration. Further characterisation of discrete 
particles may have been possible at higher magnifications, however, due to the 
magnifying limitations of the SEM the particles could not be viewed at higher 
magnifications without a significant loss in the image resolution.
The MTT toxicity assay was used to assess the cytotoxicity of the aerosolised 
pDNA treatments (Figure 4.14). The assay showed a significant reduction in 
the percentage cell viability in the presence of DOTAP. The significant 
reduction in cell viability in the presence of DOTAP concurs with previously 
published reports (Choi et al 2004; Chiaramoni et al 2007). More promisingly 
however, the toxicity assay revealed an absence of effect of washed,
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aerosolised pEGFP-Nl formulation (without DOTAP) on cell viability. This 
result confirms that the washed pEGFP-Nl aerosolised formulation per se 
exerted no significant toxic effect on cells. As diminished cell viability 
occurred with DOTAP, it may be appropriate to explore the use o f alternative 
transfection agents (Choi et al 2004; Jiang et al 2008; Prata et al 2008) and 
‘helper’ lipids (Feigner et al 1994; Bennett et al 1995). Indeed, in vivo gene 
expression has been achieved in the past without the use of a transfection 
agent, although transfection efficiency was found to be relatively low (Zabner 
et al 1997; Xenariou et al 2007).
The toxicity assay also highlighted that increasing the number of actuations 
from 9 to 80 caused a significant reduction in the percentage cell viability. This 
reduction in cell viability is likely to be a result of the cold freon effect, a 
phenomenon that has been used to describe the cessation of inhalation in 
patients in reaction to the high velocity strike and evaporative cooling of the 
propellant plume (Pedersen et al 1986; Crompton 1990). However, in the 
context of this study increased actuations would expose the cells to an increase 
in the cold freon effects. As cells are notoriously fragile and sensitive to 
temperature, an increased number of high velocity strikes on the cell 
monolayer and the evaporative cooling effects may have been the cause for cell 
damage and stress. Additionally the increase in actuations would cause cells to 
be exposed to an increased concentration of aerosolised ethanol. Ethanol is 
known for its ability to induce cell death (Ewald and Shao 1993; Jacobs and 
Miller 2001) and so the loss of cell viability observed with increasing the 
number of actuations may have also been attributed to effect of ethanol. 
Although these actuation effects would not be significant in vivo, as the 
concentration of aerosolised ethanol administered would be relatively low, this 
data does however provide important information for maintaining cell viability 
in further in vitro studies carried out in the subsequent chapter.
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4.5 Conclusion
This chapter aimed to investigate the feasibility of dispersing and aerosolising 
pDNA particles from a pMDI system whilst maintaining the pDNA biological 
functionality.
Analysis of aerosolised solvent-washed pDNA particles, using agarose gel 
electrophoresis, showed that the formulation could be incorporated into a HFA 
134a system and aerosolised using a standard valve and actuator with a 
relatively small reduction in the pDNA integrity. A549 cellular gene 
expression studies revealed that the biological functionality of solvent-washed 
pDNA particulates remained functionally active following formulation 
processing, dispersion in propellant and aerosolisation from a pMDI. The 
presence of excess surfactant coating the unwashed pDNA formulation, 
however, was found to hinder pDNA functionality.
A549 cellular cytotoxicity, investigated using the MTT assay, demonstrated 
that any loss of cell viability was a cumulative effect between the number of 
actuations used and the use of DOTAP. Promisingly the data revealed an 
absence of effect of washed, aerosolised pEGFP-Nl formulation (without 
DOTAP) on A549 cell viability. Subsequent characterisation of solvent- 
washed pDNA particles aerosolised into an ACI revealed that particles were in 
the respirable size range.
The data generated from this chapter highlights that particles prepared by this 
low-energy microemulsion process may have the potential for stable and 
efficient delivery of pDNA to cells in the lower respiratory tract via pMDIs.
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CHAPTER FIVE 
Characterisation, Transfection 
and Stability of DOTAP- 
pDNA pMDI Formulation
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5.1 Introduction
The previous chapter focussed on characterising pDNA pMDI formulations 
actuated onto cells immersed in DOTAP transfection agent. This chapter will 
attempt to incorporate the DOTAP transfection agent into the pDNA pMDI 
system and characterise the aerosolised formulation.
The need for a transfection agent to confer efficient cellular DNA delivery has 
been previously reported (Gao and Huang 1996; Zabner et al 1997). However, 
preparing the complexes to ensure effective cellular transfection is a process 
that is poorly defined and can be difficult to control. Factors including 
liposome:DNA concentrations and mixing rate have been found to affect 
complex formation efficiency resulting in variations in cellular transfection 
(Gershon et al 1993; Hirota et al 1999; Birchall et al 2000). Successfully 
incorporating DOTAP, the model transfection agent used in this thesis, into our 
pDNA pMDI formulation to form a single dosing unit would reduce the 
likelihood of encountering variations in complex formation which may occur if 
for example the DOTAP and pDNA were administered separately, even if this 
were possible. In a clinical setting, variations in complexing efficiency would 
lead to inconsistent pDNA transfection and possible variations in therapeutic 
effect between doses. Administering the DOTAP and pDNA separately would 
open the formulations up to a number of challenges and barriers. Great care 
would be required to ensure both components had similar aerodynamic particle 
size diameters so that they deposited in close proximity in vivo to ensure 
complexing. Also the presence of endogenous anionic surfactants, which have 
been shown to induce the release of DNA from cationic lipid:DNA complexes 
(Duncan et al 1997; Tsan et al 1997), may preferentially complex to the lipid 
preventing DNA complexes from even forming in the first place. Preparing the 
DOTAP:pDNA formulation prior to administration would overcome some of 
these challenges.
Freshly preparing the lipid:DNA complex prior to administration, a technique 
used with nebulisers due to the aqueous instability of lipoplexes, requires
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specialist skill from a clinician (Hyde et al 2000; Ruiz et al 2001). The use of a 
formulation which incorporates both the transfection agent and pDNA, such as 
the formulation investigated in this chapter, would have an added advantage in 
terms of patient autonomy as it would be feasible for patients to administer 
their treatment after initial consultations on good inhaler technique.
S. 1.1 Envisaged Formulation Challenges
Incorporating a transfection agent such as DOTAP into a pDNA pMDI system 
is relatively novel and to date there is extremely little published work in this 
field. The plausibility of preparing such a formulation and the challenges 
envisaged are therefore difficult to fully predict. However, delivery of 
liposomes from a pMDI system has been investigated for a number of decades. 
The preparation of lipid formulations in a pMDI has been developed as a drug 
delivery vehicle (Farr et al 1987, 1989). The limitations of such a formulation 
have, however, been reported. The incorporation of phospholipids into a CFC 
pMDI system has been found to increase the aerosolised droplet size, with a 
reduction in the respirable fraction (Farr et al 1987). The tendency of 
aerosolised lipids to associate at the droplet-air interface, retarding propellant 
evaporation, to result in larger droplets and an increased deposition in the 
upper airways is well documented (Snead and Zung 1968; Otani and Wang 
1984;). This adverse effect on the formulation deposition profile is a challenge 
that will be faced in this chapter during the incorporation of a lipid transfection 
agent into a pDNA pMDI system. Nevertheless, Farr et al (1987) demonstrated 
that a lipid could be incorporated into the nonpolar environment of a pMDI 
system and form liposomes upon aerosolisation into a aqueous environment 
such as the pulmonary epithelial lining fluid.
pMDI formulations prepared in this thesis utilised HFA propellant, due to the 
phase out of CFC propellants (United Nations Environment Programme 2006). 
HFAs are relatively polar compared to CFCs, and have insufficient capacity to 
solubilise lipids that would be soluble in CFCs (Blondino and Byron 1998; 
Vervaet and Byron 1999). Incorporation of DOTAP lipid into our pDNA pMDI
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formulation would therefore be challenging in terms of ensuring its 
dispersibility and therefore stability in HFA propellant. The use of a co-solvent 
such as ethanol, to facilitate lipid solubility may offer a potential solution to 
such a problem (Smyth 2003). Other possible ways of incorporating the 
transfection agent into the pDNA pMDI formulation include coating the pDNA 
particles with the lipid prior to incorporation into the pMDI. Spray-drying or 
freeze-drying lipids in the presence of a hydrophilic drug in either an aqueous 
or emulsion environment has been reported to yield lipid coated particles that 
can be dispersed and aerosolised from a HFA based pMDI system (Tarara et al 
2004; Cook et al 2005; Nyambura et al 2009b).
5.1.2 Characterising Liposome-DNA Complex Structure
DNA cellular transfection is promoted by the formation of lipoplexes with a 
net positive charge (Feigner et al 1987; Gao and Huang 1995). The formation 
of these lipoplexes is driven by the difference in electrostatic charge between 
the anionic phosphate backbone of pDNA molecules and the positively charged 
polar amino- head group of cationic liposomes. This interaction can cause the 
formation of structures which can exist as one or more possible geometries and 
is related to the lipidrpDNA ratio (Dan 1998). Cationic liposomes bind initially 
to the DNA molecule to form clusters of aggregated vesicles along the nucleic 
acid strand in a ‘beads on a string’ type of structure (Gershon et al 1993; 
Sternberg et al 1994). At a critical lipid:pDNA ratio (1:1 w/w) any further 
increase in the lipid was found to cause a DNA induced liposome fusion, where 
the negatively charged DNA appears to act as a fusogenic agent, drawing 
together the positively charged liposomes (Feigner et al 1995). During the 
fusion process, a lipid induced DNA collapse has been observed which results 
in the formation of a condensed DNA structure that can be completely 
encapsulated within the fused lipid bilayer (Gershon et al 1993). Similar 
observations were also made by Sternberg et al (1994) who, using freeze- 
fracture electron microscopy, identified lipoplexes as aggregates surrounding 
the DNA strand co-existing with tubular structures composed o f DNA 
molecules coated by lipid bilayers, giving rise to the ‘spaghetti and meatballs’
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analogy. Additionally, the presence of flat lamellar structures have also been 
identified, where the DNA adsorbs between the liposome layers forming an 
alternating multilamellar structure as the condensed DNA is sandwiched 
between layers (Radler et al 1997). These transfection competent lipidrDNA 
multilamellar complexes have been reported to have a characteristic 
‘fingerprint’ like appearance when viewed using transmission electron 
microscopy (TEM) (Tomlinson and Rolland 1996; Birchall et al 2000).
5.13 Characterising Aerosolised Particles
Characterisation of aerosolised particles, through aerodynamic particle size 
distribution profiles, has been typically carried out using instruments 
recognised in the compendia such as the non-viable ACI (British 
Pharmacopoeia 2010b). The Andersen viable sampler may be used as an 
alternative to such methods with possible applications in determining the 
aerodynamic size distribution of particles emitted from a pMDI.
The six stage Andersen viable sampler (AVS) was first developed in 1958 
(Andersen 1958) and was originally designed to measure the concentration and 
particle size distribution of viable aerobic bacteria and fungi. Since then it has 
been utilised as an in vitro model in predicting and assessing the health hazard 
or infection potential of biological aerosols to humans (Wendt et al 1980; Weis 
et al 2002; Fennelly et al 2004) (Section 1.4.2). In this chapter the AVS is used 
to characterise the aerodynamic particle size distribution of aerosolised pDNA 
pMDI formulations. To date the use of a viable sampler for characterising 
aerosolised particles emitted from an inhaler system has not been reported in 
published work. The viable sampler is deemed to be advantageous over other 
particle sizing methods, for the work carried out in this chapter, for a number 
of reasons. The viable sampler is designed to minimise ‘wall loss’ so that 
particle impaction is predominantly on the media contained in petri dishes as 
opposed to the walls of the apparatus as in the glass impinger (Andersen 1958). 
Sample collection from the viable sampler does therefore not require any wash 
methods, which is labour intensive and if carried out insufficiently can lead to
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poor sample collection (Andersen 1958) For this reason the use of a viable 
sampler can be deemed advantageous over other particle sizing apparatus such 
as the glass impinger, which requires washing of the overall inner surface of 
the apparatus, or ACI, where impaction plates require washing (British 
Pharmacopoeia 2010b). Often cascade impactors using impaction plates can 
have a reduced efficiency due to particle bounce and re-entrainment effects 
(Ranz and Wong 1952). However, this effect is reduced in a viable sampler as 
an impaction medium is used for particle collection (Andersen 1958). 
Additionally in particle sizing instruments where the particles are deposited 
directly into impaction medium, the viable sampler requires the use of a lower 
quantity o f medium per stage (approximately 8 ml with total volume of 48 ml 
for the six impingement stages) compared to the MSLI (20 ml per stage and 80 
ml total volume for the four impingement stages) (British Pharmacopoeia 
2010b). Maintaining a low volume of impaction medium is crucial to prevent 
any dilution effect during quantification of deposited pDNA particles using 
cellular transfection methods.
The viable sampler is also commercially available as an abbreviated system 
comprising a reduced number o f stages; typically single stage (Thermo 
Scientific 2009a) or two stage (Thermo Scientific 2009b; Westech Instruments 
2009). These labour saving abbreviated systems have been designed and used 
for applications in the characterisation of biological aerosol particles in terms 
of the respirable and non-respirable fraction rather than particle size 
distribution (Trout et al 2001; Thermo Scientific 2009b). They have been 
shown to produce characterisation data comparable with the standard six stage 
Andersen viable sampler in terms of both their precision and accuracy (Jensen 
et al 1992; Jones et al 1985). To date there is no published data available on 
the utility of an abbreviated viable sampler for collection of particles deposited 
from a pMDI. However, a two stage viable impactor based on the Andersen six 
stage viable sampler (Andersen 1958) has been developed by Westech 
Instruments Ltd. for determining the fine particle dose of pMDI using coated 
petri dishes.
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In order to assess the use of the abbreviated viable sampler for characterising 
particles emitted from a pMDI, investigations will be carried out in this chapter 
to compare the FPF generated from the ACI, six stage Andersen viable sampler 
(AVS) and the abbreviated Andersen viable sampler (AAVS) using the 
commercially available formulation Airomir® which comprises SS a molecule 
which can be relatively easily assayed.
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5.1.4 Specific Aims and Objectives of the Chapter
This chapter aims to investigate the feasibility of incorporating DOTAP into a 
pMDI system containing solvent-washed pDNA particles. One of the aims of 
this chapter is to assess the potential for delivering the DOTAP-pDNA 
formulation to cells via a pMDI using a standard valve and actuator. 
Subsequent aims of this chapter are to determine the deposition pattern of the 
aerosolised DOTAP-pDNA formulation and to assess its stability after a four 
week storage period.
The experimental objectives are to:
1. Investigate different methods to incorporate DOTAP transfection agent into 
pDNA pMDI systems. The optimum system will be identified by 
quantifying transfection efficiency of aerosolised formulations on A549 
cells using flow cytometry.
2. Characterise structure of lipid:pDNA lipoplexes formed from aerosolised 
DOTAP-pDNA formulations using TEM.
3. Determine deposition patterns of aerosolised DOTAP-pDNA pMDI using in 
vitro cascade impaction methods.
4. Assess the stability of the DOTAP-pDNA pMDI system subjected to 
accelerated storage conditions through quantifying gene expression in A549 
cells treated with the aerosolised formulation.
5. Characterise DOTAP-pDNA dispersion behaviour in pMDI canisters.
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5.2 Materials and Methods
All reagents were used as received and were purchased from Fisher Scientific 
UK Ltd. (Loughborough, UK) unless otherwise stated.
Deionised water was obtained from an Elga reservoir (High Wycombe, UK). 
Phosphate buffered saline pH 7.4 (Mg2+ and Ca2+ free) and Chloroform 
> 99.8% spectrophotometric grade were purchased from Sigma-Aldrich Ltd. 
(Poole, UK). Dulbecco’s Modified Eagle’s Medium (DMEM), foetal bovine 
serum, penicillin G 5000 units/ml and streptomycin sulphate 5000 pg/ml were 
purchased ffom Invitrogen Ltd. (Paisley, UK). A549 mammalian cell line was 
purchased ffom EC ACC (Salisbury, UK); 1,2- Dioleoyl- 3- 
Trimethylammonium propane (methyl sulphate salt) (DOTAP) was purchased 
ffom Avanti Polar Lipids Inc. (Alabama, USA). HFA 134a was a generous gift 
of INEOS Fluor Ltd. (Runcorn, UK). Airomir® pMDI was obtained courtesy 
of 3M Healthcare Ltd (Loughborough, UK).
5.2.1 Incorporation of DOTAP into a pDNA pMDI System
Investigations were carried out to assess whether DOTAP could be 
incorporated into a pMDI containing the solvent-washed pDNA particle 
formulation and successfully aerosolised to confer pDNA transfection and gene 
expression.
To achieve this goal the following DOTAP-pDNA formulations were 
produced and investigated for cellular gene expression post-actuation ffom a 
pMDI system;
In all formulations the equivalent of 79 pg pDNA and a DOTAP (474 pg) 
equivalent to a DOTAP:DNA 6:1 w/w ratio was incorporated into the pMDI 
system.
• Liposomal DOTAP + pDNA particles:
Extruded DOTAP (1 mg/ml) (prepared in Section 4.2.3) liposomes were
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pipetted directly into a fluorinated ethylene propylene (FEP) coated aluminium 
canister (3M Drug Delivery Systems, Loughborough, UK) containing 5 mg 
(equivalent to 79 pg pDNA) of solvent-washed pDNA particles. The pDNA- 
DOTAP formulation was then vortexed for 5 min and left to stand at room 
temperature for 20 min to promote lipoplex formation. Absolute ethanol (0.5 
ml) was then pipetted into the canister after which the formulation was 
vortexed for another 5 min.
• DOTAP in pDNA particle formulation:
DOTAP lipid (6 mg) was weighed and added to the surfactant phase during the 
production of an optimised microemulsion system comprising water phase: 
surfactant: organic phase, 26:52:22 w/w/w (preparation previously outlined in 
Section 2.2.1) containing 1 mg pDNA. The microemulsion was left to stand at 
room temperature for 20 min to promote lipoplex formation. After 20 min the 
microemulsion was freeze-dried (Section 2.2.2) and put through the solvent- 
wash procedure using propan-2-ol (Section 2.2.3). Once solvent-washing was 
completed, 5 mg of the pDNA sample was then weighed into a FEP coated 
canister and dispersed in 0.5 ml of absolute ethanol by vortexing for 5 min.
•  DOTAP + pDNA particles:
DOTAP lipid was weighed into a FEP coated canister containing 5 mg of 
solvent-washed pDNA particles (equivalent to 79 pg pDNA). Absolute ethanol 
(0.5 ml) was pipetted into the canister and the formulation was dispersed by 
vortexing for 5 min.
•  DOTAP coated canister + pDNA particles:
The inside of an FEP coated canister was coated with DOTAP by dissolving 
474 fig DOTAP lipid in 1 ml chloroform, adding to the canister and then 
evaporating the solvent using rotary evaporation methods outlined previously 
(Section 4.2.3). Solvent-washed pDNA particles (equivalent to 79 pg pDNA) 
were then weighed into the canister and dispersed using 0.5 ml absolute 
ethanol and vortexing for 5 min.
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All formulations were left to stand at room temperature for 20 min in order to 
allow DOTAP:pDNA complex formation to proceed prior to the addition of 
HFA 134a propellant. Spraymiser™ 50 pi retention valves (3M Drug Delivery 
Systems, Loughborough, UK) were crimped onto the aluminium canisters and 
6 ml HFA 134a was added using a Pamasol® semi-automatic filling and 
crimping machine model P2005/2 (Pamasol Willi MSder AG, Pfhffikon SZ, 
Switzerland).
The pMDl formulations were actuated from the vertical orientation (Section
4.2.7.2) onto A549 cells seeded in T25 flasks (Coming Costar Ltd., High 
Wycombe, UK) at a density of 4 x 104 cells/cm2 and cultured under the culture 
conditions outlined in Section 4.2.1 to 68% confluency. Each T25 flask was 
treated with the equivalent of 15 pg aerosolised pEGFP-Nl. pMDIs were 
primed by firing five shots to waste using an actuator with a 0.5 mm orifice 
diameter (3M Drug Delivery Systems, Loughborough, UK). To reduce any cell 
death, due to aerosol cold freon effect, the T25 flasks were placed on pre­
warmed saline infusion bags with 30 sec intervals between actuations. All 
treatments were conducted in serum-free DMEM. Treated cells were stored in 
a humidified incubator (37°C/ 5% CO2). After a period of 6 hr, cells were 
washed once with 5 ml PBS, pH 7.4, replenished with 5 ml of growth media 
(10% fetal bovine serum, 2% penicillin/streptomycin 5000 iu/ml and DMEM 
to 100%) and returned to the humidified incubator (37°C/ 5% CO2). The 
percentage of cells displaying GFP-associated fluorescence (FL1-H) was 
quantified 42 hr post-treatment by flow cytometry (FACSCalibur™ system 
Becton, Dickinson Biosciences, Oxford, UK) with analysis by WinMDI™ 
Software (Joseph Trotter, The Scripps Institute, California, USA), as described 
previously (Section 4.2.4.1).
S.2.1.1 Microscopic Characterisation of Aerosolised DOTAP-pDNA 
Formulation
A Philips 208 transmission electron microscope (TEM) (Philips, Eindhoven, 
The Netherlands) was used to characterise the actuated DOTAP-pDNA
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formulations. The method used to visualise the presence of any DOTAP:pDNA 
complexes was adapted from Zabner et al (1995). Freshly prepared DOTAP- 
pDNA formulations were actuated ten times into a 50 ml centrifuge tube 
containing 25 ml deionised waster. A pioloform-coated 200 mesh nickel grid 
was fixed between the tips of metal forceps and 5 pi of the actuated sample in 
water was pipetted onto the ‘dull side’ o f the grid. After a contact time of 5 min 
the excess formulation was wicked from the grid using filter paper. Aqueous 
uranyl acetate (2% w/w), used as the negative stain, was centrifuged for 2 min 
at 13,000 rpm prior to use. The grid surface was then placed on the surface of a 
2% aqueous uranyl acetate drop for 30 sec. After 30 sec the stain was wicked 
from the grid and the grid was rinsed twice in drops of deionised water, 
ensuring that the grid was wicked between washes, prior to analysis by TEM.
5.2.2 Assessment of DOTAP-pDNA Deposition Following Aerosolisation 
from a pMDI
Initial experiments were carried out to assess the minimum quantity of the 
aerosolised DOTAP-pDNA formulation required to ensure a detectable 
deposition result. Using the DOTAP coated canister formulation (Section 
5.2.1) three quantities of solvent-washed pDNA were investigated, 5 mg, 
10 mg and 20 mg, which were actuated with the assumption that an equivalent 
of 79 pg, 158 pg and 316 pg pEGFP-Nl respectively would be successfully 
expelled from the pMDI.
The in vitro deposition performance of aerosolised DOTAP-pDNA formulation 
was characterised using an Andersen six stage viable sampler (AVS) 
(Andersen Samplers Inc., Georgia, USA) fitted with a 90° aluminium USP-2 
induction port (throat), to act as an inlet to the device, and operated at 
28.3 l/min in a 20°C temperature controlled room. Prior to use all sampler 
components were sprayed with 70% (v/v) absolute ethanol in water and dried. 
Each stage of the A VS consisted of a sterile petri dish containing 8 ml of sterile 
serum-free DMEM as the impaction medium.
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DOTAP-pDNA pMDIs were primed by firing five shots to waste using an 
actuator with a 0.5 mm orifice diameter (3M Drug Delivery Systems, 
Loughborough, UK). During priming and testing pMDIs were shaken for 5 sec 
between actuations, as specified in compendia procedures (British 
Pharmacopoeia 2010b). Following priming each inhaler was fixed into the 
testing position using a rubber mouthpiece attached to the throat of the AVS. 
The vacuum was then turned on and the canister was depressed and held for 
five sec. Once the pMDI formulation had been actuated to completion 
(approximately 130 actuations), flow through the AVS was maintained for an 
additional 30 sec. The sampler was then disassembled and the deposited 
DOTAP-pDNA formulation was recovered quantitatively from the throat by 
washing with 8 ml DMEM. 1 ml aliquots of aerosolised DOTAP-pDNA 
deposited on the throat and in the petri dishes containing DMEM were used to 
treat A549 cells seeded into 24-well plates at a density of 4 x 104 cells/cm2 and 
cultured under the conditions outlined in Section 4.2.1 to 68% confluency. A 
total of 6 wells were treated with sample aliquots taken from each stage of the 
AVS.
After a period of 6 hr, cells were washed once with 1 ml PBS, pH 7.4, 
replenished with 1 ml of growth media and returned to the humidified 
incubator (37°C/ 5% CO2). The percentage of cells displaying GFP-associated 
fluorescence (FL1-H) was quantified 42 hr post-treatment by flow cytometry 
(FACSCalibur™ system Becton, Dickinson Biosciences, Oxford, UK) with 
analysis by WinMDI™ Software (Joseph Trotter, The Scripps Institute, 
California, USA), as described previously (Section 4.2.4.1).
S.2.2.1 Validation of the Abbreviated Andersen Viable Sampler
In order to maximise the detection of any DOTAP-pDNA aerosolised sample 
deposition, the AVS was abbreviated by reducing the number of deposition 
stages. Initial experiments using Airomir® (Salbutamol Sulphate 100 pg 
Inhalation Aerosol) pMDI were carried out to validate the use of the 
abbreviated viable sampler (AAVS). The AAVS was constructed from the six
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stage AVS (full stack) using only Stages 2, 5 and 6. The AAVS was operated 
as before at 28.3 1/min in a 20°C temperature controlled room. Each stage of 
the AAVS consisted of a petri dish containing 8 ml internal standard (IS) 
prepared as outlined previously (Section 2.2.4). Airomir® pMDIs were initially 
primed by firing five shots to waste. Following priming the pMDIs were 
actuated twice into the sampler with a 5 sec shaking interval between 
actuations using the technique outlined in Section 5.2.2. After actuation, the 
AAVS was then disassembled and the deposited SS from the Airomir® pMDI 
was recovered quantitatively from the throat and inlet by washing with 8 ml IS. 
Aliquots of the samples were then analysed quantitatively for SS using the 
HPLC protocol (previously outlined in Section 2.2.4) and compared against SS 
deposition data generated from the full stack AVS and an ACI (Westech 
Instrument Services Ltd., Bedfordshire, UK) (protocol for use in Section 2.2.6). 
The FPF parameter generated from the ACI, full stack AVS and AAVS was 
used during equipment validation. The FPF referred to the proportion of 
particles with an aerodynamic diameter smaller than 4.7 pm. This parameter 
was calculated as a ratio of the aerosolised fine particle mass to the total mass 
of drug emitted.
Following validation with regard to the FPF, the AAVS was utilised for in vitro 
deposition performance assessment of aerosolised DOTAP-pDNA. Using the 
formulation which conferred the greatest cellular gene expression, 20 mg of 
solvent-washed pDNA was incorporated into a pMDI system (Section 5.2.1). 
The formulation was primed and actuated into the validated AAVS with the 
assumption that an equivalent of 316 pg pEGFP-Nl would be successfully 
expelled from the pMDI. The samples deposited in petri dishes at the various 
stages of the AAVS were analysed for transfection competency using cell 
culture methods outlined in Section 5.2.2.
The FPF4 .7  nm was calculated for the AAVS as the level of gene expression 
observed for particles with an aerodynamic diameter smaller than 4.7 pm 
(deposited on Stages 5 and 6 of the AVS, as Stages 3 and 4 had been removed)
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as a percentage of total gene expression observed (throat to Stage 6). The 
EPF 11 jut, was also calculated which referred to the ratio of gene expression 
observed for particles with an aerodynamic diameter smaller than 1.1 pm 
(Stage 6) compared to total gene expression.
5.23 Investigating the Stability of DOTAP-pDNA pMDI Formulation 
Following Accelerated Storage
DOTAP-pDNA pMDI formulations using DOTAP coated canisters and 5 mg 
solvent-washed pDNA were prepared as previously outlined (Section 5.2.1). 
Following preparation, the pMDI canisters were stored in the valve down 
position at accelerated storage conditions 40 ± 2°C /75 ± 5% relative humidity 
(ICH Expert Working Group 2003) using a Sanyo stability chamber (Sanyo 
Gallenkamp pic., Loughborough, UK). The valve down position was used as 
pharmaceutical pMDIs are often stored and used in this position. Three 
canisters were removed from the stability chamber and tested for cell 
transfection at pre-determined time points, 0 week (freshly prepared pMDI), 
1 week, 2 weeks and 4 weeks after the pMDI formulations had been stored in 
accelerated conditions.
Canisters were actuated using a 0.5 mm orifice diameter actuator (3M Drug 
Delivery Systems, Loughborough, UK), from the vertical orientation (Section
4.2.7.2) onto A549 cells seeded in T25 flasks at a density of 4 x 104 cells/cm2 
and cultured under conditions outlined in Section 4.2.1. Each T25 flask was 
treated with the equivalent of 15 pg aerosolised pEGFP-Nl, assumed to be 
successfully expelled, in the presence of serum-free DMEM. Treated cells were 
then stored in a humidified incubator (37°C/ 5% CO2) and further handling of 
the cells was carried out as outlined above (Section 5.2.1). The percentage of 
cell fluorescence was quantified 42 hr post-treatment by flow cytometry 
(FACSCalibur™ system Becton, Dickinson Biosciences, Oxford, UK) with 
analysis by WinMDI™ Software (Joseph Trotter, The Scripps Institute, 
California, USA), as described previously (Section 4.2.4.1).
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Formulations were also prepared in plastic polyethylene terephthalate (PET) 
pMDI vials (3M Drug Delivery Systems, Loughborough, UK) and stored in the 
stability chamber under accelerated conditions, for visual assessment of 
physical stability and dispersion homogeneity.
5.2.4 Statistical Analysis
Statistical analysis was carried out using a statistical package, SPSS 16®. One­
way analysis of variance (ANOVA) followed by a Duncan’s multiple range 
test used to compare multiple groups was used with significant difference 
indicated by the p-value <0.05. Results are summarised as mean ± sd.
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5 3  Results
5.3.1 Incorporation of DOTAP into a pDNA pMDI System
The various DOTAP-pDNA formulations (Section 5.2.1) were aerosolised onto 
A549 cells in order to assess which formulation conferred the greatest cellular 
gene expression. Figure 5.1 highlights the significant increases (p<0.05) in 
fluorescent cells following aerosolisation of formulations that incorporated 
DOTAP into pMDI canisters as either a lipid powder (5.09 ± 3.83% fluorescent 
cells) or coating the canister with DOTAP (9.01 ± 3.98% fluorescent cells) 
compared with control cells (1.03 ± 0.51%). Formulations using liposomal 
DOTAP (1.83 ± 0.27%) or the incorporation of DOTAP lipid at the 
microemulsion stage (2.31 ± 2.31%) did not mediate any significant gene 
expression. Out of the four DOTAP-pDNA formulations investigated, the 
DOTAP coated canister formulation led to the largest significant increase in 
the percentage of fluorescent cells.
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Figure 5.1 Quantitative gene expression of aerosolised DOTAP-pDNA 
formulations. A549 cells were surface-treated with (i) Control- DMEM alone, or 
aerosolised: (ii) Extruded DOTAP liposomes and solvent-washed pEGFP-Nl 
particles, (iii)) DOTAP lipid incorporated into the pDNA microemulsion prior to 
freeze-drying and solvent-washing, (iv) DOTAP lipid and solvent-washed pEGFP-Nl 
particles, (v) DOTAP coating pMDI canister and solvent-washed pEGFP-Nl particles. 
Data are presented as mean ± sd; n = 3. The bar represents no significant difference 
(pX>.05).
53.1.1 Microscopic Characterisation of Aerosolised DOTAP-pDNA 
Formulation
TEM analysis was performed on actuated DOTAP-pDNA formulations to 
characterise the structural properties of the aerosolised products. DOTAP 
liposomes prepared by solvent evaporation and extrusion and added to the 
pDNA particles in the canister, revealed the presence of indistinguishable 
disperse bodies (Figure 5.2, Micrograph A). Lamellar structures indicating the 
presence of either liposomes or lipoplexes were not observed.
DOTAP lipid in powder form incorporated into a pMDI system containing 
solvent-washed pDNA, revealed a heterogeneous population made up of 
spherical and aggregated complexes (Figure 5.2, Micrograph B). The spherical 
complex was approximately 100 nm in diameter. Aggregates varied in
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diameter but were generally larger than 100 nm.
When DOTAP was pre-coated onto the canister wall prior to addition of the 
pDNA particles, TEM revealed a population of multilamellar lipoplexes 
indicated by the ‘finger print’ like structures. These lipoplexes were generally 
larger than 100 nm (Figure 5.2, Micrograph C).
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Aggregated
complex
Spherical
complex
Figure 5.2 Typical transmission electron microscopy of aerosolised DOTAP- 
pDNA formulations. A: Liposomal DOTAP + pDNA particles, B: DOTAP + pDNA 
particles, C: DOTAP coated canister + pDNA particles. Scale bar = 100 nm.
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5.3.2 Assessment of DOTAP-pDNA Deposition Following Aerosolisation 
from a pMDI
Prior to assessing aerosolised DOTAP-pDNA deposition, an initial study 
(n = 2) was carried out to assess the minimum quantity o f aerosolised 
formulation required to ensure a detectable deposition result in an AVS. This 
study was carried out using the DOTAP coating canister-pDNA formulation as 
this formulation conferred the greatest cellular gene expression. Aerodynamic 
particle size distribution data (Figure 5.3) revealed that actuating 79 pg or 
158 pg of pDNA led to relatively low levels o f gene expression with maximum 
gene expression detected from particles deposited in the throat (1.54% and 
1.80% respectively). Increasing the aerosolised pDNA quantity to 316 pg did 
confer a greater gene expression however even at this dose the maximum gene 
expression was 3.12%, detected from pDNA deposited in the throat.
3.5 i ■ 79 pg pDNA
■ 158 pg pDNA 
□ 316 pg pDNA
Control Tin SI S2 S3 S4 S5 S6
Figure 5.3 Aerodynamic particle size distribution of transfection competent 
aerosolised DOTAP coating canister-pDNA formulation. The equivalent o f 79 pg, 
158 pg and 316 pg pEGFP-Nl was expelled from the pMDI into an Andersen six 
stage viable sampler. A549 cells were surface-treated with Control: DMEM alone, or 
aerosolised DOTAP-pDNA formulation deposited on the: Thr: throat, SI to S6: 
Stages 1 to 6 of the viable sampler (n = 2).
168
Chapter Five
53.2.1 Validation of the Abbreviated Andersen Viable Sampler
In order to maximise the detection of any DOTAP-pDNA aerosolised sample 
deposition, the number of stages in the AVS was reduced to construct the 
AAVS. Initial deposition experiments, using a commercially available 
formulation Airomir®, were carried out to validate the AAVS by comparing 
the FPF4 .7  m  data generated from the ACI, AVS and AAVS (Figure 5.4).
Figure 4 reveals no significant difference (p>0.05) in FPF between the ACI 
non-viable sampler (61.3 ± 1.00%), AVS (55.3 ± 10.8%) and AAVS 
(53.6 ± 8.60%).
s3.
V
#
£
ACI AVS AAVS
Figure 5.4 A comparison of fine particle fraction (FPF4.7 ^  ex-actuator) 
measured from an ACI, AVS and AAVS using an Airomir® pMDI. ACI: eight 
stage non-viable Andersen cascade impactor, AVS: six stage Andersen viable 
sampler, AAVS: three stage Andersen viable sampler. Data are presented as mean ± 
sd; n = 3. Bar represents no significant difference in FPF4 7 ^  (p>0.05).
Once validated, with regard to the FPF4.7 nm, the AAVS was used to assess 
aerosolised DOTAP-pDNA deposition using the DOTAP coating canister- 
pDNA formulation (Figure 5.5). DOTAP-pDNA actuated from a pMDI system
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into the AAVS was assessed by quantifying gene expression of cells treated 
with the samples deposited on the various parts of the AAVS (Figure 5.5). No 
significant increase (p>0.05) in gene expression from samples deposited in the 
throat (5.65 ± 3.92%), inlet (4.57 ± 3.54%) or Stage 5 (5.60 ± 4.66%) was 
detected compared to the control (1.00 ± 0.23%) (Figure 5.5). Significantly 
enhanced cellular gene expression, however, did result from DOTAP-pDNA 
deposition on Stage 2 (9.17 ± 4.50%, p<0.05) and Stage 6 (8.54 ± 5.68%). The 
DOTAP-pDNA formulation had a FPF47 m  (ex-actuator) of 44.6 ± 18.0% and 
an EPFi.i m  (ex-actuator) of 26.9 ± 9.37%.
Control Throat Inlet >4.7 1.1 -4.7 pm 0.65 -1.1 pm
(Stage 2) (Stage 5) (Stage 6)
Figure 5.5 Aerodynamic particle size of transfection competent aerosolised 
DOTAP coating canistei^-pDNA formulation deposited in a validated abbreviated 
Andersen viable sampler. A549 cells were surface-treated with Control: DMEM 
alone, or aerosolised DOTAP-pDNA formulation deposited on the various stages of 
the sampler. Data are presented as mean ± sd; n = 3. *denotes a significant difference 
from the control (p<0.05).
5 3 3  Investigating the Stability of DOTAP-pDNA pMDI Formulation 
Following Accelerated Storage
Cellular gene expression conferred by aerosolised DOTAP-pDNA 
formulations was assessed following storage in order to investigate the 
formulation stability over time. Due to stability chamber breakdown, the 
freshly prepared DOTAP-pDNA formulations were stored in accelerated 
conditions for less than 24 hr prior to an eleven day break during which time
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formulations were stored at room temperature (Figure 5.6). This time at 
ambient conditions is not accounted for in the analysis.
The reduction in gene expression after storing DOTAP-pDNA pMDI 
formulations under accelerated testing conditions is graphically presented in 
(Figure 5.6). The percentage of fluorescent cells, i.e. gene expression 
efficiency, was significantly reduced after treatment with aerosolised DOTAP- 
pDNA formulation stored under accelerated conditions for one week at 
40°C/75RH (6.31 ± 2.87%, p<0.05) compared to that which was freshly 
prepared (9.15 ± 2.73%). A further significant reduction in the gene expression 
was observed from the formulation stored in accelerated conditions for two 
weeks at 40°C/75RH (4.96 ± 1.25%). At four weeks, however, gene expression 
(4.55 ± 0.64%). was statistically comparable (p>0.05) to the formulation tested 
at two weeks. Overall the data revealed that gene expression up to four weeks 
storage was significantly higher than compared to the control (0.94 ± 1.14%).
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Figure 5.6 Quantitative gene expression of aerosolised DOTAP coating canister- 
pDNA formulation stored under accelerated storage conditions. A549 cells were 
surface-treated with Control: DMEM alone, or aerosolised DOTAP-pDNA 
formulation: Week 0: Freshly prepared pMDI formulation, Week 1, 2 and 4: pMDI 
formulations were stored in accelerated conditions for one, two and four weeks prior 
to actuation onto cells. Formulations were subjected to an interval of eleven days 
before which accelerated conditions were applied to the freshly prepared formulation 
due to stability chamber breakdown. Data are presented as mean ± sd; n = 3. The bar 
represents no significant difference (p>0.05).
Visual observation of DOTAP-pDNA formulations loaded into PET vials was 
used to determine gross visual changes in the properties of the dispersion 
(Figure 5.7). Freshly prepared formulations (Week 0) consisted of white 
particles suspended in the liquid propellant continuous phase. After 1, 2 and 4 
weeks storage in accelerated conditions most of the formulation had 
sedimented to the bottom of the canister. Sedimented particles were readily re­
dispersed upon one inversion of the vial. A stark difference between the re­
dispersed formulations was observed when comparing the formulation at Week 
0 to Week 4. The initial opaque dispersion observed at Week 0 gradually 
turned clearer throughout the duration of storage until it was relatively clear
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with few suspended particles at Week 4. Visual observations o f the particles 
suspended in the propellant at Week 4 appeared to be larger compared to the 
particles at Week 0 implying the possibility of aggregation.
y
l 1 days
without 
accelerated 
conditions 
< ►
WeekO
Figure 5.7 Photograph of plastic PET pMDI vials containing DOTAP coating 
canister-pDNA formulation in HFA 134a propellant with absolute ethanol as a 
co-solvent. Images were taken Week 0: Freshly prepared pMDI formulation, Week 
1, 2 and 4: pMDI formulations were stored in accelerated conditions for one, two and 
four weeks. Photographs were taken of vials after one inversion o f the vial. 
Formulations were subjected to an interval o f eleven days at ambient conditions before 
exposure to accelerated conditions.
Week 1 Week 2 Week 4
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5.4 Discussion
5.4.1 Incorporation of DOTAP into a pDNA pMDI System
A549 cellular gene expression data revealed that pEGFP-Nl transfection could 
be successfully conferred using aerosolised DOTAP-pDNA particle pMDI 
formulations. However, the success of transfection was found to be reliant on 
the method used to incorporate DOTAP into the pDNA pMDI formulation. 
Incorporating a transfection agent such as DOTAP into a pDNA pMDI system 
is relatively novel and to date there is little published work in this field 
(Birchall 2007).
Brown and Chowdhury (1997) demonstrated gene expression in the respiratory 
epithelial cells of aerosol exposed mice using pDNA lyophilised in the 
presence of both non-ionic surfactant (Tween 40) and ionic transfection agent 
(lipofectin or lipofectamine) suspended in dimethylether propellant pMDI 
system. In the study carried out in this chapter however, aerosolisation of a 
DOTAP-pDNA formulation using pDNA lyophilised in the presence of 
DOTAP, incorporated at the microemulsion stage, resulted in no significant 
transfection. A possible reason for the lack of transfection could be due to the 
presence of lecithin surfactant used to stabilise the microemulsion. Lecithin is 
composed of anionic lipids and is able to compete with the pDNA on an 
electrostatic level to displace any DOTAP:pDNA complexes that may have 
formed prior to lyophilisation (Xu and Szoka 1996; Duncan et al 1997). 
DOTAP:pDNA complex displacement was not observed by Brown and 
Chowdhury (1997) as they used a non-ionic surfactant. Additionally, as 
DOTAP is freely soluble in solvents such as alcohol (Merck 2007), the solvent- 
wash procedure utilised in this thesis following lyophilisation may have also 
caused the removal of DOTAP. As in vitro cellular uptake of pDNA without 
the use of a transfection agent is relatively inefficient (Zabner et al 1997), the 
possible loss of DOTAP through solvent-washing may have led to the poor 
pDNA transfection observed.
Aerosolisation of formulations using preformed liposomal DOTAP added to
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the pDNA particles also resulted in no significant cell transfection. The effect 
of water in pMDI systems is known to promote chemical instability, particle 
cohesion and particle adhesion onto canister walls (Vervaet and Byron 1999; 
James et al 2008). The presence of 7.6% v/v water in the pMDI system, from 
the DOTAP liposomes, may have had a detrimental effect on the formulation 
stability causing a loss in formulation activity, reduced aerosolisation 
efficiency and consequently poor gene expression.
Transfection competent DOTAP:pDNA multilamellar complexes have a 
typical characteristic ‘fingerprint’ like appearance (Tomlinson and Rolland 
1996; Birchall et al 2000). TEM analysis, of the aerosolised liposome DOTAP 
formulation, revealed DOTAP:pDNA multilamellar complexes were not 
present.
The addition of DOTAP, by either coating the canister or using the lipid in 
powder form, to pMDIs containing pDNA particles did confer a significant 
increase in gene expression. As it is well known that pDNA complexed to the 
transfection agent is a prerequisite for successful in vitro and in vivo 
transfection (Gao and Huang 1995; Zabner et al 1997), the significant gene 
expression demonstrated by these formulations suggests the formation of 
functional lipoplexes. However, as there is no published work on this topic, the 
mechanism of complex formation in the non-aqueous pMDI environment is 
unclear.
The DOTAP coating canister formulation was prepared using a solvent 
evaporation method commonly used to form lipid films originally described by 
Bangham et al (1965). As DOTAP is soluble in alcohol (Merck 2007), 
agitation of this film in the presence of ethanol would have caused the DOTAP 
film to disperse into the solvent. In the presence of HFA 134a propellant, based 
on its chemistry, the DOTAP hydrophobic lipid anchor group may have 
orientated towards the propellant whilst the cationic head group 
electrostatically interacted with the pDNA to form a lipoplex with a reverse
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micelle like structure (Brown 1996). Introducing the DOTAP in the form of a 
lipid powder may have also lead to the dispersion of the lipid and interaction 
with pDNA in the same way. Also, as it is well known that liposomes interact 
spontaneously with pDNA to form lipoplexes in aqueous conditions (Feigner et 
al 1987), lipoplexes may have formed post-aerosolisation of the DOTAP- 
pDNA formulation into an aqueous environment.
TEM of formulations utilising DOTAP lipid in powder form revealed a 
heterogeneous population of spherical complexes, similar to those seen with 
the DOTAP coating canister formulation, and aggregated complexes. This 
infers that DOTAP:pDNA complexation may not have been complete (Birchall 
et al 2000). The DOTAP coating canister formulation generally revealed a 
population of DOTAP:pDNA complexes, as neither free DOTAP nor pDNA 
was observed. It is possible therefore that the aerosolised pDNA may have 
been completely condensed which could be a possible reason for the observed 
superior cell transfection (Zabner et al 1995; Birchall et al 2000).
As a result of this transfection study, further investigations in this chapter to 
assess aerosolised particle size distribution and storage stability were carried 
out using the DOTAP coated canister formulation.
5.4.2 Assessment of DOTAP-pDNA Deposition Following Aerosolisation 
from a pMDI
Aerodynamic particle size distribution data generated from the three doses of 
aerosolised pDNA, 79 pg, 158 pg and 316 pg, into the AVS revealed the 
maximum percentage cell fluorescence was 3.12% detected from an estimated 
316 pg dose. Dry powder inhalation (DPI) pDNA formulations containing 
transfection agents actuated into a MSLI, at a dose of 133 pg, revealed A549 
cell fluorescence percentages at various stages ranging from approximately 2% 
to 22% (Li et al 2005a). The relatively low percentage cell fluorescence 
detected, from the stages of the AVS, in this chapter using more than double 
the pDNA dose to that used in the DPI studies could be due to the variations
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between the formulations, as a transfection agent may be more stable as a dry 
powder than in the propellant environment of a pMDI. The aerosolisation of 
pDNA using 130 successive actuations, in this study, may also have affected 
the viability of the temperature sensitive DNA due to the cold freon effect 
which would cause the formulation to rapidly cool, however as evidence of a 
dose response was observed this effect may have been minimal.
In an attempt to generate significant deposition data with a more pronounced 
percentage gene expression, DOTAP-pDNA formulations were actuated into a 
viable sampler (AVS) after reducing the number of stages and validating the 
system as an abbreviated viable sampler (AAVS). During validation with 
regards to the FPF, the AAVS generated an FPF that was not significantly 
different from the AVS and the Andersen cascade impactor (ACI). This was to 
be expected as although the number of stages in the AAVS were reduced, the 
cut-off stage (Stage 2) which defined the FPF4 .7  m  parameter remained in 
place. Although the data generated from the AAVS is limited as it would not 
provide a particle size distribution profile, it would however characterise 
particles in terms of the respirable and non-respirable fractions.
Particle deposition in the AAVS revealed significant gene expression from 
particles deposited in Stage 2 (particle diameter cut-off 4.7 pm) as well as 
Stage 6 (cut-off 0.65 pm) compared to control. No significant difference 
between these two stages was detected. It is generally acknowledged that 
particles require an aerodynamic diameter of < 5 pm to allow efficient 
penetration and deposition in the peripheral pulmonary regions (Hickey 1993). 
The data generated from the AVS therefore predicted that aerosolised DOTAP- 
pDNA formulation may significantly deposit in the lower respiratory tract as 
well as the upper respiratory tract.
The FPF4 .7  m  (ex-actuator) is a ratio often used as a guide to understanding the 
portion of the aerosolised drug that is likely to reach the lung (the respirable 
portion). Example FPF data from commercially available inhalers intended for
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localised pulmonary delivery include Proventil® HFA FPF4.7 m  is 
approximately 45% (Harris et al 2006) and Airomir® FPF5.8 nm approximately 
64% (Dubus et al 2001). Aerosolised DOTAP-pDNA had a FPF4.7 nm 44.6 ± 
18.0%. Although the DOTAP-pDNA formulation has yet to be optimised, 
comparisons between the FPF data demonstrate the potential of this 
formulation for localised pulmonary delivery. It is important to remember that 
the FPF data generated from this study was a measure of cellular gene 
expression conferred by the pDNA formulation deposited on the various stages 
of the AAVS. The FPF generated may therefore have been an underestimate of 
the actual deposited pDNA. This is because, given the sensitive nature of 
conferring gene expression, not all the pDNA deposited in the AVS would 
have gone on to successfully transfect the cells and express GFP.
Published reports in the aerosolised gene therapy field reveal FPF6.8 data for 
DPI formulations, containing freeze-dried or spray-dried 
lipid:protamine:pDNA (LPD) complexes in the presence of cryoprotectants, in 
the range of approximately 7% to 16% (Li et al 2003, 2005a). The FPF6.8 nm 
was only increased to between approximately 38% to 58% when dispersibility 
enhancers and cellular uptake enhancers were incorporated into the 
formulations (Li et al 2003; Li and Birchall 2006). The FPF data generated 
from the unoptimised DOTAP-pDNA pMDI formulation in this chapter 
(FPF4  7 ^  44.6 ± 18.0%),compared to DPI LPD formulations, reveals the utility 
of a pMDI system for the pulmonary delivery of transfection competent 
DOTAP-pDNA. A possible avenue of further work to optimise the formulation 
and confer greater gene expression values includes exploring the utility of 
newer transfection agents. Nevertheless, stability data is critical in order to 
assess the feasibility for use of the DOTAP-pDNA pMDI formulation over 
extended periods of time.
5.43  Investigating the Stability of DOTAP-pDNA pMDI Formulation 
Following Accelerated Storage
Stability data generated from aerosolised DOTAP-pDNA formulation stored
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under accelerated conditions revealed that gene expression was reduced over 
time. However significant gene expression, although reduced, was maintained 
for up to four weeks. As accelerated storage conditions expose the formulation 
to harsh conditions which can accelerate degradation (ICH Expert Working 
Group 2003), maintenance of a transfection competent formulation for up to 
four weeks provides an insight into the potential use of this formulation after 
storage in less extreme conditions. Nevertheless gene expression was reduced 
and as there is a lack of published data reporting the long-term stability of 
pDNA formulations in pMDI systems, the mechanism for the loss in 
transfection is poorly understood. Generally, as macromolecules are 
hydrophilic they have a low solubility in non-polar HFA propellants causing 
them to aggregate and denature (Byron 1990). More recently however, 
macromolecules have been demonstrated to have maintained stability and 
biological activity after storage for up to six months at room temperature with 
the use of formulation excipients such as polysaccharides and the polymeric 
surfactant polyvinyl alcohol (Liao et al 2005; Jones et al 2006; Li and Seville 
2009). Such formulation excipients have been used to coat protein using drying 
methods and shown to prevent denaturation by protection from the external 
propellant conditions and reducing particle aggregation (Liao et al 2005).
Visual observations (Figure 5.7) of freshly prepared DOTAP-pDNA pMDI 
formulations revealed a physically stable readily dispersible flocculated 
system. The presence of surfactant excipient coating the pDNA particles may 
have prevented any irreversible sedimenting due to sterically conferred 
repulsive forces between the surfactant tails which extend into the propellant 
(Vervaet and Byron 1999). However, although the freshly prepared 
formulation appeared to be physically stable, as it did not rapidly sediment, the 
observed increase in aggregated particles over time (Figure 5.7) could be a 
possible reason for the loss in gene expression (Figure 5.6). The phenomenon 
of aggregation and resulting loss in gene expression could have occurred due to 
the inherent instability of lipid-pDNA complexes (Feigner et al 1995) or the 
ingress o f water during storage in accelerated conditions.
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The aggregation of lipoplex formulations in aqueous environments is a known 
phenomenon which has been shown to be exacerbated at heightened 
temperatures causing a reduction in the pDNA transfection activity over time 
(de Lima et al 2003). Additionally unextruded liposomes have been reported to 
form heterogeneous lipoplexes which have exhibited a greater tendency to 
aggregate leading to poor transfection compared to extruded homogenous 
liposomes (Zelphati et al 1998). As any liposomes formed from the DOTAP 
coated canister formulation would be of the unextruded form, these reports 
shed some light on possible reasons for the reduction in cellular gene 
expression observed after exposure to accelerated storage conditions. However 
as previous reports have only been carried out in an aqueous environment, it 
may not be appropriate to extrapolate this data to non-aqueous environments 
found in pMDI systems.
Stability of pMDI formulations is reliant upon the strict control over impurities 
such as water (Vervaet and Byron 1999). Possible sources of water in the 
DOTAP coating canister-pDNA formulation include; water residues left behind 
after chloroform rotary evaporation during formulation preparation, or 
moisture ingress through seals and valve components during stability testing 
using accelerated storage conditions (Reynolds and McNamara 1996; Williams 
III and Hu 2000). The presence of trace amounts of water in a pMDI system 
has been shown to influence the stability of drug formulations causing 
aggregation of the formulation components (Williams III et al 1997; Blondino 
and Byron 1998). The interfacial tension between the relatively non-polar HFA 
134a propellant and water can cause the water to accumulate and adsorb onto 
the surface of drug particles and canister components rather than mix with the 
propellant (Peguin et al 2006; James et al 2008). These adsorbed water layers 
interact with each other by hydrogen bonding and have been shown, using 
atomic force microscopy, to cause adhesion between the drug particles and 
interior of the pMDI components (James et al 2008).
The presence of water in a pMDI system can influence formulation stability
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over time by increasing interparticulate attraction causing particle aggregation 
(Williams III and Hu 2000) and drug adhesion onto the walls of the canister 
(Vervaet and Byron 1999; James et al 2008). These interactions could result in 
the loss of DOTAP-pDNA biological activity and inefficient device 
performance, both of which are possible reasons to explain the observed 
reduction in gene expression.
Although this stability study did give an indication as to the biological activity 
of DOTAP-pDNA formulations in a pMDI system, using accelerated storage 
conditions over a period of four weeks, this study was limited for a number of 
reasons. Due to breakdown of the stability chamber, the freshly prepared 
DOTAP-pDNA formulations were stored under accelerated conditions for less 
than 24 hr prior to an eleven day break during which time formulations were 
stored at room temperature. As fluctuations in the storage temperature are 
known to intensify degradation (Kommanaboyina and Rhodes 1999), the 
enforced eleven day break from accelerated storage conditions may have 
caused a further reduction in the formulation biological activity. However, 
these fluctuations in temperature would have had minimal additional 
degradative effect on the formulation, as exacerbated degradation is normally 
only observed if the product is subjected to repetitive temperature cycling 
(Carstensen and Rhodes 1993). Additionally, moisture uptake into the pMDI, 
which is known to affect formulation stability, is temperature and humidity 
dependent (Williams III and Hu 2000). As any degradation of the formulation 
is hastened due to increased temperature and humidity conditions used during 
accelerated storage, it is likely that any loss of formulation biological activity 
would have been relatively minimal during the eleven days the formulation 
was kept at room temperature (Kommanaboyina and Rhodes 1999; ICH Expert 
Working Group 2003).
Accelerated storage conditions are typically carried out for a minimum of six 
months, in order to generate any clear conclusions as to the stability of the 
formulation (ICH Expert Working Group 2003). This time period and
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conditions used are used to reflect a sufficient time to cover duration for 
storage, shipment and use in the pharmaceutical industry. The stability study 
carried out in this chapter provides limited information as it was carried out 
only over a four week period. However, as a preliminary study, relevant 
information was generated regarding whether transfection competency of a 
formulation stored in a propellant environment could be maintained for 
subsequent weeks after being freshly prepared.
Although reductions in the biological activity of the formulation was assessed 
over time during the stability study, assessing other important factors such as 
changes in the aerodynamic particle size distribution and emitted dose would 
have been of benefit. As formulation stability can be reduced through adhesion 
and cohesion, the utility of in vitro cascade impaction tests and emitted dose 
studies would have been invaluable in confirming and evaluating the presence 
of aggregation, a possible avenue for further work.
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5.5 Conclusion
This chapter aimed to investigate the potential for incorporating DOTAP into a 
pDNA pMDI formulation and delivering the formulation to cells via a pMDI 
using a standard valve and actuator.
Gene expression studies demonstrated that a transfection agent can be 
incorporated into the pDNA pMDI formulation, successfully actuated to confer 
gene expression and remain functional for up to four weeks in accelerated 
storage conditions. The incorporation of a transfection agent into a pDNA HFA 
pMDI system to successfully confer gene expression is novel and to date there 
is no published work in this field. Although further optimisation is required to 
maximise transfection efficiency, the work carried out in this chapter 
demonstrated an important concept that a transfection agent can be 
incorporated into a pDNA pMDI system to form a single dosing unit with gene 
expression capability.
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CHAPTER SIX 
General Discussion
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6.1 Discussion
The incorporation of pDNA into a pMDI system for pulmonary administration 
is a relatively unexplored area of research due to the inherent challenges of 
formulating and maintaining pDNA stability. The aim of this thesis was to 
research the potential of developing a low-energy process (Dickinson et al 
2001), previously used for small molecules, to formulate surfactant-coated 
pDNA particles suitable for incorporation into a pMDI system. Subsequently, 
this thesis aimed to investigate whether it is viable to aerosolise these particles 
and determine their deposition characteristics.
Development work began with the optimisation of the microemulsion stage of 
the process. An optimised microemulsion with a surfactant to water ratio of 2.0 
was found to yield a stable isotropic system whilst maximising the volume of 
the aqueous phase and maintaining the minimum surfactant concentration 
possible. The incorporation of a model drug, salbutamol sulphate (SS), into the 
aqueous phase led to the formation of a stable drug-loaded microemulsion 
which, upon lyophilisation, resulted in the production of surfactant-coated SS 
particles.
The presence of excess surfactant after the lyophilisation stage of the process 
could potentially cause particle aggregation, hinder surface morphology 
characterisation and potentially adversely affect particulate dispersibility and 
stability in a pMDI (Blondino and Byron 1998). For this reason a washing 
technique was developed which served to successfully remove some of the 
excess surfactant from the SS particles with a 10-fold reduction in surfactant 
content. The utility of this additional procedure was shown when handling 
surfactant-coated pDNA particles. The wash procedure was successful in 
removing some of the excess surfactant from the pDNA particles whilst 
maintaining a relatively small reduction in the pDNA integrity.
In both cases, even though some of the excess surfactant was removed, 
particles remained aggregated post-washing. This aggregation was of concern,
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as the aerosolisation of such aggregates could adversely affect pulmonary 
deposition (Berry et al 2004; Traini et al 2007). However, particle sizing prior 
to incorporation into a pMDI system revealed that in either case, using SS or 
pDNA, the solvent-washed aggregated particles were in the respirable size 
range. Additionally, aerodynamic particle size data for aerosolised solvent- 
washed SS particles confirmed that the developed technology had generated 
smaller SS particles than commercially available formulations with significant 
improvements in the MMAD, FPF and EPF. Aerosolised particle 
characterisation highlights the potential for the use of this novel low-energy 
microemulsion process technology in delivering macromolecules to the lower 
respiratory tract. Although the technology explored was originally reported to 
generate particles of the nanoparticle size range (Dickinson et al 2001), such 
particles were not detected in this thesis. A possible reason for this may due to 
the observed aggregation caused by the presence of a sticky surfactant. 
Nevertheless the particles were observed to be of smaller dimensions than 
those that can be prepared using other procedures; previous reports of 
lyophilised powders have often shown particles with diameters unsuitable for 
pulmonary delivery and generally require further processing using a milling 
step prior to incorporation into an inhaler (Seville et al 2002; Shoyele and 
Cawthome 2006).
The next series of experiments presented in this thesis related to investigating 
the utility of the developed technology for the preparation of pDNA particles. 
As the native structure of the macromolecule is susceptible to damage during 
processing conditions (Carpenter and Crowe 1988a; Anchordoquy et al 1997), 
applying the developed technology to pDNA invariably brought about new 
formulation challenges previously not faced when dealing with the small 
molecular weight model drug SS.
Investigations revealed that the developed technology, which utilised the low 
energy microemulsion lyophilisation process in the presence of a sugar 
lyoprotectant, was capable of preparing surfactant-coated pDNA particles.
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Analysis of the integrity of the processed pDNA revealed that there was, 
however, a reduction in the pDNA supercoiled fraction. Although linear DNA 
forms have been found to be transfection competent (Chancham and Hughes 
2001; von Groll et al 2006), most published literature supports the opinion that 
pDNA supercoiled structure should be retained to optimise cellular transfection 
efficiency (Chemg et al 1999; Remaut et al 2006) and to comply with 
regulatory requirements on product quality (Arulmuthu et al 2007). The 
observed reduction in the supercoiled fraction may therefore have adverse 
implications on the pDNA gene expression efficiency. This data highlights a 
possible limitation of the developed technology and the need for further 
optimisation of the process in order to maintain pDNA integrity and maximise 
cellular transfection efficiency.
That said, the observed reduction in the supercoiled fraction is considered to be 
relatively small as it was found to be similar to previously published reports 
observed for spray-dried lipid:protamine:pDNA (LPD) dry powders for 
inhalation prepared in the presence of a lyoprotectant (Seville et al 2002; Li et 
al 2005a). Furthermore, despite observing a reduction in the supercoiled 
fraction, initial transfection results showed no significant difference in 
expression of reporter gene in cells treated with unprocessed pDNA and pDNA 
following processing. This data demonstrates the ability of this developed 
process to generate biologically active pDNA particles.
Experiments involving quantifying pDNA gene expression confirmed the 
importance of the wash procedure developed for the removal of excess 
surfactant. Although the integrity of the unwashed surfactant-coated pDNA 
particles remain intact post-lyophilisation, this formulation was unable to 
confer significant cellular gene expression. This lack of significant gene 
expression may have been due to the adverse effect of excess surfactant on 
pDNA functionality which has been discussed in previous studies (Xu and 
Szoka 1996; Duncan et al 1997; Tsan et al 1997). Gene expression however, 
was observed in cells which were treated with the solvent-washed variant of
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the lyophilised pDNA formulation.
The biological activity of the solvent-washed pDNA after incorporation and 
aerosolisation from a pMDI was also investigated. Prior to in vitro analysis of 
gene expression, the maintenance of pDNA integrity post-aerosolisation was 
confirmed. Cellular gene expression studies revealed that the solvent-washed 
pDNA particles conferred a significant rise in the percentage of fluorescent 
cells in the presence of DOTAP. This suggests that solvent-washed pDNA 
particulates remained functionally active following formulation processing, 
dispersion in propellant and aerosolisation from a pMDI. These data 
demonstrate proof-of-concept that the developed technology can successfully 
formulate pDNA suitable for a pMDI system with potential for pulmonary 
gene delivery. This is of importance as the incorporation of pDNA into a pMDI 
for pulmonary administration is a sparsely explored area of research. The 
anticipated challenges include ensuring the stability and preventing aggregation 
of the pDNA particles in the pMDI propellant environment through effective 
formulation. As conventional delivery devices such as nebulisers can be 
inefficient, the investigations carried out in this thesis reveal pMDIs to offer a 
potential alternative. However, due to the differences between the in vitro and 
in vivo environments, including the difference in cellular proliferation rate 
which has been reported to effect gene transfer efficiency (Wilke et al 1996; 
Brunner et al 2000; Remaut et al 2006), understanding the barriers encountered 
in vivo is required to progress this work towards clinical therapy.
Regarding the topic of clinical therapy, the studies in this thesis demonstrated 
that 316 pg of pDNA can be aerosolised from a pMDI system to successfully 
confer gene expression. As pre-clinical and clinical research studies in 
pulmonary gene therapy have required larger doses of pDNA (often mg 
quantities) (Alton et al 1999; Ruiz et al 2001), 316 pg may not be a sufficient 
dose to confer a therapeutic effect. However, these clinical trials used 
nebulisers to deliver the pDNA where a larger dose of pDNA is often required 
as nebulisers can cause instability to the nucleic acid cargo, resulting in a 40 to
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75% reduction in supercoiled pDNA post-nebulisation compared to a non­
nebulised control (Kleemann et al 2004; Lentz et al 2005; Arulmuthu et al 
2007). Also as this pMDI technology is not yet optimised, increasing the 
deliverable dose further is highly probable. Additionally as gene therapy 
vectors continue to improve, the dose of deliverable pDNA is likely to reduce.
The work carried out in this thesis substantiates previous research that 
transfection of naked DNA in vitro is relatively inefficient and that a 
transfection agent must be employed to promote the cellular uptake of the 
nucleic acid (Zabner et al 1997; Davies et al 2008). Due to this, the feasibility 
of incorporating the transfection agent DOTAP into the pDNA pMDI system to 
form a pre-complexed single dosing unit was therefore investigated. A number 
of approaches were used in this thesis to incorporate DOTAP into the pDNA 
pMDI formulation. Investigations demonstrated that coating the pMDI canister 
with DOTAP prior to the incorporation of the solvent-washed pDNA resulted 
in a significant level of gene expression. However, the level of gene expression 
was less than half of that conferred from previous experiments which 
aerosolised the pDNA formulation onto cells treated with DOTAP i.e. DOTAP 
was pipetted onto cells. The lower expression level generated from cells treated 
with the aerosolised DOTAP-pDNA formulation may have been due to 
inefficient DOTAP-pDNA complexing in the non-aqueous propellant 
environment. Nevertheless the incorporation of any transfection agent into a 
pDNA pMDI system is relatively novel and to date there is little published 
work in this field. Although further optimisation is required to maximise 
transfection efficiency, through the use of perhaps different transfection agents, 
the work carried out in this thesis demonstrated an important concept that a 
transfection agent can be incorporated into a pDNA pMDI system to form a 
single dosing unit with gene expression capability. Particle sizing of the 
aerosolised formulation demonstrated that a significant proportion of the 
formulation had the potential for gene expression in the lower respiratory tract.
Stability experiments involving the DOTAP-pDNA formulation revealed that
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although there was a reduction in the gene expression, the formulation 
remained functional for up to four weeks in accelerated storage conditions. 
This study was limited in the sense that accelerated storage conditions are 
typically carried out for a minimum of six months in order to generate any 
clear conclusions as to the stability of the formulation (ICH Expert Working 
Group 2003). However, as a preliminary study, this experiment revealed that 
the transfection and biological activity of the DOTAP-pDNA formulation 
stored in a propellant environment could be retained for subsequent weeks after 
being freshly prepared.
The various experiments conducted during the course of this thesis demonstrate 
the feasibility of preparing a DOTAP-pDNA formulation suitable for 
incorporation into a generic HFA134a pMDI system and aerosolised using a 
standard valve and actuator with potential for pulmonary gene delivery. These 
studies however highlight the need for process optimisation in order for the 
developed technology to be realised in a clinical setting.
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6.2 Further Work
In view of the findings described above, further research is suggested which 
may optimise the technology and lead to a greater understanding of the 
potential of this technology in delivering aerosolised pDNA capable of eliciting 
a therapeutic response.
Optimise the formulation: The developed technology has demonstrated its 
utility in preparing pDNA particles suitable for delivery by a pMDI system to 
confer significant gene expression. However, further development of the 
process may result in maximising gene expression levels through a number of 
ways. pDNA degradation during freeze-drying conditions has been shown to 
be related to lyoprotectant concentration (Anchordoquy et al 1997; Chemg et 
al 1997). It may therefore be viable to investigate optimal lyoprotectant 
concentrations to effectively maintain pDNA integrity. The use of a 
transfection agent has been shown to promote efficient cellular uptake of the 
nucleic acid (Zabner et al 1997). As newer transfection agents are being 
developed, it may be appropriate to explore the use of these alternative 
transfection agents (Choi et al 2004; Jiang et al 2008; Prata et al 2008) and 
‘helper’ lipids (Feigner et al 1994; Bennett et al 1995) which have the potential 
for enhancing pDNA transfection and subsequently gene expression whilst 
minimising cellular toxicity. Investigating the maximum capacity of processed 
pDNA that can be incorporated into a pMDI system would also be worthy of 
further work in order to ascertain the feasibility of delivering a manageable 
therapeutic dose using the pMDI in a clinical setting.
Assess formulation stability: Although a four week stability test was carried 
out, increasing the test period to the generally accepted six months in 
accelerated conditions would give a better understanding of the formulation 
stability (ICH Expert Working Group 2003). Additionally formulation 
instability can manifest itself in a number of ways other than a reduction in the 
pDNA biological activity which was the criteria tested in this thesis. One such 
form of instability includes particle aggregation in the pMDI system. A
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possible avenue of further work could therefore entail assessing the pMDI 
formulation for susceptibility to aggregation, by examining any changes in the 
aerodynamic particle size distribution and emitted dose, through the use of in 
vitro cascade impaction tests.
Alternative vectors: Plasmid constructs used in pre-clinical and clinical 
research studies are larger than the 4.7 kb pEGFP-Nl plasmid used in this 
thesis (Hyde et al 2000; Ruiz et al 2001). Although to date there are no 
published reports on the size dependent effects of plasmid aerosolisation via a 
pMDI, size dependent degradation of pDNA exposed to shear forces has been 
previously demonstrated in nebulisers (Arulmuthu et al 2007). Investigations 
are required to understand whether the developed technology can be used to 
prepare larger plasmids with the potential for incorporation and aerosolisation 
from a pMDI system.
In vivo studies: The in vitro experimental work described in this thesis has 
demonstrated proof-of-concept that the developed technology can formulate 
pDNA suitable for a pMDI system with potential for pulmonary gene delivery. 
However, there is a need to move these studies into animal models as a clear 
understanding of the barriers encountered in vivo is required to progress this 
work towards clinical therapy. An example of an appropriate model to use for 
further work would be the mouse (Grosse et al 2008). The in vivo study could 
entail aerosolising the DOTAP-pDNA pMDI formulation into a chamber 
containing the mouse, causing the mouse to inhale the pDNA therapy.
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ABSTRACT: Aerosolised DNA administration could potentially advance the treatment of 
inheritable lung diseases, lung malignancies and provide genetic immunisation against infec­
tion. Jet nebulisation, the current standard for introducing DNA formulations into the lung, 
is inherently inefficient. Pressurised metered dose inhalers (pMDIs) offer a potentially more 
efficacious and convenient alternative, especially for repeat administration. We aim to modify a 
novel low-energy nanotechnology process to prepare surfactant-coated pDNA nanoparticles for 
pulmonary gene delivery via a pMDI. Water-in-oil microemulsions containing green fluorescent 
protein reporter plasmid were snap-frozen and lyophilised. Lyophilised pDNA, in some cases 
following a surfactant wash, was incorporated into pMDIs with hydrofluoroalkane 134a 
(HFA134a) propellant and ethanol as cosolvent. To assess biological functionality, A549 human 
lung epithelial cells were exposed to aerosolised pDNA particles in the presence of dioleoyl- 
trimethylammonium propane (DOTAP). Transfection studies demonstrated that pDNA biolo­
gical functionality was maintained following aerosolisation. In vitro toxicity assays (MTT) 
showed no significant cell viability loss following aerosolised pDNA treatment. We have 
demonstrated that pDNA particles can be incorporated into an HFA134a formulation and 
aerosolised using a standard valve and actuator. Particles prepared by this novel process have 
potential for stable and efficient delivery of pDNA to the lower respiratory tract via standard 
pMDI technology. <D 2010 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci
K eyw ords: pulmonary drug delivery; pressurised metered dose inhaler; aerosol; plasmid 
DNA; nonviral gene delivery; nanotechnology; formulation; microemulsion
INTRODUCTION
Pulmonary administration of nucleic acids may be 
particularly relevant for treating localised lung 
disorders of genetic origin.1,2 The pulmonary route 
would also be appropriate for the delivery of inhaled 
DNA vaccines, as this would follow the natural route 
of infection for many common airborne diseases,3,4 
such as measles,5 Mycobacterium tuberculosis6 and 
respiratory syncytial virus.7 Cellular uptake of naked 
deoxyribonucleic acid (DNA) in its native form 
remains relatively inefficient.8,9 As a consequence, 
gene transfer vectors are employed to promote 
cellular uptake and processing of the nucleic acid 
cargo.8,10,11 Although viral gene delivery systems are
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often very efficient at stimulating cell transfection 
and can be modified to reduce both their pathogeni­
city and ability to replicate, they still face inherent 
safety and immunogenicity issues and are sometimes 
inappropriate for repeated use.12 As an alternative, 
nonviral gene vectors employ synthetic carriers that 
complex with plasmid DNA (pDNA) to form particu­
lates that are generally regarded as safer and less 
immunogenic,13 although not as efficient.14,16 In this 
category of nonviral agents, cationic lipids and 
liposomes have demonstrated proof of principle for 
gene transfer to the airway for over two decades.16-18 
Whilst impressive results have been achieved in some 
animal models including mice,18,19 rats,20,21 rab­
bits,22 monkeys17 and pigs,23 nonviral gene transfer 
has yet to deliver a clear therapeutic benefit in human 
studies. For example, although the correction of the 
chloride transport defect in cystic fibrosis has been 
demonstrated to some extent in most clinical 
trials,24,25 the level of effect has been found to be
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variable, usually lasting for <15 days,26,27 and thus 
will require repeated administration. Clinical trials 
using gene therapy have also been undertaken in an 
attempt to restore normal a-1 antitrypsin deficiency 
(AAT) function. This involved either nasal instillation 
of the AAT gene with a cationic liposome,28 or 
intramuscular injection of the gene with a viral 
vector.29 As with the cystic fibrosis trials, although 
proof of principle of successful gene expression has 
been demonstrated, there was a notable lack of 
significant functional correction.
It is accepted, therefore, that the development of 
more efficient vectors is essential for the progression 
of gene delivery science towards the clinic.26,30,31 
Equally, however, the administration method selected 
to deliver the therapeutic material to the cellular 
target is of paramount importance, yet is often 
overlooked. The efficiency of delivery to the cell 
targets, the avoidance of biological barriers and 
clearance mechanisms,32 the physical and chemical 
durability of the nucleic acid cargo during delivery1 
and the manageable dose are all critical parameters 
that require optimisation.33
To date, most preclinical and clinical research 
studies in pulmonary gene therapy have used nebu- 
lisers to deliver the gene ‘cargo’ in liquid suspen­
sion.24,25,34 Nebulisation is, however, an inherently 
inefficient process for the delivery of large charged 
macromolecules4,35 due to: adhesion of the formulated 
therapeutic agent to the device components, large 
residual dead volume, limitations on suspension 
concentration without causing precipitation, chemi­
cal degradation through high shearing forces35-37 and 
evaporation.
Conventional jet and ultrasonic nebulisers have 
both been reported to extensively damage naked 
pDNA due to the shearing forces generated on 
creation of the aerosol.37-39 Recently, newer nebuliser 
technologies have claimed greater pDNA aerosolisa­
tion efficiency.40 Aerosolisation, based on electrohy­
drodynamic (EHD) delivery for example, has been 
found to cause no detectable pDNA degradation or 
loss in transfection efficiency in plasmids up to 15 kb 
in size.40 Whilst these encouraging new-generation 
nebuliser technologies are under development, pres­
surised metered dose inhalers (pMDIs) offer a 
sparsely investigated alternative to nebulisers. 
Potential advantages of pMDIs over other pulmonary 
delivery systems include their portability, low cost, 
rapid drug administration and disposability.41 Many 
doses can be stored in a relatively small canister and 
the metering valve ensures reproducible dose deliv­
ery. pMDIs offer a more convenient alternative 
to nebulisers, especially for therapies requiring 
repeated administration.
To date, there has been very little published 
research on methods for incorporating pDNA into
pMDIs.42 Brown and Chowdhury42 demonstrated 
that pDNA, lyophilised in the presence of a both 
nonionic (Tween 40) and ionic (lipofectin or lipofecta- 
mine) surfactant, could be incorporated into a 
metered dose inhaler resulting in suspended pDNA 
particles in dimethylether propellant. In addition, 
they demonstrated that gene expression could be 
obtained in the lungs of mice following exposure to the 
aerosolised pDNA formulation.42 Clearly, further 
investigations in this area are warranted.
This study aims to explore the potential of adapting 
a formulation process to prepare surfactant-coated 
pDNA particulates suitable for pulmonary gene 
delivery.43 Previously, this technology had only been 
investigated with low molecular weight drugs in 
nanoparticles in pMDI formulations. The approach 
utilises a reverse microemulsion as a ‘template’. 
Reverse micelles containing the drug are subse­
quently reduced to solid surfactant-coated nanopar­
ticles using lyophilisation, prior to pressure filling 
with HFA 134a propellant. This investigation aims to 
develop an optimised surfactant microemulsion 
system based on HLB and HFA solubility, to confer 
pDNA stability and propellant dispersion and retain 
pDNA biological activity on aerosolisation.
MATERIALS AND METHODS 
Materials
Chemicals were used as received. Tris-borate EDTA 
buffer (TBE Buffer) electrophoresis grade, propan-2- 
ol, lecithin (egg ~90%), ethidium bromide (EtBr) 
solution and ethanol (absolute, analytical grade 
reagent) were from Fisher Scientific UK Ltd. (Lough­
borough, UK). Iso-octane (2,2,4-trimethylpentane 
99+ %), sodium chloride (NaCl), trizma HC1, protei­
nase K, sucrose 99+ %, phosphate-buffered saline 
(PBS) pH 7.4 (Mg2+ and Ca2+ free), trypan blue and 
MTT-based assay kit were from Sigma-Aldrich Ltd. 
(Poole, UK). Agarose (LE analytical grade) and 
Wizard® DNA Clean-Up System product A7280 were 
from Promega UK Ltd. (Southampton, UK). Dulbec- 
co’s Modified Eagle’s Medium (DMEM), foetal bovine 
serum, penicillin G 5000 units/mL, streptomycin 
sulphate 5000|xg/mL, trypsin-EDTA and Library 
Efficiency® DH5a Competent Cells were from Invi- 
trogen Ltd. (Paisley, UK). Other reagents used were: 
5 x coloured loading buffer blue (Bioline Ltd., London, 
UK); A549 mammalian cell line (ECACC, Salisbury, 
UK); pEGFP-Nl (4.7 kb) reporter pDNA (Clontech 
Laboratories, Inc., Palo Alto, CA); Qiagen Plasmid 
Mega Kit (Qiagen, Crawley, UK); and 1,2-Dioleoyl- 3- 
Trimethylammonium propane (methyl sulphate salt) 
(DOTAP) (Avanti Polar Lipids, Inc., Alabaster, AL). 
HFA 134a was a generous gift of INEOS Fluor Ltd. 
(Runcorn, UK).
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Experimental Methods
O ptim isa tion  o f  M icroem u lsion  
F orm ulation Param eters
Water-in-oil microemulsions were prepared at ambi­
ent temperatures using distilled water (aqueous 
phase), lecithin in propan-2-ol (1:3, w/w) (stabilising 
surfactant system) and iso-octane (organic phase), 
iso-octane was added to the surfactant: co-surfactant 
mixture in a 15 mL polypropylene centrifuge tube and 
gently agitated using a vortex mixer. Nineteen 
formulations were investigated with surfactant con­
centrations, based on previous studies, ranging from 
30% to 64% (w/w). The water content was sequentially 
increased to determine the phase boundary between 
a clear micellar (isotropic) phase and an opaque 
(nonisotropic) multiphase system. Samples that were 
potentially isotropic were visually inspected at 10 min 
and 24 h, after the final water addition, to ensure that 
equilibrium had been fully established. Any visual 
changes over this period were noted. A pseudoternary 
phase diagram was constructed to show the phase 
boundary and identify optimum microemulsion for­
mulation constituent ratios.
Preparation o f  p D N A  Particles
The 4.7 kb pDNA construct pEGFP-Nl, encoding the 
enhanced green fluorescent protein (GFP) reporter 
gene under the control of a cytomegalovirus promoter, 
was amplified using a transformed DH5a strain of 
Escherichia coli, using kanamycin to ensure selective 
growth of transformed bacteria. The pDNA was 
purified using the Qiagen Plasmid Mega Kit. Prior 
to subsequent use, the pDNA concentration and 
purity were determined by the 260/280 UV absor­
bance ratio and plasmid integrity was assessed by 
agarose gel electrophoresis using a specific restriction 
enzyme digest.
The pEGFP-Nl and 3% (w/v) sucrose, as lyopro- 
tectant, were incorporated into the aqueous phase of 
the optimised microemulsion system. The microemul­
sions were snap-frozen by submersion in liquid nitro­
gen and lyophilised for 24 h using a Heto Drywinner 
freeze-drier (Heto-Holten, Alleroed, Denmark) with 
the condenser chamber set at -110°C. The process of 
freeze-drying was carried out by applying tempera­
tures and pressures below that of the sample triple 
point in order to promote sublimation and subsequent 
removal of solvent from the solid phase directly into 
the gaseous phase. Excess surfactant in the micro­
emulsion and resulting particulates could potentially 
adversely affect particulate dispersibility, physical 
stability, toxicity and pDNA cellular functionality. A 
sequential washing method was therefore adapted 
from Dickinson et al.43 for certain test samples, 
whereby excess surfactant was removed from the
freeze-dried pEGFP-Nl particles using an organic 
solvent followed by centrifugation.
A nalysis o f  Lyophilised  p D N A  Particles
Integrity of Lyophilised pDNA. Agarose gel 
electrophoresis, with EtBr staining, was used to 
determine the physical integrity of the processed 
pEGFP-Nl. Following the microemulsion and solvent 
removal stages, surfactant from the lyophilised 
surfactant-coated pEGFP-Nl was removed using a 
Wizard® DNA Clean-Up System. pDNA samples 
were mixed with gel-loading dye and loaded into the 
wells of a 1% (w/v) agarose gel. The gel was developed 
for 30 min at 200 V and analysed using Molecular 
Analyst® software and Bio-Rad Gel Doc 1000 (Bio- 
Rad Laboratories Ltd., Hertfordshire, UK) or Alpha 
DigiDoc™ RT (Alpha Innotech Corporation, San 
Leandro, CA, USA).
Measurement of Particle Size. The mean dia­
meter of the solvent-washed pDNA particles was 
determined by photon correlation spectroscopy using 
a Coulter® N4 Plus (Coulter Electronics Ltd., Luton, 
UK). Particles of lyophilised pEGFP-Nl were dis­
persed in iso-octane and agitated using a vortex mixer 
for ~3 min. Samples were transferred into a quartz 
cuvette, which was seeded to prevent evaporation. 
Meeisurements were expressed using the unimoded 
size distribution model and repeated six times.
A ssessing  th e  Transfection  C o m p e ten c y  o f  Lyophilised  
p D N A  P articu la tes (before  P ropellan t D ispersion  
a n d  A eroso lisa tion)
Cell Culture. All cell investigations were performed 
using A549 human lung epithelied cells, which were 
maintained as adherent monolayer cultures in 25 cm2 
angled neck, cell culture flasks (T25) (Corning Costar 
Ltd., High Wycombe, UK) in growth medium (10% 
fetal bovine serum, 2% penicillin/streptomycin 
5000 IU/mL and DMEM to 100%). Cells were 
incubated in a humidified incubator at 37°C contain­
ing 5% C02. Confluent adherent cells were released 
enzymatically (every 72 h) using trypsin-EDTA and 
reseeded at 1 x 106 cells/T25 flask. All cells used in the 
transfection studies were a result of at least two 
passages, post-thawing, and were in their log growth 
phase, as determined by previous cell growth studies. 
Cells were seeded into 24-well plates at a density of 
4 x 104 cells/cm2 and submerged under 1 mL growth 
media 48 h before transfection.
Cell Treatment. Cells were subjected to one of 
seven treatments (Fig. 1): (i) DMEM alone (no pDNA), 
(ii) unprocessed pEGFP-Nl (positive control), (iii) an 
unwashed formulation of lyophilised DNA-loaded
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Figure 1. Diagrammatic representation of the produc­
tion of samples for subsequent in vitro analysis.
particles and (iv) a solvent-washed variant of 
formulation (iii). In the case of (ii), (iii) and (iv), the 
formulations were added directly onto cells covered 
with (A) DMEM alone or (B) DMEM-containing 
dioleoyl-trimethylammonium proprane (DOTAP) 
liposomes, which had been previously prepared 
through solvent evaporation, resuspension in sterile 
water and membrane extrusion using 100 nm poly­
carbonate filters (Millipore, Watford, UK) and an 
Extruder™ (Lipex Biomembranes, Inc., Vancouver, 
Canada). A549 cells, in each well of a 24-well plate, 
were treated with the equivalent of 5 fig pEGFP-Nl. 
In the case of cells treated in the presence of DOTAP, 
a 6:1 (w/w) DOTAP liposome: DNA ratio was used. All 
treatments were conducted in serum-free DMEM. 
Treated cells were incubated in a humidified incu­
bator (37°C/5% CO2 ). After a period of 6 h, cells were 
washed once with 1 mL PBS (pH 7.4) and replenished 
with 1 mL of growth media.
A nalysis of Gene Expression. The biological 
functionality of the aerosolised reporter plasmid 
pEGFP-Nl, was assessed qualitatively at 42 h post­
treatment, using fluorescent microscopy. Following 
microscopy, cells were surface rinsed with 1 mL PBS, 
trypsinised with 150 fiL trypsin-EDTA solution, and 
resuspended in 600 fiL growth media. The percentage 
of cells displaying GFP-assodated fluorescence (FL1- 
H) was quantified by flow cytometry (FACSCalibur™ 
system; Becton Dickinson Biosciences, Oxford, UK) 
with the analysis by WinMDI™ Software (Joseph 
Trotter, The Scripps Institute, La Jolla, CA), as 
described previously.44
Production  o f  pM D I Form ulations
Two pMDI formulations were aerosolised and inves­
tigated for pEGFP-Nl biological functionality. The 
first ‘unwashed’ formulation used unwashed surfac­
tant-coated, lyophilised pEGFP-Nl particles. The 
second ‘washed’ formulation used the same batch of 
particles after washing to remove excess surfactant. 
Particles were added directly to fluorinated ethylene 
propylene (FEP) coated aluminium canisters (3M 
Drug Delivery Systems, Loughborough, UK) and 
dispersed using ethanol as a cosolvent (8% v/v). 
Spraymiser™ 50 jxL retention valves (3M Drug 
Delivery Systems) were crimped onto the aluminium 
canisters and HFA 134a was added using a Pamasol® 
semi-automatic filling and crimping machine (Pama­
sol Willi Mader AG, Pfaffikon SZ, Switzerland). 
Washed formulations were also prepared in plastic 
polyethylene terephthalate (PET) pMDI vials (3M; 
Drug Delivery Systems), for visual assessment of 
physical stability and dispersion homogeneity. pMDI 
vials were stored at room temperature with visual 
observation at 24 h and 5 months.
A sse ssm en t o f  p D N A  p M D I F orm ulations
M icroscopic C haracterisation of Particles. The
solvent-washed pDNA pMDI formulation was actu­
ated into a Volumatic spacer (Allen and Hanburys, 
Middlesex, UK) connected to an eight-stage Ander- 
sen-type cascade impactor (ACI) (Westech Instru­
ment Services Ltd., Bedfordshire, UK). Double-sided 
carbon tape was attached at various points on the wall 
of the spacer and the plates in the ACI. The ACI was 
operated at a flow rate of 28.3 L/min. Particles that 
had deposited on the carbon tape, postactuation, were 
mounted onto a scanning electron microscopy (SEM) 
aluminium stub and sputter coated with gold before 
being viewed using a Philips XL-200 Scanning 
Electron Microscope (TEI Company, Eindhoven, the 
Netherlands).
A erosol D elivery to Cell Culture Flask. Initial 
pilot studies, using pMDIs containing Brilliant 
Blue dye, were carried out to determine the most 
efficient orientation for delivery to cell culture 
medium (Fig. 2). Brilliant Blue actuated from the 
pMDI five times into a T25 cell culture flask, 
containing 6 mL of water, was assayed by UV 
absorbance at 629 nm. Data from the two actuation 
orientations were compared with a positive control. 
Control absorbance data were generated by actuating 
the Brilliant Blue pMDI into a conical flask contain­
ing 6 mL of water and swirling the water around the 
flask to collect the total emitted dye present in the 
flask.
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A  Top Orientation
pMDI T25 Flask
Water
B  Side Orientation
Figure 2. Schematic representation of actuation into a 
cell culture flask. (A) Top orientation with actuation depos­
iting directly onto liquid; (B) side orientation with actuation 
depositing across the liquid.
A ssessm ent of pDNA Functionality Follow ing  
A ctuation from a pMDI. Biological functionality of 
DNA actuated from the pMDI formulation was 
assessed in A549 cells seeded into T25 flasks at a 
density of 4 x 104 cells/cm2 and cultured under the 
aforementioned culture conditions to 50% confluency. 
Cells were subjected to the following treatments: (i) 
DMEM (negative control), (ii) an unwashed formula­
tion of lyophilised DNA-loaded microemulsion incor­
porated into a pMDI, (iii) a solvent-washed variant 
of formulation (ii). In the case of (ii) and (iii), the 
formulations were actuated from pMDI canisters 
directly onto cells covered with (A) DMEM, and (B) 
DMEM-containing extruded DOTAP liposomes. Each 
T25 flask was treated with the equivalent of 15 fig 
aerosolised pEGFP-Nl. In the case of cells treated 
in the presence of DOTAP, a ratio of 6:1 (w/w) 
DOTAP:washed DNA was used, based on the 
assumption that 15 fig of pDNA would be successfully 
expelled from the pMDI. MDIs were primed by firing 
five shots to waste. To reduce any cell death, due to 
aerosol cold freon effect, the T25 flasks were placed on 
prewarmed saline infusion bags with 30 s intervals 
between actuations.
C ell T oxic ity  Assay
In vitro toxicity of treatments was assessed using the 
colorimetric 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl 
tetrazolium bromide (MTT) based assay kit. Initially, 
A549 cells were treated with pEGFP-Nl from pMDI 
formulations in T25 flasks. After 42 h post-treatment, 
cells were washed twice with 5mL aliquots of cold 
PBS (pH 7.4). PBS was removed and 1 mL trypsin- 
EDTA was added to the cell surface. After 1 min, the 
trypsin was removed from the wells and the T25 
flasks incubated in a humidified incubator at 37°C
containing 5% CO2  for 10 min. After 10 min incuba­
tion, cells were re-suspended in growth media.
Reconstituted MTT was added at 10% of the culture 
medium volume in a 96-well plate. Samples were 
incubated (37°C/5% C02) for 4h. Subsequently, 
formazan crystals were dissolved using 100 |xL of 
MTT solubilisation solution. Cell culture samples 
were incubated (37°C/5% C02) for a further 30 min 
and assayed by UV absorbance at 570 nm using a 
Sunrise™ microplate reader (Tecan Trading AG, 
Mannedorf, Switzerland). Background absorbance, 
measured at 690 nm, was subtracted from the 570-nm 
readings automatically using Magellan™ data reduc­
tion software (Tecan Trading AG).
Statistical Analysis
One-way analysis of variance (ANOVA) was followed 
by either a Duncan’s multiple range test, used to 
compare multiple groups, or Dunnett’s test, used to 
compare groups against a reference group with 
significant differences indicated by p-values <0.05 
or <0.001. Results are summarised as mean ± SD.
RESULTS
Initial studies were aimed to identify optimised 
constituent ratios that form stable isotropic water- 
in-oil microemulsions. Microemulsions with a surfac­
tant to water ratio of approximately 1.5 and greater 
formed stable isotropic systems. Unstable biphasic 
systems were formed when the surfactant to water 
ratio fell below 1.5. Stable microemulsion systems 
with the lowest surfactant to water ratio were deemed 
as optimal from a drug loading and surfactant content 
perspective. Optimised formulations resulted in 
effective incorporation of pDNA (1.2 mg) into the 
aqueous pool (2.08 g) of reverse micelles.
Agarose gel electrophoresis with EtBr staining was 
used to assess the physical integrity of processed 
pDNA Figure 3 shows the supercoiled signal band 
relating to pEGFP-Nl, prior to and following freeze- 
drying and solvent wash cycles. The integrity of 
pEGFP-Nl was maintained through processing, 
although a partial reduction in pDNA signal intensity 
was observed. Semi-quantitative signal analysis 
was used to compare fluorescence emission. The 
supercoiled band of unprocessed pDNA contributed 
88 ± 7% (mean ± SD, n = 3) of emitted fluorescence 
from the total pDNA Once the pEGFP-Nl had been 
incorporated into a microemulsion and freeze-dried, 
fluorescence from the supercoiled fraction was 
reduced to 81 ± 12% and then further reduced to 
76 ± 14% of the total after solvent wash.
Figure 4 shows the result of an in vitro transfection 
experiment to assess the biological functionality of 
pDNA following processing into particles. DOTAP
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Figure 3. A typical gel electrophoresis image of pEGFP 
before and after freeze-drying and solvent washes. The 
percentage values represent a semi-quantitative analysis 
of the ratio of fluorescence emitted from the supercoiled 
band compared with the total pDNA. All percentages are 
mean of n = 3 (SC, supercoiled fraction).
cationic lipid was added to selected cell culture flasks 
to form an electrostatic complex with the pDNA 
and enable cell transfection. A significant increase 
(p  < 0.001) in the percentage of fluorescent cells, 
attributed to expression of GFP, was observed when 
A549 cells were treated with unprocessed (control) 
pEGFP-Nl in the presence of DOTAP (14.49 ±  
1.76%). The unwashed surfactant-coated pDNA
DMF.M IInproccHicdInprnccvvod t'nwAslwii Cnwwhcd Wmhml Wadieil
pDNA pONA + pDNA pDNA pDNA pDNA
DOTAP particle*. pun itles * partktei panicle* ♦
DOTAP DOTAP
Figure 4. Quantitative gene expression of pDNA parti­
cles. A549 Cells were surface-treated with (i) DMEM, 
(ii) unprocessed pEGFP-Nl into DMEM alone, (iii) unpro­
cessed pEGFP-Nl into DMEM-containing DOTAP, (iv) 
unwashed pEGFP-Nl particles into DMEM alone, (v) 
unwashed pEGFP-Nl particles into DMEM-containing 
DOTAP, (vi) solvent-washed pEGFP-Nl particles into 
DMEM alone arid (vii) solvent-washed pEGFP-Nl particles 
into DMEM-containing DOTAP. Data are represented as 
mean ± SD, n = 6. * denotes a significant difference from the 
control (p < 0.001). Inset: Fluorescence microscopy image 
of A549 cells following treatment with (A) unprocessed 
pEGFP-Nl into media-containing DOTAP, and (B) sol­
vent-washed pEGFP-Nl formulation into media-containing 
DOTAP.
particles did not mediate any gene expression, 
regardless of whether DOTAP was present (0.59 ±  
0.11%) or not (0.67 ±0.31%). Gene expression was, 
however, statistically comparable (p  > 0.05) with the 
positive control in DOTAP-supplemented samples 
that had undergone the washing procedure to remove 
excess surfactant (14.28 ± 1.82%). Formulations trea­
ted in the absence of DOTAP showed no significant 
increase (p  > 0.05) in cell fluorescence against the 
negative control. Fluorescent microscopy inserts 
confirmed the presence of fluorescent protein in 
transfection-positive cells.
SEM images of material aerosolised from the pMDI 
formulation and collected using an ACI showed 
the presence of DNA-lyoprotectant aggregates. The 
micrographs in Figure 5a and b confirm the presence 
of a heterogeneous population comprising rounded 
and angular particle protrusions from a continuous 
matrix. Although variable in size, all of these particle 
protrusions were <10|xm in diameter. Microscopic 
observations showed that ACI stages four (Fig. 5a) 
and five (Fig. 5b) with cut-off diameters of 2.1 and 
1.1 |xm respectively contained the greatest number 
of particle protrusions, potentially indicating that 
the majority of the aerosolised material is within 
the respirable size range. However, SEM images 
(Fig. 5a and b) revealed the presence of particle 
protrusions larger than the quoted cut-off diameters. 
Possible reasons for this could include particle 
agglomeration upon impaction onto each of the stages 
and changes in particle size through SEM analysis. 
Particle size analysis using photon correlation 
spectroscopy was also performed on solvent-washed
Figure 5. Scanning electron micrographs of a solvent- 
washed freeze-dried pMDI formulation containing 
pEGFP-Nl and sucrose collected at (a) Stage 4 and (b) Stage 
5 of an ACI. Scale bar = 10 p,m.
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lyophilised particles prior to incorporation into 
propellant dispersions. Analysis revealed particles 
with a mean diameter of 1.9p,m±0.8 (mean±SD, 
n = 6).
Visual observations of the washed pDNA particu­
late formulation, in transparent PET pMDI vials, 
provided a simple indication to the physical stability 
of the formulation in situ. When the surfactant-coated 
lyophilised pDNA particles were subjected to eight 
cycles of the solvent-wash procedure, excess surfac­
tant was removed to leave an off-white powder. Upon 
addition of the washed pEGFP-Nl particles into a 
pMDI vial, initial observations showed that particles 
were suspended throughout the propellant co-solvent 
mix. After a 24 h period, suspended particles were still 
visible, although most particles had formed loose 
sedimented floccules that were easily dispersed by 
one inversion of the PET vial. Redispersible floccules 
were also observed after a period of 5 months.
Prior to experiments assessing biological function­
ality of aerosolised pDNA particles, pilot studies, 
using Brilliant Blue dye actuated from a pMDI into 
T25 flasks, were performed to ascertain the most 
quantitatively efficient orientation to actuate pro­
cessed pDNA formulations onto adherent cells in vitro 
(Fig. 6). Figure 6 shows that actuating the Brilliant 
Blue pMDI from the top orientation gave a greater 
relative collection efficiency (78% of the actuated dye 
was deposited into the collection medium at the 
bottom of the flask) than actuating onto a flask from 
the side orientation (19% deposition). In each case, 
the metering chamber of the valve was allowed to fill 
in the upright position prior to actuation. Statistical 
analysis confirmed no significant reduction (p  > 0.05) 
in the concentration of deposited dye when actuated 
from the top orientation (0.15 |xg/6mL± 0.04 fig, 
mean ± SD, n =  3) compared with the control 
(0.19 ±0.01 |xg).
As a result of the Brilliant Blue pilot study, pDNA- 
loaded pMDI formulations were actuated onto A549
e
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Figure 6. Relative deposition efficiency of Brilliant Blue 
when actuated from a pMDI in the top and side orientation 
relative to the control. Data are represented as mean ± SD, 
n = 3. * denotes a significant difference from the control 
(p < 0.05).
cells directly from above. Flow cytometry was used to 
determine whether pEGFP-Nl remained biologically 
active subsequent to particle processing, propellant 
dispersion and actuation from a pMDI canister and 
valve (Fig. 7). As previously, DOTAP cationic lipid 
was added to selected cell culture flasks to facilitate 
in vitro cell transfection. No increase in gene 
expression was observed for the unwashed aeroso­
lised formulation (p  > 0.05) regardless of whether it 
was actuated in the presence (1.35 ±0.33%) or 
absence (1.16 ±0.94%) of DOTAP. Aerosolising the 
washed formulation onto cells in normal media also 
conferred no significant rise in the percentage of cells 
emitting GFP fluorescence (1.74 ± 0.67%, p  > 0.05). 
However, a significant increase in the percentage of 
cells expressing GFP (p < 0.001) was apparent 
following aerosolisation of the washed pEGFP-Nl 
particulates into DOTAP-containing media (24.75 ±  
2.35%, n = 4) compared with control cells (0.96 ±  
0.30%).
Fluorescence microscopy (Fig. 7, inset) further 
confirmed the presence of gene expression in cells 
following actuation of the washed formulation from a 
pMDI onto cells in DOTAP-supplemented media.
An in vitro MTT toxicity assay was performed on 
A549 cells to determine whether any component of 
the pEGFP-Nl particulate pMDI formulation caused 
a reduction in cell viability (Fig. 8). Statistical 
analysis showed no significant loss in cell viability 
(p  > 0.05) between blank, untreated cells and cells 
treated with the washed, aerosolised pDNA formula­
tion. A significant reduction in cell viability (p  < 0.05) 
was, however, observed when DOTAP was added to
DMEM Unwashed Unwashed Washed Washed 
pDNA pDNA pDNA pDNA 
panicles panicles + particles particles +
DOTAP DOTAP
Figure 7. Quantitative gene expression of aerosolised 
pDNA particles. A549 cells were surface-treated with (i) 
DMEM, (ii) unwashed pEGFP-Nl particles into DMEM 
alone, (iii) unwashed pEGFP-N 1 particles into DMEM-con­
taining DOTAP, (iv) solvent-washed pEGFP-Nl particles 
into DMEM alone and (v) solvent-washed pEGFP-Nl par­
ticles into DMEM-containing DOTAP. Data are represented 
as mean ± SD, n = 4. * denotes a significant difference from 
the control (p<  0.001). Inset: Fluorescence microscopy 
image of A549 cells following treatment with solvent- 
washed pEGFP-N 1 formulation into media-containing 
DOTAP.
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Figure 8. Percentage cell viability of cells following 
actuation of treatments. Cells were surface-treated with: 
(i) DMEM (control cells: 100% viability), (ii) nine actuations 
of a solvent-washed pEGFP-N 1 pMDI formulation actuated 
into DMEM alone, (iii) nine actuations of a solvent-washed 
pEGFP-Nl pMDI formulation actuated onto DMEM-con­
taining DOTAP, (iv) nine actuations of placebo pMDI for­
mulation containing HFA 134a and ethanol actuated onto 
DMEM alone, (v) nine actuations of placebo pMDI formula­
tion containing HFA 134a and ethanol actuated onto 
DMEM-containing DOTAP and (vi) eighty actuations of 
placebo pMDI formulation containing HFA 134a and etha­
nol actuated onto DMEM-containing DOTAP. Data are 
represented as mean±SD, n = 3. * denotes a significant 
difference from the control (p < 0.05). ** denotes a signifi­
cant difference from both the control and the treatment 
with nine actuations (p < 0.05).
the cell culture medium. The MTT assay was also 
used to ascertain the effect of actuation on cell 
viability. Statistical analysis showed a significant 
reduction (p < 0.05) in cell viability when cells were 
treated with 80 pMDI-aerosolised doses, compared 
with 9 doses of the same formulation; this demon­
strates the sensitivity of the MTT assay and is 
likely due to the cold-freon effect of repeated 
aerosolisations.
DISCUSSION
Ternary phase microemulsions are made up of three 
phases: an aqueous phase, organic phase and a 
surfactant system. In order to maximise the loading 
capacity of a water-soluble therapeutic molecule such 
as pDNA, an optimum microemulsion should consist 
of a large aqueous phase and a small volume of 
surfactant. Freeze-drying the microemulsion phase 
serves to remove solvent to leave surfactant-coated 
particles. If the concentration of surfactant coating 
the particles is high, the excess surfactant could 
potentially adversely affect cellular toxicity, parti­
culate dispersibility, the physical stability of the 
formulation and, ultimately, pDNA transfection 
functionality. In this study, an optimum microemul­
sion was found to have a surfactant to water ratio of
approximately 1.5. Controlled lyophilisation of the 
pDNA-incorporated microemulsions enabled the 
removal of solvent and water to produce surfactant- 
coated pDNA particles.
DNA integrity, assessed by electrophoresis, was 
studied following incorporation into the microemul­
sion, freeze-drying and solvent washing to remove 
excess surfactant. Although Unear DNA forms have 
also been found to be transfection competent,45,46 
most puhUshed Uterature supports the opinion that 
pDNA-supercoiled structure should be retained to 
optimise cellular transfection efficiency8,47,48 and to 
comply with regulatory requirements on product 
quality.35,40 Analysis of our unprocessed pDNA 
indicated that 88% (±7%) was in the supercoiled 
form and this is within the expected range (80-90%) 
for small-scale, freshly made pDNA preparations.49 
Further analysis of freeze-dried, and freeze-dried 
then solvent-washed preparations, showed a reduc­
tion in the supercoiled fraction to approximately 81% 
(±12%) and 76% (±14%) respectively. Previous 
research has demonstrated that jet nebuhsation 
can result in significant loss of pDNA with only 5- 
60% 36>38>39 of supercoiled pDNA, of a similar size to 
that of pEGFP-Nl, being recoverable after nebulisa- 
tion compared with non-nebulised control. Our 
results infer that the process of freeze-drying the 
pDNA-loaded microemulsion had a comparatively 
small adverse effect on the supercoiled form and that 
further processing, via solvent washing, was not 
particularly detrimental. The relatively small change 
in supercoiled fraction we observe through proces­
sing, that is 88-76%, is similar to that previously 
observed for spray-dried lipid:protamine:pDNA 
(LPD) dry powders for inhalation prepared in the 
presence of a ciyoprotectant.44,50
Degradation of the supercoiled topology of the 
pDNA may have detrimental effects on both the 
safety and transfection efficiency of the pDNA.35,45,48 
Further work is required in optimising procedures to 
preserve the supercoiled pDNA structure, for exam­
ple through the use of alternative lyoprotectants. 
Despite observing a reduction in the supercoiled 
fraction, initial transfection results showing no 
significant difference in expression of reporter gene 
in cells treated with unprocessed pDNA and pDNA 
following processing for incorporation into a pMDI 
formulation demonstrate the utility of our processes. 
Our transfection data also highlight that a washing 
stage is essential to maintain pDNA functionality, 
indicating that excess surfactant may reduce forma­
tion of the electrostatic lipid:pDNA complex and/or 
affect interactions of the lipid:pDNA complex with 
the cell surface. The lecithin surfactant is composed 
of various substances including anionic lipids. As 
anionic lipids have been shown to have a strong 
ability to displace pDNA from cationic lipid:pDNA
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complexes,61 a reduction in transfection may be 
anticipated. Previous research has shown that 
anionic surfactants have the ability to reduce 
transfection efficiency by inducing release of DNA 
from cationic lipid:DNA complexes before it reaches 
the target cell.52,63
SEM of the aerosolised, washed pEGFP-Nl for­
mulation revealed a continuous matrix (which may be 
the sticky surfactant system) interspersed with 
protrusions of a heterogeneous particle population 
comprising of angular particles (likely to be the 
sucrose cryoprotectant) and more rounded particles 
(possibly including surfactant-coated pEGFP-Nl 
particles). Although micrographs showed that more 
of these particle protrusions were present at Stage 5 
of the ACI (cut off diameter 1.1 p,m), the observed 
larger particle dimensions suggest that particle 
agglomeration was prevalent. Whilst particles were 
solvent-washed to remove excess surfactant, the 
presence of the surfactant, even at a minimal 
quantity, may have caused the particles to agglom­
erate as they impacted on the ACI plate. It is also 
possible that sample heating during SEM processing 
and analysis may cause particle agglomeration. 
Further characterisation of discrete particles may 
have been possible at higher magnifications; however, 
increasing the magnification resulted in a reduction 
of the image resolution as the SEM was operating 
towards its limit.
Visual observations of solvent-washed pDNA for­
mulations in PET vials with time highlighted a 
number of points. Solvent-washing the surfactant- 
coated pDNA particles removed the excess surfactant 
to produce an off-white powder, which initially 
dispersed in the propellant-cosolvent mixture. Sedi­
mentation of the particles did occur after 24 h but the 
sedimented particles were readily redispersed by one 
inversion of the vial confirming the presence of loose 
floccules. This flocculated system showed no signs 
of caking following storage at ambient temperatures 
for 5 months. Surfactants are often incorporated 
into suspensions to stabilise the drug dispersion 
by reducing the electrostatic charge of the drug. 
Observations of a dispersible flocculated system 
indicate that drug aggregation of the formulation 
was suitably controlled within the 5-month time 
span. The lack of solubility of hydrophobic surfactants 
(e.g. lecithin) in HFA 134a propellant is well 
documented and commonly requires the use of a co­
solvent in commercial formulations. Our observations 
of a dispersed system suggest that the quantity of 
surfactant. in the solvent-washed formulation fell 
within the range of that which can be solubilised into 
the propellant with the aid of ethanol as cosolvent 
(8%, v/v).
Transfection studies, using various aerosolised 
formulations, revealed that only the solvent-washed
pDNA particles conferred a significant rise in the 
percentage of fluorescent cells in the presence of 
DOTAP. This suggests that the solvent-washed 
pEGFP-Nl particulates remained functionally active 
following formulation processing, dispersion in pro­
pellant and aerosolisation from a pMDI. Statistical 
analysis showed no significant difference in the 
percentage of cells expressing GFP following treat­
ment with the washed pEGFP-Nl formulation 
actuated onto cells without the presence of DOTAP 
compared with control cells. These data substantiate 
previous research that a transfection agent is 
essential in conferring gene expression in vitro8 
and acts as a control to confirm that the fluorescence 
detected during FACS analysis was indeed due to 
intact pEGFP-Nl transfecting cells with the aid of a 
transfection agent. These in vitro cell culture studies 
establish that pDNA can be formulated to remain 
transfection competent when actuated from a pMDI. 
However, whilst in vitro studies are necessary to 
demonstrate proof of concept, a clear understanding 
of the barriers encountered in vivo is required to 
progress this work towards clinical therapy. The 
lungs possess numerous biological barriers and 
mechanisms that all contribute to the clearance of 
foreign particles, and therefore hinder their ability to 
exert any therapeutic effect. The presence of a mucus 
layer and the mucociliary escalator are crucial in 
trapping and removing foreign particles in the upper 
airways. Lung surfactant at the air-water interface 
not only causes macromolecule aggregation and thus 
promote particle removal by macrophage engulfment, 
but has also been shown to interact with cationic 
lipid:pDNA complexes to reduce pDNA transfec­
tion.52,53 In addition, due to the mechanism of gene 
transfer, the differences between cell proliferation 
rates in vitro and in vivo has revealed significant 
variation in pDNA transfection efficiency.8,54
The absence of effect of washed, aerosolised 
pEGFP-Nl formulation (without DOTAP) on cell 
viability is promising. The significant reduction in cell 
viability in the presence of DOTAP concurs with 
previously published reports65,56 and it may be 
appropriate to explore the use of alternative transfec­
tion agents10,66,67 and ‘helper’ lipids.68,69 Indeed, 
in vivo gene expression has been achieved in the 
past without the use of a transfection agent, although 
transfection efficiency was found to be relatively 
low.9,60
CONCLUSION
Methods have been developed and evaluated to 
freeze-dry pDNA microemulsions to produce surfac­
tant-coated pDNA particles whilst successfully main­
taining the integrity of the pDNA. Furthermore, we
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have demonstrated that the pDNA particles can be 
incorporated into a HFA 134a formulation and 
aerosolised using a standard valve and actuator. 
The transfection studies demonstrated that the 
biological functionality of the pDNA can be main­
tained after aerosolisation from this type of pMDI 
formulation. Particles prepared by this novel low- 
energy microemulsion process may have the potential 
for stable and efficient delivery of pDNA to cells in the 
lower respiratory tract via pMDIs. Further studies 
will focus on the requirements for and the effects of 
transfection agents.
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